

**FOR Ph.D COURSE(S) FOR A.Y. 20<sup>23</sup>-20<sup>24</sup>**

(Please submit separate report for each subject)

Date of Inspection	:	
--------------------	---	--

Faculty: Medicine

Subject/Specialty: Medical Genetics

1. Name & Address of the College/Research Centre: -Mahatma Gandhi Institute of Medical Sciences, Sevagram, Center for Genetics & Genomics, Department of Anatomy  
Name of Head of the Department: - Dr. Jwalant Eknath Waghmare

Designation: Professor &amp; Head

2. Department / Subject wise details of available PhD Guides: -  
(Attach Annexure 'A')

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed sixdays Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1.	Dr. N. M. Gangane	Director professor Pathology & Dean MGIMS	11/06/1961	Left institute on 13/01/2023. But as per MUHS guidelines will be guiding the candidates registered under him.	03	Yes	MUHS/UDC(PhD)/Guide/37/2020. dt:10/02/20 (AnnuxureA)

4. Details of available infrastructure for Research:
- Adequate number of Computers with Internet facility is available? **Yes 03**
  - Adequate number of Books / Journals are available? **Yes**  
**Number of Dept. Library Books: 373**
  - Any other specific thing available at the Department: **Annexure of Instruments available in Genetic Lab**
5. Details of Central Research Laboratory:
- Available Area (in sq. ft): **3230Sq.ft.**
  - Is Drugs/Medicines/Chemicals etc. are available for research? **Yes**
  - Is Adequate number of Instruments are available? **Yes**
  - Is Records of Stock book available? **Yes**

6. Details of Central Animal House:  
i) Available Area in sq. ft: **1175 sq.ft.**  
ii) Functioning Central Animal House? **Yes**

7. Details of Institutional Ethical Committee: **(Annexure "B" a,b,c,d,e,f)**

**Date of Composition: As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022).**

- i) Total Number of Members: **13 (Copy enclosed)**  
ii) Number of meetings held in previous year: **05 (October 2021 - October 2022)**  
iii) Whether Records of proceedings are maintained properly? **Yes**  
iv) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes.**

8. Details of Research Advisory Committee: **(Annexure "C")**  
Date of Composition: **14/09/2017**

- i) Total number of Members: **8**  
ii) Number of meetings held in previous year: **02 (2021-22)**  
iii) Whether records of proceedings are maintained properly? **Yes**

9. Is Doctoral Committee constituted in the lines of RAC? **Yes** **Annexure of Doctoral Committee**

- i) If Yes, Date of Composition: **21/07/2022**  
ii) Total number of Members: **15**

- Name of External Subject Expert: **Dr. Shabana Borate**, Grant Med. College, Sir J.J. Hospital Compound, Byculla, Mumbai

10. Is Plagiarism detection software facility available? **Yes**

If Yes, Name of the Software: **Original by Turnitin**

11. Is attendance of the Ph.D. Scholar maintained properly? **Yes**

12. Whether Research Centre is registered under MPCB provisions? **Yes**

13. Whether BMW facility is available? **Yes**



14. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:

1) We have started BCR-ABL FISH diagnostic test to Chronic Myeloma Leukocytes (CML) patients as a routine diagnostic test. It is rapid diagnosis for Philadelphia positive CML patients. Rapid detection of Philadelphia chromosome is very important for prognosis and management of the CML patient. Now, we are also going to start FISH diagnosis for other hematological disorders.

2) We have also established FISH diagnostic service for HER2/Neu detection in breast cancer patients.

3) This molecular cytogenetic facility is being utilized for postgraduate and PhD research work at Center for Genetic Genomics, department of Anatomy, MGIMS, Sevagram

#### DECLARATION BY LIC

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows: -

.....  
.....  
.....  
.....  
.....

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	





**महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक**  
**MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK**

दिंडोरी रोड, म्हसळ, नाशिक-४२२००४ Dindori Road, Mhasrul, Nashik-422004

Phone : 0253 - 2539196/206, 0253 - 6659196/206

Email: [udc@muhs.ac.in](mailto:udc@muhs.ac.in) Website: [www.muhs.ac.in](http://www.muhs.ac.in)

**MUHS**

डॉ. सुनिल ह. फुगारे

एमएस्सी. पीएच.डी.

उपकुलसचिव

Dr. Sunil H. Fugare

MSc.Ph.D.

Deputy Registrar

O.No.MUHS/UDC(Ph.D.)/Guide / 37 /2020

Date 10/02/2020

To,


✓ The Dean/Principal,

Mahatma Gandhi Institute of Medical Sciences,

Post-Sevagram,

Wardha- 442 102.

Email - [dean@mgims.ac.in](mailto:dean@mgims.ac.in)



**Subject** : Recognition as Ph.D. Guide...

**Reference** : 1) Your Application dated - 22/01/2020.

2) Ph.D. Direction No. 01/2020

Sir/Madam,

With reference to the above cited subject, I am directed to inform you that in view of the norms prescribed as per the provision u/s 29 (2) of (i) of MUHS Act, 1998 & clause 07 (2) (a) (ii) of Direction No. 01/2020 Hon'ble Vice Chancellor is pleased to grant recognition as Ph.D. Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order, for guiding the Ph.D. student in the subject mentioned against his/her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D. Guide
1	Genetics	Dr. Gangane Nitin Mrigrajendra	Dean, MGIMS Sevagram	Approved w.e.f. 03/02/2019, onwards

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service of the said teaching college/institute or till attaining the age of superannuation whichever happens earlier.

The above teacher is required to attend the Research Methodology Workshop conducted by this University or any other Centre authorized by the University.

*[Handwritten Signature]*  
Dean


A.O

(P.T.O.)



You are requested to handover the copy of this letter to the concerned teacher for further necessary action.

Yours,

  
Dy. Registrar  
University Dept. Cell  
(Ph.D.)

[Note :-

1. In case, at later stage, if it is found that the information furnished in the Ph. D. recognition form by any Guide is incorrect, Ph.D. Guide Recognition granted by the University will stand cancelled.
2. It is required that the Dept. of Genetics., Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha. should be recognized place of research of Ph.D.]

Copy to :

1. Dr. Gangane Nitin Mrigrajendra  
Professor  
Dept. of Genetics  
Mahatma Gandhi Institute of Medical Sciences,  
Post-Sevagram,  
Wardha- 442 102.  
Email - [nitingangane@gmail.com](mailto:nitingangane@gmail.com)



## Instruments Available in Genetic Lab

### MOLECULAR GENETICS LABORATORIES (13)

1. Working Hood (Yorco) -1,
2. Binocular Research Microscope (Olympus)-1,
3. Refrigerator-1,
4. Deep Freezer (Celfrost)-1,
5. UV Spectrophotometer with software (Elico)-1,
6. PCR Machine (Applied Biosystem)-2
7. Gel Documentation System (Uvi Tec.)-1,
8. Electrophoresis (Hoffer)-1,
9. Micro Centrifuge (Remi)-1,
10. Ph Meter Labindia – 1.
11. Ultra Water Purifier- 1
12. Seq. Studio DNA Analyser – 1
13. ELISA reader-1

### CYTOGENETICS AND MOLECULAR CYTOGENETICS LABORATORIES (20)

1. Laminar Flow Clean Air Work Station (Klenzaid)-1,
2. BOD Cooling Incubator (Remi)-1,
3. CO2 Incubator (Forma)-2,
4. Phase Contrast Inverted Tissue Culture Microscope with Micro-photographic Attachment (Olympus)-1,
5. Trinocular Research Microscope with Digital Camera (Nikon)-1,
6. Centrifuge (Remi)-2, Hot Air Oven (Scientific & Electronics)- 1,
7. Water Bath Shaker (Yorco)-1,
8. Refrigerator-1,
9. Deep Freezer (Blue Star)-1,
10. Vortex Mixer-1,
11. Magnetic Stirrer-1,
12. Micro-slide Cabinet (3000 Slides)-2
13. Electronic Weighing Machine (Ohaus)-1,
14. Autoclave with Drums (Vertical type) (Yorco)-1,
15. Water Deionizer (MC Dalal)- 1,
16. Water Softner – 1,
17. Double Distillation – 1.
18. Fluorescence Microscope with software - 01

Copy to Secy

Ethics Committee

File No. ECR/54/Mahatma/Inst/Maha/2013

Bsw

14/5/13

AO

From:

The Drugs Controller General (India)  
Directorate General of Health ServicesFDA Bhawan, Kotla Road,  
New Delhi - 110 002  
Dated: 20-04-2013

To

Dr. B. S. Garg,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram, Wardha-442102, Maharashtra.

SUB: - Ethics Committee Registration No. ECR/47/Inst/MH/2013 issued under Rule 122DD of the Drugs &amp; Cosmetics Rules 1945.

Dear Sir

Please refer to your application no. nil dated: 10.03.2013, FTS no. 15615 dated: 15.03.2013 submitted to this office for the Registration of Ethics Committee.

Based on the documents submitted by you, this office hereby Registers the **Institutional, Ethics Committee for Research in Human Subjects** situated at **Maharashtra** with Registration number ECR/47/Inst/MH/2013 as per the provisions of Rule 122DD of the Drugs and Cosmetics Rules, 1945 subject to the following conditions:

1. This Registration is subject to the conditions specified under Rule 122DD and Appendix VIII of Schedule-Y of Drugs and Cosmetics Act, 1940 and Rules 1945.
2. The Ethics Committee shall review and accord its approval to a clinical trial at appropriate intervals as specified in Schedule Y and the Good Clinical Practice Guidelines for Clinical Trials in India and other applicable regulatory requirements for safeguarding the rights, safety and well being of the trial subjects.
3. In the case of any serious adverse event occurring to the clinical trial subjects during the clinical trial, the Ethics Committee shall analyze and forward its opinion as per procedures specified under APPENDIX XII of Schedule Y.
4. The Ethics Committee shall allow inspectors or officials authorized by the Central Drugs Standard Control Organization to enter its premises to inspect any record, data or any document related to clinical trial and provide adequate replies to any query raised by such inspectors or officials, as the case may be, in relation to the conduct of clinical trial.
5. The licensing authority shall be informed in writing in case of any change in the membership or the constitution of the ethics committee takes place.
6. All the records of the ethics committee shall be safely maintained after the completion or termination of the study for not less than five years from the date of completion or termination of the trial (Both in hard and soft copies).
7. If the Ethics Committee fails to comply with any of the conditions of registration, the Licensing Authority may, after giving an opportunity to show cause why such an order should not be passed, by an order in writing stating the reasons therefore, suspend or cancel the registration of the Ethics Committee for such period as considered necessary.
8. This registration shall be in force for a period of three years from the date of issue, unless it is sooner suspended or cancelled.



9. Ethics Committee shall consist of not less than seven members and is subject to a maximum of 15. One among its members, who is from outside the institute, shall be appointed as chairman, one member as a Member Secretary and rest of the members shall be from Medical, Scientific, Non Medical and Non-scientific fields including lay public
10. The committee shall include at least one member whose primary area of interest or specialization is Non-scientific and at least one member who is independent of the institution besides; there should be appropriate gender representation on the Ethics Committee.
11. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.
12. Members should be conversant with the provisions of clinical trials under this Schedule, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.
  - a) For review of each protocol the quorum of Ethics Committee shall be at least five members with the following representations:
    - I. Basic medical scientist (preferably one pharmacologist)
    - II. Clinician
    - III. Legal expert
    - IV. Social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person.
    - V. Lay person from community
13. The members representing medical scientist and clinicians should have Post graduate qualification and adequate experience in their respective fields and aware of their role and responsibilities as committee members.
14. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.
15. There should be no conflict of interest. The members shall voluntarily withdraw from the Ethics Committee meeting while making a decision on an application which evokes a conflict of interest which may be indicated in writing to the Chairman prior to the review and be recorded so in the minutes. All members shall sign a declaration on conflict of interest.
16. Subject experts or other experts may be invited to the meetings for their advice. But no such expert shall have voting rights.
17. This certificate is issued to you on the basis of declaration/submission by you that yours is a institution and registration is sought for the Institutional Ethics Committee.

Yours Faithfully



(Dr. G.N. Singh)

Drugs Controller General (I) & Licensing Authority





सत्यमेव जयते

File No. EC/19/000199

Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotta Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

S  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:41:40 +05'30'  
(Dr. S. Eswara Reddy)  
Drugs Controller General (I) &  
Central Licensing Authority

#### Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,

non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



- such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.
20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.
21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.
22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.
23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.
24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.
25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.
26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.
27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.
28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.
29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.
30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.
31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.
32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licensing Authority  
Stamp  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:39:25 +05'30'





Mahatma Gandhi Institute of Medical Sciences  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
*For Research on Human Subjects*

Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in)

Reg. No. ECR/47/Inst/MH/2013/RR-19  
(Under New Drugs and Clinical Trials Rules, 2019)



EC-CT-2021-0168

05 Mar 2021 - 04 Mar 2024

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID, and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raisonni University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Raisonni University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director, Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smitta@mgims.ac.in">smitta@mgims.ac.in</a>	Clinician	Director Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Chief Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jarnalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Professor, Faculty of Nursing

Date: 11<sup>th</sup> July 2022

Dr. Sushil Kumar Varma

Member Secretary

Institutional Ethics Committee  
Mahatma Gandhi Institute of Medical Sciences  
Sewagram - 442102, Maharashtra, India

Dr. Ashok Pawade

Chairperson

Institutional Ethics Committee  
MGIMS, Sevagram, India

FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19


The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licencing Authority  
Stamp  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:39:25 +05'30'





No. 25/471/2009-AWD  
Government of India  
Ministry of Fisheries, Animal Husbandry and Dairying  
Department of Animal Husbandry and Dairying  
O/o Committee for the purpose of Control and Supervision of Experiments on Animals  
\*\*\*\*\*

Krishi Bhawan, New Delhi – 110001  
Date: 10/07/2020

To

Dr. Satish Kumar, Chairman IAEC,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram, Wardha (District) pin: 442102,  
Mobile: 9422144468  
E-mail: [satishkumar@mgims.ac.in](mailto:satishkumar@mgims.ac.in)

Subject: Revision of Institutional Animals Ethics Committee (IAEC) – regarding

Sir,

Kindly refer to your application on the above subject. CPCSEA hereby accords approval to your request for revision of IAEC.

2. Accordingly, the revised IAEC is as under:

S.No.	Name of IAEC Members	Designation in IAEC
1	Dr. Vijayshri Deotale	Biological Scientist
2	Dr. Vinod Shende	Scientist from different biological discipline, Member Secretary
3	Dr. Sushil Kumar Varma	Scientist from different biological discipline
4	Dr. Satish Kumar	Scientist In charge of Animal House Facility, Chairperson
5	Dr. Sandip Joge	Veterinarian
6	Dr. Kailash Marwah	Main Nominee
7	Mr. Jugalkishor V. Vyas	Link Nominee
8	Dr. Mohan M. Sagdeo	Scientist from outside the Institute
9	Shri. Vijay V. Bansod	Socially Aware Nominee


3. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6), and Main Nominee, Scientist from outside the Institute and Socially aware nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, Link Nominee should be invited once in a year to update him/ her about the activities of IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

.....2



4. Further, you are advised that veterinarian should be available at the time of animal experiment in the animal house facility.
5. The above composition of IAEC is valid upto the renewed period of registration i.e. 14.09.2021.

Yours sincerely,



(Dr. S. K. Dutta)  
Member Secretary (CPCSEA)

Copy for information to Nominees of CPCSEA:

- 1 Dr. Kailash Marwah, Main Nominee
- 2 Mr. Jugalkishor V. Vyas, Link Nominee
- 3 Dr. Mohan M. Sagdeo, Scientist from outside the Institute
- 4 Shri. Vijay V. Bansod, Socially Aware Nominee



File No. EC/NEW/INST/2020/490



सत्यमेव जयते

Government of India  
Ministry of Health & Family Welfare  
Department of Health Research  
(National Ethics Committee Registry for Biomedical and Health Research)

2nd Floor, IRCS Building,  
Red Cross Road, New Delhi – 110001  
Date : 03-Mar-2022

FORM CT-03

(See rules 17 and 18)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO BIOMEDICAL HEALTH RESEARCH

Registration No. EC/NEW/INST/2022/MH/0072

The designated authority hereby registers and permits Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Kasturba Health Society Sevagram, City-Wardha, District-Wardha - Maharashtra - 442102 Contact No.: 07152-284341-355 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter IV of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 03-Mar-2022

ANU

NAGAR

Designated Registration Authority  
Stamp

Digitally signed  
by ANU NAGAR  
Date: 2022.03.03  
11:01:12 +05'30'



C/Gen/9978  
Office of the Dean,  
MGIMS, Sevagram  
Date: 15/02/2023

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned

CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



**Ph. D. Doctoral Committee Member List**

<b>Sr. No.</b>	<b>Course</b>	<b>Name of Subject Expert</b>	<b>Email ID of Subject Expert</b>	<b>Mobile No. of Subject Expert</b>
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	<a href="mailto:drshabaana@gmail.com">drshabaana@gmail.com</a>	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	<a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	<a href="mailto:samarth21174@gmail.com">samarth21174@gmail.com</a>	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	<a href="mailto:gargimudey@hotmail.com">gargimudey@hotmail.com</a>	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	<a href="mailto:anujab803@gmail.com">anujab803@gmail.com</a> , <a href="mailto:anuja_bhalerao@yahoo.com">anuja_bhalerao@yahoo.com</a>	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	<a href="mailto:sanjay.zodpey@phfi.org">sanjay.zodpey@phfi.org</a>	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (€), Mumbai 400012	<a href="mailto:anitachalak@rediffmail.com">anitachalak@rediffmail.com</a>	9850620123

**FOR Ph.D COURSE(S) FOR A.Y .2022-2023**  
(Please submit separate report for each subject)

Date of Inspection	:	
--------------------	---	--

Faculty: Medicine Subject/Specialty:...Physiology

1. Name & Address of the College/Research Centre:- Mahatma Gandhi Institute of Medical Sciences,

Mahatma Gandhi Institute of Medical Sciences,  
Sewagram, Dist.- Wardha- 442102, (MS)

Name of Head of the Department:-... Dr. A. R. Chaudhari

Designation:... Director Prof. & Head

2. Department/Subject wise details of available PhD Guides:-

(Attach Annexure“ A”)

Sr. No	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	Ph D Recognition No. And Date
1	Dr. A. R. Chaudhari	Director Prof. & Head	11/07/1959	31/07/2023	nil	No	MUHS/UDC/Ph.D/E-1/531/2013 dated 06/06/13
2							
3							
4							
5							

4. Details of available infrastructure for Research:

- i) Adequate number of Computers with Internet facility is available? **Yes**
- ii) Adequate number of Books/Journals is available? **Yes**
- iii) Any other specific thing available at the Department **Having RMS – EMG – Mark –II , Computerized Polysomnography video study system with EEG , Sperm Quality Analyzer ( SQA-II CP) and Exercise Physiology Recording and Analysis System ,**

5. Details of Central Research Laboratory:

- i) Available Area(in sq. ft):. **3230Sq.ft. .**
- ii) Is Drugs/Medicines/Chemicals etc. are available for research? **Yes**



- iii) Is Adequate number of Instruments are available? **Yes**
- iv) Is Records of Stock book available? **Yes**
6. **Details of Central Animal House:**
- i) Available Area in sq. ft.: **1175 sq.ft.**
- ii) Functioning Central Animal House? **Yes**
7. **Details of Institutional Ethical Committee: (Attach Annexure "B")**
- i) Date of Composition As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No . ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated (03- Mar-2022)  
- Copies enclosed
- ii) Total Number of Members:.. **13**
- iii) Number of meetings held in previous year: **05 (October 2021 - October 2022)**
- iv) Whether Records of proceedings are maintained properly? **Yes**
- v) Is Human and Animal Ethics Committee ,registered under the appropriate authority? **Yes**
8. **Details of Research Advisory Committee:(Attach Annexure "C")**
- i) Date of Composition:.. **12/07/2013**
- ii) Total number of Members:.. **8**
- iii) Number of meetings held in previous year: **02(2021-22)**
- iv) Whether records of proceedings are maintained properly? **Yes**
9. **Is Doctoral Committee constituted in the lines of RAC?** **Yes**
- i) If Yes, Date of Composition:..**21/07/2022**
- ii) Total number of Members:..**15**
- iii) Name of External Subject Expert **List Attached**
10. **Is Plagiarism detection software facility available?** **Yes**  
If Yes , Name of the Software...**Our original anti Plagiarism software**
11. **Is attendance of the Ph.D. Scholar maintained properly?** **NA**
12. **Whether Research Centre is registered under MPCB provisions?** **Yes**
13. **Whether BMW facility is available?** **Yes**
14. **Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:**

**There is well functioning Neurophysiology lab in the department where the investigation like NCV,EMG, VEP,BERA are routinely done on the patients Further there is well functioning Reproductive Biology Unit in the department where the semen analysis is routinely done for the patients. Both the labs provide good opportunity to carry out good research work under this**

department. In 2010, sleep lab & in 2015 Respiratory lab was introduced in the dept. for research purpose. 'Sports Physiology Lab' started in June 2018 which is well equipped with a complete exercise physiology recording and analysis system for monitoring cardio respiratory and metabolic function which is able to assess the Cardio-Pulmonary efficiency of sportsmen across India

**DECLARATION BY LIC**

We, the LIC Members, here by certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows:-

.....  
.....  
.....  
.....  
.....  
.....

Name of Inspectors		Sign. Of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4)	Member	



# Nagpur University



आयुःशल्य विज्ञान स्नातक  
(Bachelor of Medicine &  
Bachelor of Surgery)

—\*\*—

*This is to certify that*

*Shri Ajay Rajeshwar Chavhan*

*obtained the degree of आयुःशल्य विज्ञान स्नातक*

*(Bachelor of Medicine & Bachelor of Surgery)*

*in this University in the Examination of*

*November, 1982.*

Nagpur University:  
28th January, 1984.

True Cert.  
Attested

*[Signature]*  
Vice-Chancellor



**Maharashtra Medical Council, Bombay**  
**CERTIFICATE OF REGISTRATION**

Registration No. : 52196

This is to certify that the within-  
signed <sup>A.R. Chaudhari</sup> **A. R. CHAUDHARI** Doctor Shri/Shrimati/


Kumari CHAUDHARI AJAY RAJESHWAR

possessing the qualifications of M.B.D.S. (NAGPUR), 1984;

has been duly registered under the Maharashtra  
Medical Council Act, 1965 (Mah. XLVI of 1965), in  
Part I of the register.

In witness whereof are herewith affixed the  
seal of the Maharashtra Medical Council, Bombay  
and the signature of the Registrar.

Dated the 4TH MAY 1984.



True Copy  
Attested

*Dr. Rajiv Singh M.D.*  
Prof. & Head of Physiology,  
M.G.I.M.S. L. Vastam-442102

*Grnel S.A.*  
Registrar.



# Nagpur University



आयुर्विज्ञान पारंगत (शरीर)  
[Doctor of Medicine]  
(Physiology)  
-\*\*-

*This is to certify that*

*Shri Ajay Rajeshwar Chandhari*  
having been found to be duly qualified in  
the written examination, clinical, practical  
and viva-voce examinations and on  
examination of the thesis on: "The study  
of some physical and biochemical characteristics  
of semen in normal and infertile men"  
was admitted to the degree of आयुर्विज्ञान पारंगत  
(शरीर) (Doctor of Medicine in Physiology) in  
this University in the Examination held  
in November, 1987.

Nagpur :  
9th November, 1990

  
Vice-Chancellor



# MEDICAL COUNCIL OF INDIA

POCKET-14, SECTOR-8, DWARKA, NEW DELHI-110075

Certificate of Registration of Additional Qualification(s) u/s 26 of the  
Indian Medical Council Act, 1956

Date 22.06.2006

No. 4476


I hereby certify that the following additional qualification(s) as shown in column 4 below has/have been entered  
in the Indian Medical Register.

Name	Qualification as entered in the Indian Medical Register	Regn. No. Date and State Medical Council with which registered.	Additional qualification entered in the Indian Medical Register	Address
1	2	3	4	5
CHAUDHARI, AJAY RAJESHWAR	M.B.B.S. (U. Nagpur) 1984.	52196 04.05.1984 Mah.	M.D.(Physiology), (U. Nagpur) 1987.	'Madhu-Gunjan', Plot No.-11, Dehankar Layout, Near Sai Nagar, Wardha - 442001.



A.R. Chaudhari



  
LT. COL (DR.) A.R.N. SIRCAR (RETD.)  
Medical Council of India

\* Only recognised qualification (i.e. Included in the schedules) are mentioned.





# महाराष्ट्र आरोग्य विज्ञान विद्यापीठ

MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

वणी रोड, म्हससुळ, नाशिक-४२२००४,

Vani Road, Mhasrul, Nashik-422 004,

Phone: 0253-2539191 / EPABX: 0253- 2539100-300 / Fax: 0253-2539195

E-mail : ugacademic@muhs.ac.in / Web : www.muhs.ac.in

Mahendra N. Kothavade

M.C.S.


Asst. Registrar

Phone: 0253 - 2539191

No MUHS/UG/E-1/1504/227572014

Date: 21/05/2014

To,  
The Dean,  
Mahatma Gandhi Institute of  
Medical Sciences,  
Post:- Sevagram,  
Wardha - 442 102



Sub: Approval to the appointment of teacher of your college

Ref.: Your letter no. C/Gen/240 dated 12/04/2014

Sir / Madam,

With reference to the above cited subject, regarding the proposal for approval to the appointment of teachers, I am to inform you that Hon'ble Vice-Chancellor is pleased to grant approval (UG) to the appointment of following teachers as indicated below as per the terms and conditions mentioned in University Direction 02/2012.


Sr. No.	Subject	Name of the Teachers	Designation	Status of Approval
1.	Gen. Medicine	Dr. Vishakha V. Jain	Associate Professor	The candidate is selected against SC category post, hence is approved as Associate Professor w.e.f. 06/02/2014 for one year only.
2.	Physiology	Dr. Ajay R. Chaudhari	Professor	w.e.f. 06/02/2014 & onwards.
3.	Microbiology	Dr. Nandkishor J. Bankar	Tutor	w.e.f. 06/02/2014 & onwards.
4.	Gen. Medicine	Dr. Jyoti Jain	Professor	w.e.f. 06/02/2014 & onwards.
5.	Paediatrics	Dr. Varsha H. Chauhan	Associate Professor	The candidate is selected against ST category post, hence is approved as Associate Professor w.e.f. 06/02/2014 for one year only.

Further, it is mandatory for the teachers approved by the University to comply according to Medical Council of India Notification No. MCI-12(2)/2009-Med.-22654 dated 21/07/2009 and MCI-12(2)/2009-Med.Misc./56925 dated 15/12/2009.

You are requested to handover a photo copy of letter to the concerned teachers.

Yours,

  
Asst. Registrar

Copy to: I/c PG (Academic) Section, MUHS, Nashik. 





महाराष्ट्र आरोग्य विज्ञान विद्यापीठ  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

वणी रोड, म्हसळ, नाशिक - ४२२ ००४  
Vani Road, Mhasrul, Nashik - 422 004

Phone: 0253-2539190-91 / EPABX: 0253-2539100 - 300 / Fax: 0253-2539195  
E-mail: academic@muhsnashik.com / Web: www.muhsnashik.com

Dr. S.H. Fugare

M.Sc., Ph.D.

Dy. Registrar


Phone: 0253 - 2539190

No. MUHS/ E-1/PG/ 1504/1904/2007

Date: 10/01/2007

To,

The Dean,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram,  
Wardha - 442 102.



Sub :- Recognition as Post-Graduate Teacher.  
Ref :- Your letter No:C/Gen/6724/dated 18/01/2007.

Sir / Madam,

With reference to the above cited subject & letters, I am directed to inform you that in view of the norms prescribed as per provision under the section 29 (2) (I) of the MUHS Act, 1998 Hon'ble Vice-Chancellor is pleased to grant recognition as Post-Graduate Teacher to the following teachers of your College for imparting instructions to the Post Graduate Degree & Diploma course(s) in the subject mentioned against their names.

Sr. No.	Name of the Teacher	Designation	Subject	With effect from
1	Dr. Indira V. Ingole	Asso. Prof.	Anatomy	18/01/2007
2	Dr. Pradeep S. Dhande	Professor	Anaesthesiology	18/01/2007
3	Dr. Sucheta S. Tidke	Reader	Anaesthesiology	18/01/2007
4	Dr. Sudha Jain	Asso. Prof.	Anaesthesiology	18/01/2007
5	Dr. Maryada V. Reddy	Professor	Biochemistry	18/01/2007
6	Dr. Neelam Garg	Lecturer	Biochemistry	18/01/2007
7	Dr. Satish Kumar	Lecturer	Biochemistry	18/01/2007
8	Dr Swarup B. Garg	Professor	Community Medicine	18/01/2007
9	Dr. Ashok M. Mehendale	Asso. Prof.	Community Medicine	18/01/2007
10	Dr Pradeep R. Deshmukh	Lecturer	Community Medicine	18/01/2007
11	Dr. Prakash S. Nagpure	Professor	E.N.T.	18/01/2007
12	Dr. Manish P. Puttevar	Reader	E.N.T.	18/01/2007

Regd.  
89  
1-check  
initials all are  
correct.  
copy to  
all concerned



13	Dr. Bipinchandra H. Tirpude	Professor	F.M.T.	18/01/2007
14	Dr. Dilip O. Gupta	Reader	Gen. Surgery	18/01/2007
15	Dr. Ulhas N. Jajoo	Professor	Gen. Medicine	18/01/2007
16	Dr. Shriprakash Kalantri	Reader	Gen. Medicine	18/01/2007
17	Dr. Deepak Kumar Mendiratta	Professor	Microbiology	18/01/2007
18	Dr. Vijayashri S. Deotale	Asso. Prof.	Microbiology	18/01/2007
19	Dr. Dipak C. Thamke	Asso. Prof.	Microbiology	18/01/2007
20	Dr. Shakuntala A. Chhabra	Professor	Obst. & Gynaec	18/01/2007
21	Dr. Swarnalata Samal	Professor	Obst. & Gynaec	18/01/2007
22	Dr. Poonam S. Varma	Reader	Obst. & Gynaec	18/01/2007
23	Dr. Sangeeta D. Daf	Lecturer	Obst. & Gynaec	18/01/2007
24	Dr. Ajay K. Shukla	Professor	Ophthalmology	18/01/2007
25	Dr. Smita Singh	Lecturer	Ophthalmology	18/01/2007
26	Dr. Kisan R. Patond	Professor	Orthopaedics	18/01/2007
27	Dr. Chandrashekhar M. Bhadole	Reader	Orthopaedics	18/01/2007
28	Dr. Barick D. Ratnakar	Lecturer	Orthopaedics	18/01/2007
29	Dr. Subodh S. Gupta	Lecturer	P.S.M.	18/01/2007
30	Dr. Satishchandra M. Sharma	Asso. Prof.	Pathology	18/01/2007
31	Dr. Nitin M. Gangane	Professor	Pathology	18/01/2007
32	Dr. Narayan S. Ingole	Reader	Pathology	18/01/2007
33	Dr. Anupama Gupta	Lecturer	Pathology	18/01/2007
34	Dr. Vitaladevani B. Shivkumar	Lecturer	Pathology	18/01/2007
35	Dr. Premendran John	Professor	Pharmacology	18/01/2007
36	Dr. Rajesh K. Gupta	Asso. Prof.	Pharmacology	18/01/2007
37	Dr. Sushil Kumar	Lecturer	Pharmacology	18/01/2007




38	Dr. Ranjana I. Brahmane	Lecturer	Pharmacology	18/01/2007
39	Dr. Ramji Singh	Professor	Physiology	18/01/2007
40	Dr. Ajay R. Chaudhari	Reader	Physiology	18/01/2007
41	Dr. Prakash B. Behere	Professor	Psychiatry	18/01/2007
42	Dr. Atul T. Tayade	Professor	Radio-diagnosis	18/01/2007
43	Dr. Virendra J. Vyas	Reader	Radiotherapy	18/01/2007
44	Dr. Sumit Kar	Reader	Skin & VD	18/01/2007

Kindly note that the recognition given by the University is valid till the above said teacher is on the same post & in services of the said Medical College or attains the age of superannuation which ever is earlier. You are requested to handover the copy of letter to the concerned teacher.

Thanking you,

Yours faithfully,

  
Dy. Registrar 9/14

Copy to: The concerned teacher.





महाराष्ट्र आरोग्य विज्ञान विद्यापीठ  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

वणी रोड, म्हसळ, नाशिक-४२२००४  
Vani Road, Mhasrul, Nashik-422004

Phone: 0253-2539196, Fax: 0253-2539197

E-mail: udc@muhs.ac.in / Web: www.muhs.ac.in


Vidya Thakare

Dy. Registrar

No. MUHS/UDC/Ph.D/E-1/ 53/ 2013

Date: 06/06/2013

To,  
The Dean/Principal  
Mahatma Gandhi Institute of Medical Sciences,  
Post- Sevagram,  
Wardha - 442 102



Subject : Recognition as a Ph.D. Guide

Reference: 1) Your Letter No 285/4235 dt.18/09/2012

2) Our letter No.MUHS/UDC/Ph.D/Medical/868/2012 dt. 06/10/2012

3) Your Letter No 338 dt.10/11/2012

4) BOR Meeting dated 07/03/2013

Sir/Madam,

With reference to the above cited subject, I am directed to inform you that in view of the norms prescribed as per the provision u/s 29 (2) of (i) of MUHS Act, 1998, Hon'ble Vice Chancellor is pleased to grant recognition as Ph.D Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order for guiding the Ph.D student in the subject mentioned against his/her/their name .

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D Guide
1.	Physiology	Dr. Ajay Rajeshwar Chaudhari	Professor	Approved w.e.f. 07/03/2013 as per clause 10 (c) (i) of Direction No. 8/2012 till the age of (70) years

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service of the said teaching college/institute/ or till attaining the age of superannuation, whichever happens earlier.

Dear

HO

to  
Step to Chaudhari

(P.T.O)



The above teacher is required to attend the Research Methodology Workshop conducted by Regional Centre, Pune of this University or any other centre authorised by the University.

You are requested to handover the copy of this letter to the concerned teacher for further necessary action.

Yours,

*S. Indya*

Dy. Registrar

*(Note: In case, at later stage, if it is found that the information furnished in the Ph.D recognition form by any Guide is incorrect, Ph.D Guide Recognition granted by the University will stand cancelled.)*

**Copy to:**

**Dr. Ajay Rajeshwar Chaudhari**  
Professor  
Dept of Physiology  
Mahatma Gandhi Institute of Medical Sciences,  
Post- Sevagram,  
Wardha - 442 102





सत्यमेव जयते

File No. EC/19/000199

Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

S

ESWARA

REDDY

(Dr. S. Eswara Reddy)

Drugs Controller General (I) &  
Central Licensing Authority

Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:41:40 +05'30'

#### Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licensing Authority  
Stamp  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
Date: 2019.08.09  
13:39:25 +05'30'







Reg. No. ECR/47/Inst/MH/2013/RR-19  
(Under New Drugs and Clinical Trials Rules, 2019)

**Mahatma Gandhi Institute of Medical Sciences**  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**





Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in) 05 Mar 2021 - 04 Mar 2024

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID. and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Rasoni University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Rasoni University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smita@mgims.ac.in">smita@mgims.ac.in</a>	Clinician	Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Senior Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jannalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Dean (Academics) & Professor, Faculty of Nursing

Date: 5<sup>th</sup> March 2021

  
Dr. Sushil Kumar Varma  
Member Secretary  
Institutional Ethics Committee  
Mahatma Gandhi Institute of Medical Sciences  
SEVAGRAM - 442102 Maharashtra, India

  
Dr. Ashok Pawade  
Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India



No. 25/471/2009-AWD  
Government of India  
Ministry of Fisheries, Animal Husbandry and Dairying  
Department of Animal Husbandry and Dairying  
O/o Committee for the purpose of Control and Supervision of Experiments on Animals  
\*\*\*\*\*

Krishi Bhawan, New Delhi - 110001  
Date: 10/07/2020

To  
Dr. Satish Kumar, Chairman IAEC,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram, Wardha (District) pin: 442102,  
Mobile: 9422144468  
E-mail: [satishkumar@mgims.ac.in](mailto:satishkumar@mgims.ac.in)

Subject: Revision of Institutional Animals Ethics Committee (IAEC) - regarding

Sir,  
Kindly refer to your application on the above subject. CPCSEA hereby accords approval to your request for revision of IAEC.

2. Accordingly, the revised IAEC is as under:

S.No.	Name of IAEC Members	Designation in IAEC
1	Dr. Vijayshri Deotale	Biological Scientist
2	Dr. Vinod Shende	Scientist from different biological discipline, Member Secretary
3	Dr. Sushil Kumar Varma	Scientist from different biological discipline
4	Dr. Satish Kumar	Scientist In charge of Animal House Facility, Chairperson
5	Dr. Sandip Joge	Veterinarian
6	Dr. Kailash Marwah	Main Nominee
7	Mr. Jugalkishor V. Vyas	Link Nominee
8	Dr. Mohan M. Sagdeo	Scientist from outside the Institute
9	Shri. Vijay V. Bansod	Socially Aware Nominee


3. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6), and Main Nominee, Scientist from outside the Institute and Socially aware nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, Link Nominee should be invited once in a year to update him/ her about the activities of IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

.....2



4. Further, you are advised that veterinarian should be available at the time of animal experiment in the animal house facility.
5. The above composition of IAEC is valid upto the renewed period of registration i.e. 14.09.2021.

Yours sincerely,



(Dr. S. K. Dutta)  
Member Secretary (CPCSEA)

Copy for information to Nominees of CPCSEA:

- 1 Dr. Kailash Marwah, Main Nominee
- 2 Mr. Jugalkishor V. Vyas, Link Nominee
- 3 Dr. Mohan M. Sagdeo, Scientist from outside the Institute
- 4 Shri. Vijay V. Bansod, Socially Aware Nominee




Page 807

Office of the Dean,  
M.C.I.S.H. of Medical Sciences,  
Savagran, Date: 31/10/2019

OFFICE ORDER

Dr. Rahul Narang, Professor, Department of Microbiology is given responsibility of  
Co-ordinator & Member Secretary, Research Society, MGIIMS, Savagran, in place of  
Dr. B. K. Mehra, w.e.f. 1<sup>st</sup> October 2019.

  
Dr. N. M. Gangan  
DEAN

Copy to:

- Secretary, KHS.
- Medical Superintendent KH.
- Dr. Rahul Narang, Professor, Department of Microbiology.
- Dr. B. K. Mehra, Member Secretary, Research Society.
- All HOD's.
- Dr. Anshu, Professor, Department of Pathology & Incharge, Documentation Committee.

Members

- Dr. M. R. Shende, Professor & Head, Department of Anatomy.
- Dr. Solish Kumar, Professor & Head, Department of Biochemistry.
- Dr. Vijaysini Deotale, Professor & Head, Department of Microbiology.
- Dr. A. M. Mehendale, Professor & Head, Department of Community Medicine.
- Dr. P. S. Nagpure, Professor & Head, ENT.
- Dr. Subodh Gupta, Professor, Department of Community Medicine.
- Dr. Manish Jain, Professor & Head, Department of Paediatrics.
- Mr. M. S. Bharambhe, Associate Professor, Statistics, Community Medicine.



CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



**Ph. D. Doctoral Committee Member List**

<b>Sr. No.</b>	<b>Course</b>	<b>Name of Subject Expert</b>	<b>Email ID of Subject Expert</b>	<b>Mobile No. of Subject Expert</b>
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	drshabaana@gmail.com	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	drshaileshnagpure@gmail.com	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	samarth21174@gmail.com	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	gargimudey@hotmail.com	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	anujab803@gmail.com anuja_bhalerao@yahoo.com	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	sanjay.zodpey@phfl.org	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (€), Mumbai 400012	anitachalak@rediffmail.com	9850620123



C/Gen/ 9978  
Office of the Dean,  
MGIMS, Sevagram  
Date: 15/02/2023

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



**FOR Ph.D COURSE(S) FOR A.Y. 2022 - 2023**

(Please submit separate report for each subject)

Date of Inspection : 

Faculty: ..... Medicine ..... Subject/Specialty: ..... Biochemistry. ....

**1. Name & Address of the College/Research Centre: -**

Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha -442001

Name of Head of the Department: - Dr. Satish Kumar.

Designation: Director Professor &amp; Head

**2. Department / Subject wise details of available PhD Guides: -  
(Attach Annexure "A")**

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed sixdays Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Satish Kumar	Director Professor & Head	15/05/1965	31/5/2029	3	Yes	MUHS/UDC/PhD/Me d/773/2011 dated 20.7.2011
2							
3							
4							
5							

**4. Details of available infrastructure for Research:**i) Adequate number of Computers with Internet facility is available? Yes / Noii) Adequate number of Books / Journals are available? Yes / No

iii) Any other specific thing available at the Department:

.....

.....

.....

**5. Details of Central Research Laboratory:**i) Available Area (in sq. ft) : **2355 Sq.ft.**ii) Is Drugs/Medicines/Chemicals etc. are available for research? Yes / Noiii) Is Adequate number of Instruments are available? Yes / Noiv) Is Records of Stock book available? Yes / No**6. Details of Central Animal House:**i) Available Area in sq. ft: **1175 sq.ft**ii) Functioning Central Animal House? Yes / No**7. Details of Institutional Ethical Committee: (Attach Annexure "B")**



i) Date of Composition: **Registered on 20/4/2013 under DCGI (As per available records, IEC started operating 2002 onwards) and last reregistered on 09/08/2019**

ii) Total Number of Members: **13**

iii) Number of meetings held in previous year: **11 (September 2020 - September 2021)**

iv) Whether Records of proceedings are maintained properly? **Yes / No**

v) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes / No**

**8. Details of Research Advisory Committee: (Attach Annexure "C")**

i) Date of Composition: .....

ii) Total number of Members: .....

iii) Number of meetings held in previous year: .....

iv) Whether records of proceedings are maintained properly? **Yes / No**

**9. Is Doctoral Committee constituted in the lines of RAC? **Yes / No****

i) If Yes, Date of Composition: **21-7-22**

ii) Total number of Members: **15**

iii) Name of External Subject Expert:.....

**10. Is Plagiarism detection software facility available? **Yes / No****

If Yes, Name of the Software:.....

**11. Is attendance of the Ph.D. Scholar maintained properly? **Yes / No****

**12. Whether Research Centre is registered under MPCB provisions? **Yes / No****

**13. Whether BMW facility is available? **Yes / No****

**14. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:**

.....  
 .....  
 .....

**DECLARATION BY LIC**

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research Centre. The overall observations of the Inspection Committee are as follows: -

.....  
 .....  
 .....

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	




## ANNEXURE -A

## List of Ph.D. Guides Available at Ph.D. Research Centre

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Satish Kumar	Director Professor & Head	15/05/1965	31/5/2029	3	Yes	MUHS/UDC/PhD/Med /773/2011 dated 20.7.2011



# Nagpur University



## Doctor of Medicine

(Biochemistry)

(Faculty of Medicine)

*This degree of Doctor of  
Medicine in Biochemistry is awarded  
to Satishkumar  
having been found to be duly qualified in the  
written examination, clinical, practical and  
viva-voce examinations and on examination of the  
thesis in this University in the Examination held  
in Summer 1994*

Nagpur  
February 6, 1996

  
Vice-Chancellor





# महाराष्ट्र आरोग्य विज्ञान विद्यापीठ MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

वणी रोड, म्हसळ, नाशिक-४२२००४  
Yani Road, Mhasrul, Nashik-422004

Dr. A.N.Suryakar  
Ph.D., FACBI  
Registrar

Phone: 0253-2531837/EPABX:0253-2539100-300/Fax:0253-2539295  
E-mail: registrar@muhsnashik.com / Web: www.muhsnashik.com  
Ph. No. : 0253-2539292

MUHS /UDC/ Ph.D/Med./ 773 /2011

Date: 20/07/2011

To  
Dr. Satish Kumar  
Professor  
Dept. of Biochemistry  
Mahatma Gandhi Institute of Medical Sciences,  
Post Sevagram,  
Dist. Wardha – 442 102.



Sub: -Recognition as a Ph.D. Guide.  
Ref:- MGIMS, Sevagram, Wardha Letter No. C/Gen/823  
dated: 07/05/2011.

Sir/Madam,

With reference to your application for Recognition as a Ph.D Guide of this University, I am directed to inform you that on the recommendations of the Board of Research, Hon'ble Vice-Chancellor is pleased to grant you Recognition as a Ph.D Guide of this University in the Subject of Medical Biochemistry (Faculty of Medicine) with effect from 22/06/2011 till attaining the age of 70 years.

Kindly note that the recognition granted to you will always be subject to the terms and conditions prescribed by the University from time to time.

Thanking you,

*Dear*

Yours,  
*Suryakar*  
Registrar  
*copy to Dr. Satish Kumar  
& HOD Biochem.*

Copy to :-  
The Dean/Principal  
Mahatma Gandhi Institute of Medical Sciences,  
Post Sevagram,  
Dist. Wardha – 442 102.

for information please





Mahatma Gandhi Institute of Medical Sciences  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**

Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in) 05 Mar 2021 - 04 Mar 2024

Reg. No. ECR/47/Inst/MH/2013/IR-19 (Under New  
Drugs and Clinical Trials Rules, 2019)



EC-CT-2021-0168

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID. and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raison University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678, 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Raison University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smita@mgims.ac.in">smita@mgims.ac.in</a>	Clinician	Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Senior Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jamnalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Dean (Academics) & Professor, Faculty of Nursing

Date: 5<sup>th</sup> March 2021

Dr. Sushil Kumar Varma  
Member Secretary  
Institutional Ethics Committee  
Mahatma Gandhi Institute of Medical Sciences  
SEVAGRAM, Dist. Solapur-442102 Maharashtra, India

Dr. Ashok Pawade

Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India





File No. EC/19/000199  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

**S**  
**ESWARA**  
**REDDY**  
(Dr. S. Eswara Reddy)  
Drugs Controller General (I) &  
Central Licensing Authority

Digitally signed  
by S.ESWARA  
REDDY  
Date: 2019.08.09  
13:41:40 +05'30'

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licensing Authority  
Stamp  
REDDY  
Digitally signed  
by S ESWARA  
Date: 2019.08.09  
13:39:25 +05'30'



CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



**FOR Ph.D COURSE(S) FOR A.Y. 2023-2024**

(Please submit separate report for each subject)

<b>Date of Inspection</b>	<b>:</b>	
---------------------------	----------	--

Faculty: Medical

Subject/Specialty: Pharmacology.

1. **Name & Address of the College/Research Centre: -**  
MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRRAM

Name of Head of the Department: - Dr. Sushil Kumar Varma

Designation: Dir. Prof. &amp; Head

2. **Department / Subject wise details of available PhD Guides: -**  
(Attach Annexure "A")

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Sushil Kumar Varma	Prof. & Head	15.09.59	30.09.2024	3		MUHS/UDC/ Ph.D/Med/472/2012 Dt. 07.06.12
2	Dr. Devesh D. Gosavi	Professor	07.02.73	28.02.2037	0		MUHS/UDC(Ph.D.)/G uide/422/2021 dt. 31/12/21
3	Dr. Ranjana S. Kale	Professor	23.09.71	30.09.2035	1		MUHS/UDC(Ph.D.)/G uide/422/2021 dt. 31/12/21

4. **Details of available infrastructure for Research:**

i) Adequate number of Computers with Internet facility is available?

Yes / No

ii) Adequate number of Books / Journals are available ?

Yes / No

iii) Any other specific thing available at the Department:.....

.....  
 .....  
 .....

5. **Details of Central Research Laboratory:**

i) Available Area (in sq. ft) : 3230 Sq.Ft. .

ii) Is Drugs/Medicines/Chemicals etc. are available for research?

Yes / No

iii) Is Adequate number of Instruments are available?

Yes / No

iv) Is Records of Stock book available?

Yes / No

6. **Details of Central Animal House:**

i) Available Area in sq. ft: 1175 Sq.Ft.

ii) Functioning Central Animal House? Yes / No

7. **Details of Institutional Ethical Committee: (Attach Annexure "B")**

i) Date of Composition: **As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration**



No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022) - Copies enclosed . . . .

- ii) Total Number of Members: **13 (copy enclosed)**.
- iii) Number of meetings held in previous year: **05 (October 2021 - October 2022)**
- iv) Whether Records of proceedings are maintained properly? **Yes / No**
- v) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes / No**

**8. Details of Research Advisory Committee: (Attach Annexure "C")**

- i) Date of Composition: **12/07/2013**
- ii) Total number of Members: **8**
- iii) Number of meetings held in previous year: **02(2021-22)**
- iv) Whether records of proceedings are maintained properly? **Yes / No**

**9. Is Doctoral Committee constituted in the lines of RAC?**

**Yes / No**

- i) If Yes, Date of Composition: **21/07/2022** .
- ii) Total number of Members: **15**
- iii) Name of External Subject Expert **Dr. Shailesh kumar Nagpure**

**10. Is Plagiarism detection software facility available?**

**Yes / No**

If Yes, Name of the Software **ORIGINAL Antiplagiarism Software**

**11. Is attendance of the Ph.D. Scholar maintained properly?**

**Yes / No**

**12. Whether Research Centre is registered under MPCB provisions?**

**Yes / No**

**13. Whether BMW facility is available?**

**Yes / No**

**14. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:**

.....  
.....  
.....

**DECLARATION BY LIC**

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows: -

.....  
.....  
.....

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	





डॉ. सुनिल ह. फुगारे  
 एमएससी. पीएच.डी.  
 उपकुलसचिव

Dr. Sunil H. Fugare  
 MSc, Ph.D.  
 Deputy Registrar

O. No. MUHS/UDC/Ph.D./E-1/76/2022

Date: 25/05/2022

By Email / Speed Post

To,  
 The Dean / Principal,  
 Mahatma Gandhi Institute of Medical Sciences,  
 Sewagram, Wardha - 442 102.  
 Email - dean@mgims.ac.in

129  
 23/7/22

435647

- Sub: Continuation of Recognition as Ph.D. Research Centre for Academic Year 2021-22.  
 Ref: 1) University Direction No. 01/2020.  
 2) Research Centre Proposal Dt. 26/11/2020.  
 3) Academic Council Resolution No. 17/2022, dt. 22/04/2022.

Sir/Madam,

As per the provisions u/s 35 of University Direction No. 01/2020 and on the basis of the Academic Council resolution No. 17/2022, dated 22/04/2022, I am directed to inform you that, the Hon'ble Vice Chancellor is pleased to grant Continuation of Recognition to your College / Institute as a Ph.D. Research Centre for Academic Year 2021-22 in following Departments / Subjects under the Faculty of Medicine as per details given below:-

Sr. No.	Name of the College/Institute	Name of the Department/Subjects	Academic Year
1	Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha.	1) Anatomy 2) Biochemistry 3) Physiology 4) Pathology 5) Pharmacology 6) Microbiology 7) Obstetrics & Gynecology 8) Community Medicine 9) Orthopedics 10) Genetics	2021-22

Kindly note that, for the process of Continuation of Recognition as a Ph.D. research Centre, the College / Institute shall have to follow University Direction No. 01/2020 and it is mandatory to apply to the University in prescribed format along with fees for continuation of Ph.D. research Centre, every year before 31<sup>st</sup> October.

This is for your kind information and necessary action.

Ph.D.


*(Handwritten signatures)*

*(Handwritten signature)*  
 Dy. Registrar 24/5  
 University Department Cell  
 (Ph.D.)

*(Handwritten mark)*

*(Handwritten note)*  
 In copy 2022





महाराष्ट्र आरोग्य विज्ञान विद्यापीठ  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

दिंडोरी रोड, म्हासुल, नाशिक, Dindori Road, Mhasul, Nashik-422004

Tel : (0253) 2539292, Fax : (0253) 2539295

Website : www.muhsnashik.com, E-mail : registrar@muhsnashik.com

डा. आदिनाथ सुर्यकर  
महा. वि. , म्हासुल, नाशिक  
कुलसचिव


Dr. Adinath Suryakar  
Ph.D., FACBI  
Registrar

No.MUHS/AUC/ Ph.D /Med/ 4702 /2012

Date: 07/06/2012

To

Dr. Sushil Kumar  
Prof. & Head, Dept. of Pharmacology  
Mahatma Gandhi Institute of  
Medical Sciences,  
Post Seavagram  
Dist. Wardha - 442 102.



Sub: - Recognition as a Ph.D. Guide.

Ref:- Your Letter No. 3123 dtd. 02/05/2012.

Sir/Madam,

With reference to your application for Recognition as a Ph.D Guide of this University, I am directed to inform you that on the recommendations of the Board of Research, Hon'ble Vice-Chancellor is pleased to grant you Recognition as a Ph. D Guide of this University in the Subject of Pharmacology (Faculty of Medicine) with effect from 16/05/2012 till attaining the age of 70 years.

Kindly note that the recognition granted to you will always be subject to the terms and conditions prescribed by the University from time to time.

Thanking you,

Yours,

*Dr. Adinath Suryakar*

Registrar

Copy to:-

The Dean/Principal  
Mahatma Gandhi Institute of  
Medical Sciences,  
Post Seavagram  
Dist. Wardha - 442 102.

For information please

*16*  
*16*  
*16*





MUHS

महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK

दिंडोरी रोड, म्हस्रुळ, नाशिक-४२२००४ Dindori Road, Mhasrul, Nashik-422004

Phone : 0253 - 2539196/206, 0253 - 6659196/206

Email: udc@muhs.ac.in Website: www.muhs.ac.in

डॉ. सुनिल ह. फुगारे  
एमएस्सी. पीएच.डी.  
उपकुलसचिव

Dr. Sunil H. Fugare  
MSc.Ph.D.

Deputy Registrar

O.No.MUHS/UDC(Ph.D.)/Guide /422/2021

Date : 31/12/2021

By Email

To,  
The Dean / Principal,  
Mahatma Gandhi Institute Of  
Medical Sciences,  
Sevagram, Wardha- 442 102.  
Email – dean@mgims.ac.in

**Subject** : Recognition as Ph.D. Guide (Suo-Motto) ...  
**Reference** : 1) Your Proposal dated - 17/12/2020  
2) Ph.D. Direction No. 01/2020  
3) Board of Research Resolution No. 13/2020, dated - 19/10/2020.  
4) Academic Council Resolution No. 77/2021, dated 28/07/2021.


Sir/Madam,

With reference to the above cited subject, I am directed to inform you that Academic Council in its meeting has Passed the Resolution No. 77/2021, dated 28/07/2021 to grant recognition as Ph.D. Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order, for guiding the Ph.D. student in the subject mentioned against his/her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D. Guide
1	Pharmacology	Dr. Rajana S. Kale	Professor	Approved w.e.f. 28/07/2021, onwards
2	Pharmacology	Dr. Devesh D. Gosavi	Professor	Approved w.e.f. 28/07/2021, onwards

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service or till attaining the age of superannuation whichever happens earlier.

You are requested to handover the copy of this letter to the concerned teacher for further necessary action

Yours,  
  
Dy. Registrar  
University Dept. Cell  
(Ph. D.)





महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक  
Maharashtra University of Health Sciences, Nashik

वणी - दिंडोरी रोड, म्हासळ, नाशिक - ४२२००४, Vani-Dindori Road, Mhasrul, Nashik- 422 004

EPABX: 0253-2539100-300, Fax - 0253-2539200, Phone: 0253-2539205  
E-mail : pgacademic@muhsnashik.com Web.: www.muhs.ac.in

डॉ. सुनिल एच. फुगारे  
एम.एससी., पीएच.डी.  
शैक्षणिक विभागप्रमुख (पदव्युत्तर)

Dr. Sunil H. Fugare  
M. Sc., Ph. D.  
I/c, Academic Section (PG)

No. MUHS/PG/E-1/1504/25/12

Date: 02/11/2012

To,  
The Dean / Principal,  
Mahatma Gandhi Institute of  
Medical Sciences, Sevagram,  
Wardha - 442 102



Sub :- Change of designation of Recognised PG Teachers.

Ref :- 1) Your letter no. i) C/Gen/2269 dated 04/07/2012.

ii) C/Gen/5238 dated 25/10/2012.

2) University Letter No. i) MUHS/E-1/PG/1504/1904/2007 dated 10/04/2007.

ii) MUHS/UG/E-1/057569/5369/2011 dated 21/12/2011

Sir / Madam,

With reference to the above cited subject & letter, I am to inform you that the University is in receipt of the information regarding changes in the Post held by the following recognized Post Graduate teacher.

Sr. No.	Subject	Name of the Teacher	Designation	Status of PG recognition
1	Pharmacology	Dr. Sushil Kumar Verma	Asso. Professor	w.e.f.07/09/2011 & Onwards

It is further informed that University has amended the designation of above mentioned teachers in the record.

This for your information only.

Yours faithfully,

I/C Academic Section (PG)

By  
Dean

A.O.

Dr. Sushil Kumar





## महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक

MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES

दिंडोरी रोड, म्हसळ, नाशिक - ४२२००४ Dindori Road, Mhasrul, Nashik - 422004

Tel : (0253) 2539190 Phone: 0253-2539234,191

Website : www.muhs.ac.in, E-mail : academic1@muhs.ac.in

डॉ. उदयसिंह रावराणे  
[एम.डी.(आयु.)]  
उपकुलसचिव

Dr. Udaysinh Raorane  
[M.D.(Ayurved)]  
Dy. Registrar

No. MUHS/PG/E-1/1504/27/ 378/18

By e-mail

Date : 27/01/2018

To,  
The Dean / Principal,  
Mahatma Gandhi Institute of  
Medical Sciences, Sevagram,  
Wardha - 442 102.

Sub :- Regarding Change in Designation of Post graduate Teacher.

Ref :- 1. Your Letter No. i) C/Gen/6605 Dated 27/12/2017.

ii) C/Gen/6591 Dated 23/12/2017.

2. University Letter No. i) MUHS/UG/E-1/1504/1721/2010 Dated 19/05/2010;  
ii) MUHS/UG/E-1/1504/2275/2014 Dated 21/05/2014;  
iii) MUHS/UG/E-1/53/1504/3684/2017 Dated 02/11/2017  
iv) MUHS/UG/E-1/1504/1603/2014 Dated 29/03/2014;  
v) MUHS /E-1/UG /1504/140/2007 Dated 11/01/2007;  
vi) MUHS/UG/E-1/057569/5369/2011 Dated 27/12/2011;  
vii) MUHS /UG/E-1/1504/1721/2010 Dated 19/05/2010;  
viii) MUHS /UG/E-1/1504/1403/2009 Dated 26/05/2009;  
ix) MUHS/UG/E-1/1504/3294/2009 Dated 30/11/2009.

Sir / Madam,

With reference to the above cited subject, I am to state that recognition granted as PG Teacher by MUHS to any teacher working at affiliated Medical College remains valid till the concerned teacher remains in continues services of such Medical College / attains age of Superannuation / resigned/removed from service from the said college whichever is earlier. Provided that such teacher must have Approval as UG Teacher for the present designation.

On perusal of above referred letter, it is informed that the change of new designation with date UG Teacher's approval for the same in respect of following Teachers recorded at the University.

Sr. No.	Subject	Name of the Teacher	Designation	Status of PG recognition
01	Anatomy	Dr. Aaditya M. Tarnekar	Asso. Professor	w.e.f. 03/02/2010 & onwards
02	Physiology	Dr. Ajay R. Chaudhari	Professor	w.e.f. 06/02/2014 & onwards
03	Physiology	Dr. Sachin M. Pawar	Asso. Professor	w.e.f. 01/09/2017 & onwards
04	Pathology	Dr. Anupama Gupta	Asso. Professor	w.e.f. 06/02/2014 & onwards
05	Pathology	Dr. Vitaladevani B. Shivkumar	Asso. Professor	w.e.f. 08/10/2006 & onwards
06	Pathology	Dr. Anshu	Asso. Professor	w.e.f. 02/09/2017 & onwards
07	Microbiology	Dr. Vijayashri S. Deotale	Professor	w.e.f. 01/09/2017 & onwards
08	Pharmacology	Dr. Devesh D. Gosavi	Asso. Professor	w.e.f. 06/02/2014 & onwards
09	Pharmacology	Dr. Benigno S. Kela (Nep)	Asso. Professor	w.e.f. 07/02/2014 & onwards





महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES,  
NASHIK

दिंडोरी रोड, म्हासळ, नाशिक - ४२२००४ Dindori Road, Mhasrul, Nashik - 422004  
Tel : (0253) 2539191/2539291 Student Helpline : 0253-2539111/6659111  
Website: www.muhs.ac.in, E-mail: academi1@muhs.ac.in



डॉ. कलिदास द. चव्हाण

एम.बी.बी.एस., एम.डी. (न्यायवैद्यनशास्त्र), पीएच.डी., डी.एससी.

कुलसचिव

No. MUHS/PG/E-1/1504/27/1040/2022

Dr. Kalidas D. Chavan

M.B.B.S., M.D. (Forensic Medicine), Ph.D., D.Sc.

Registrar

Date: 27/04/2022

To,  
The Dean / Principal,  
Mahatma Gandhi Institute of  
Medical Sciences, Sevagram,  
Wardha - 442 102.



73  
3/5/2022

Sub:- Recognition as Post-Graduate Teacher.

Ref :- 1) University Direction No. 01/2017 Dated 13/04/2017.

2) College Letter No. C/Gen/MUHS/3274 dated 14/09/2020

3) University Letter No. मआवि/शै.वि./ई.१/पदवी व पदव्युत्तर/२५४७/२०२०  
दिनांक २२/१२/२०२०

4) E-mail dated 15/04/2022 of Dr. Mohan Pethe

Sir / Madam,

With reference cited above, I am directed to inform you that, the proposal of Recognition as Post-Graduate Teacher of the following teacher(s) has been considered by the University subject to terms and conditions of appointment order for imparting instructions to the Post Graduate Degree, Diploma or Super-Speciality Course(s) (as applicable) in the subject mentioned against his /her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of PG recognition
01	Pharmacology	Dr. Mohan Pethe	Assistant Professor	w.e.f. 14/09/2020 & onwards

Dean

Registrar

Copy to : i) Concern Teacher  
ii) The Controller of Examinations, MUHS

AO

Dr. Mohan Pethe  
&  
HOD

Note :- The above letter is issued subject to fulfillment of all other conditions laid down in Medical Council of India, New Delhi., Regulation of "Minimum Qualification of Teachers in Medical Institution Regulation 1998".





## महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक

Maharashtra University of Health Sciences, Nashik

(An ISO 9001:2008 Certified University)

वणी - दिंडोरी रोड, म्हसरुळ, नाशिक - ४२२००४, Vani-Dindori Road, Mhasrul, Nashik- 422 004

EPABX: 0253-2539100-300, Fax - 0253-2539200, Phone: 0253-2539235

E-mail : [pgacademic@muhs.ac.in](mailto:pgacademic@muhs.ac.in) Web.: [www.muhs.ac.in](http://www.muhs.ac.in)

राजेंद्र चं. शहाणे  
शैक्षणिक विभागप्रमुख (पदव्युत्तर)

Rajendra C. Shahane  
I/c, Academic Section (PG)

No. MUHS/PG/E-1/1504/27/ 670116

Date : 10/03/2016

To,  
The Dean / Principal,  
Mahatma Gandhi Institute of  
Medical Sciences, Sevagram,  
Wardha - 442 102

10000  
11/3/16

Sub :- Recognition as Post-Graduate Teacher.

Ref :- 1) Your Letter No. I) C/Gen/PGT/2197 Dated 02/07/2015;

ii) C/Gen/PGT/10014 Dated 01/03/2016.

2) Postgraduate Teacher Recognition Committee meeting dated 13/07/2015.


Sir / Madam,

With reference to the above cited subject, I am directed to inform you that in view of the norms prescribed as per provision under the section 29(2)(I) of the MUHS Act, 1998 Hon'ble Vice-Chancellor is pleased to grant recognition as Post-Graduate Teacher to the following teacher(s) of your Institute/College subject to the terms and conditions of appointment order for imparting instructions to the Post Graduate Degree, Diploma or Super-Specialty Course(s) (as applicable) in the subject mentioned against his/ her/ their name.


Sr. No.	Subject	Name of the Teacher	Designation	Status of PG recognition
1	Pharmacology	Dr. Leena V. Chimurkar	Asst. Professor	w.e.f 01/03/2016 & onwards.


Kindly note that the recognition granted by the University is valid till the above said teacher is in the services of said Medical College/ PG teaching Institute or attains the age of superannuation, whichever happens earlier.

You are requested to handover the copy of letter to the concerned teacher(s) for further necessary action.

  
Dean  
11-3-16

Org - Ao  
Copy - to concerned teacher  
through HOD

  
15/03/16

Yours,  
  
I/C Academic Section (PG)



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM.**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS.**

Sr. No.	Acc.No.	Name of the Books	Author
1	12287	Pharmacological basic of therapeutics 8 <sup>th</sup> edition	Goodman and Gilman
2	10867	The pharm. Basis of therapeutics 7 <sup>th</sup> Edition 1985	Goodman and Gilman
3	9989	Lewis Pharmacology fifth Edition 1980	James Crosland
4	7181	Review of medical pharmacology fifth edition 1976	Frederick Mayers Ernest Jawetz
5	2013	Drills Pharmacology in medicine 3 <sup>rd</sup> Edition 1965	Edited by JHoseph R. Dipalma
6	7613	Pharmacologic principles of medical practice e8th edition 1972	Domingo M. Aviadós
7	7621	Clinical pharmacology 4 <sup>th</sup> edition 1973	D. R. Laurence
8	2767	Pharmacology and pharmaco-therapeutics Sixth Edition 1970	J. C. David, V. Iswariah
9	6233	Pharmacology and therapeutics 7 <sup>th</sup> edition 1970	Arthur Grollman and evelyn
10	3511	Essentials of pharmacology 1969	Edited by John A. Bevan
11	7526	Applied pharmacology 1976	Walter model, Heinz O. Schild
12	231	Pharmacology, Materia medica and therapeutics 19 <sup>th</sup> edition 1952	Birendranath Ghosh
13	3273	Text book of medical treatment 12 <sup>th</sup> edition 1971	Stanley Alstead, Alastair G.
14	1442	Text book of pharmacology, 3 <sup>rd</sup> printing 1970	W.C. Bowman, M. J. Rand
15	4522	General principles of Drug action 1967	Dr. B. D. Gaitonde
16	1661	Clinical Pharmacology section 6, Vol. II 1966 (International Encyclopedia of pharmacology of therapeutics.	Edited by L. Lasagna
17	1772	Gaddum's pharmacology 6 <sup>th</sup> edition	revised by A.S.V.Burgen and J.F.Mitchell.
18	10182	Text book of Medical physiology 6th edition illustrated 1981	Arthur C. Guyton
19	8425	Text book of medicine 15th edition 1979	Edited by Paul B. Beeson
20	2866	Toxicology, mechanism and Analytical methods Vol. I 1960	Edited by C.P. Stewart
21	4516	Drugs in Anaesthetics practice, 3 <sup>rd</sup> edition 1968	F. G. Wood smith H.C. Stewart
22	3274	Remington's Pharmaceutical sciences, 4 <sup>th</sup> edition 1070	Managing edition John F. Hover.
23	10399	Indian Pharmaceutical Guide 1984	Editor Mohan C. Bazaz
24	1768	Text book of pharmaceutical chemistry 7 <sup>th</sup> edition 1960	T. F. Walls.
25	5866	Textbook of pharmacognosy 5 <sup>th</sup> edition 1967	T. F. Walls.
26	1556	British pharmacopoeia 1968	Published by General Medical Council.
27	1557	Addendum 1969 to the British Pharmacopoeia 1968	General medical council.
28	5852	Manual for pharmacy technician 1972	Sister Jane M. Durgin, Charles O.
29	1567	Tutorials in pharmacology 1970 2 <sup>nd</sup> edition	B. B. Gaitonde and A. S. Manivadekar
30	1658	The control of chemotherapy 1970	Edited by P.K. watt.
31	6606	Drugs useful vs. Infectious Diseases 1974	Edited by F. Gilpert memoham. Ass. Editir
32	3829	Drug Interactions 1971	Philip D. Hansten
33	6260	Pharmacology and Pharmacokinetics 1972	Edited by Torsten Teorell
34	11327	Drug Treatment(Principles and practice of clinical pharmacology & therapeutics)3 <sup>rd</sup> edition 1987	Edited by Greme S. Avery
35	3256	Pharmacological Experiments on isolated preparations 1970 2 <sup>nd</sup> edition	By the staff of Dept.m of Pharmacology Edinburgh E & S Livingstone.
36	2979	Pharmacological experiments on intact preparations 1970	By the staff of the Dept. of Pharmacology University of Edinburgh E & s Livingstone.



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM.**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS.**

Sr. No.	Acc.No.	Name of the Books	Author
37	3021	Statistical methods in Biological Assay second edition 1964	D. J. Finney
38	6641	Evaluation of Gastrointestinal, pulmonary, Anti-inflammatory and Immunological agents 1975	Edited by F. GILBERT MEMOHAN, h. HUGH
39	2921	Experimental Pharmacogenetics 1963	Hans Meier
40	1897	The RAT in laboratory investigation 1967	By a staff of 29 contributors Edited by Edmond J. Farris & John Q. Griffith
41	2938	Screening methods in Pharmacology Vol II 1971	Edited by Robert A. Turner
42	2922	Screening methods in pharmacology 1965	Robert A. Turner
43	2923	Evaluation of Drug Activities Pharmacometrics Vol. I 1964	Edited by D.R. Laurence
44	1784	Evaluation of Drug Activities-Pharmacometrics	Edited by D. R. Laurenc
45	1664	First international pharmacological meeting mode of action od drugs Vol. (I) 1962	Gen. editor, Borje Uvnas Edited by Rugaer Gullemin.
46	1665	First international pharmacological meeting vol(2)1963 Effects of drugs on synthesis and mobilization of lipids.	Edited by E.C.Horning Percy Lindgren
47	1666	First international meeting pharmacological vol(3)1963 New aspect of cardiac glycosides	Edited by W.Wilbrandt and Percy Lindren.
48	1667	First International pharmacology meeting Vol.(4) 1963 "Drug and Membranes"	Edited by C. Adrian M. Hogben & percy lindgren.
49	1668	First International pharmacological meetings Vol.(5) 1963	Edited by Oliver H. Lowry
50	1669	First International Pharmacological meeting Vol.(6) 1962	Edited by Bernard B. Bradie
51	1670	First International pharmacological meeting Vol.(7) 1963	Edited by Karl J. Brunings
52	1671	First International pharmacological meeting vol.(8)1962	Edited by W.D.M.Paton.
53	1672	First International pharmacological meeting vol.(9)1963	Edited by M. Rocha E. Silva
54	1673	First International pharmacological meeting vol.(10)1963	Edited by Percy Lindgren
55	2859	Oral Hypoglycaemic agents, pharmacology and therapeutics 1969	G. D. Campbell
56	2861	Advances in Drug Research Vol. 2 1965	Edited by H. J. Harper
57	2860	Advances in Drug Research Vol. 1 1964	Edited by H. R. Harper
58	1905	Androgens and anabolic agents and pharmacology 1969	Julius A. Vida
59	2863	Advances in Drug Research Vol. 4 1967	Edited by H. J. Harper
60	4933	Advances in Drug Research Vol. 5 1970	Edited by H. J. Harper
61	2862	Advances in Drug Research Vol. 3 1966	Edited by H. J. Harper
62	3020	Prostaglandins(Med. chemistry) 1967	U. S. Von Euler
63	1971	Psychopharmacological agents Vol. I 1964	Edited by Maxwell Gordon
64	2925	Analgetics 1965 (Med. Chem.)	Edited by George de Stevens.
65	1747	Diuretics chemistry and Pharmacology 1963	George De Stevens
66	2926	Antihypertensive agents(Med. Chem.) 1967	Edited by Emil Schlittler
67	2919	Molecular Pharmacology.The mode of action Vol. I 1964	Edited by E. J. Ariens
68	2920	Molecular Pharmacology.The mode of action Vol.II 1964	Edited by E. J. Ariens.
69	5850	Ocular Pharmacology second edition 1970	William H. Havener.
70	4777	Cardiovascular therapy "The art of science"1971	Edited by Henry I. Russek



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS .**

Sr. No.		Name of the books	Authors
71	5129	Modern Drug Encyclopedia and therapeutic index 12th edition 1973	Edited by Arthur J. Lewis & Gertrude
72	6232	Smooth muscle 1970	Edited by Edith Bulbring,
73	5815	Trace element metabolism in Animals 1970	Edited by C. F. Mills
74	1775	Cell physiology and pharmacology 1968	James Frederic Danielli
75	2954	Scientific Basis of Drug Dependence 1969	Edited by Hannah Steinberg
76	1836	Immunity, cancer and chemotherapy	Edited by Enrico Mihich
77	1657	Fundamental concepts in Drug –receptor 1970	Edited by J.F. Danielli
78	5566	Relief of Symptoms second edition 1961	Walter model.
79	1904	Calcium and cellular function (a symposium) 1970	Edited by A. W. Cuthbert
80	3215	The Pharmacology of Synapses Vol. 43 1st edition.1970	J. W. Phillis
81	5817	Adverse Drug Reactions their prediction – 1972	Edited by D. J. Richards
82	4799	Therapeutic evaluation of Hypnotics – 1971	W. G.Zelvelder
83	6660	Amphetamines and related drugs – 1974	Oriana Jossean Kalant
84	4797	Recent Hypoglycemic Sulfonyl –ureas – 1971	Edited by U.C. Dubach
85	1776	Advances in Pharmacology Vol. I (1962)	Edited by Silvio Garahini
86	1777	Advances in pharmacology Vol. 2(1963)	Edited by Silvio Garahini
87	1778	Advances in Pharmacology Vol. 3 (1964)	Edited by Silvio Garahini
88	1779	Advances in Pharmacology Vol. 4(1966)	Edited by Silvio Garahini
89	1780	Advances in Pharmacology Vol. 5 (1967)	Edited by Silvio Garahhini
90	1674	Advances in Pharmacology Vol. 6(A) 1968	Edited by Silvio Garattini
91	1675	Advances in Pharmacology Vol. 6(B) 1968	Edited by Silvio Garattini
92	4932	Advances in Pharmacology Vol. 7	Edited by Silvio Garattini
93	7570	Advances in Pharmacology Vol. 8, 1970	Edited by Silvio Garattini
94	7709	Advances in Pharmacology Vol. 9 (1971)	Edited by Silvio Garattini
95	7572	Advances in Pharmacology Vol. 10 (1972)	Edited by Silvio Garattini
96	7663	Advances in Pharmacology Vol. 11 (1973)	Edited by Silvio Garattini
97	7754	Advance in Pharmacology and chemotherapy Vol.12(1975)	Edited by Silvio Garattini, A. Goldin, F. Hawking
98	6856	The year book of Drug Therapy (1975)	Edited Dale G. Friend.
99	6855	The year book of Drug therapy (1976)	Edited by Dale G. Friend.
100	7050	The year book of Drug Therapy (1977)	Edited by Daniel, L. Azarnoff
101	7574	Physiological pharmacology “A compressive treatise” Vol. I (1963)	Edited by Walter S. Root and Frederige
102	7575	Physiological Pharmacology “A compressive treatis” Vol.II (1965)	Edited by Walter S. Root and Frederige
103	7576	Physiological Pharmacology “A compressive treatis” Vol.III (1967)	Edited by Walter S. Root and Frederige
104	7577	Physiological Pharmacology “A compressive treatis” Vol.IV (1967)	Edited by Walter S. Root and Frederige
105	7668	Physiological Pharmacology “A compressive treatis” Vol.V (1974)	Edited by Walter S and Nathariel J. Berlin
106	3262	Recent Advances in Pharmacology, 4th edition (1968)	J. M. Robson and R. S. Stacey
107	4934	Advances in Drug Research Vol. 6 (1971)	Edited by H. J. Harper and Alma B. Simmonds
108	6824	Advances in the drug therapy of mental illness (1976)	World Health organization Genevasponsord
109	10556	Pharmacology and pharmacotherapeutics 9th edition 1985	R. S. Satoskar and S. D. Bhandarkar.



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS .**

Sr. No.		Name of the books	Authors
110	10557	Pharmacology and pharmacotherapeutics II revised 9th edition 1985	R. S. Satoskar and S. D. Bhandarkar
111	11672	Modern pharmacology 2nd edition 1986	Edited by Charles R. Craig
112	11611	Basic and clinical pharmacology 3rd edition 1987	Edited by Bertram G.
113	12045	Clinical Pharmacology 6th edition (1987)	Laurance D. R.
114	12081	Fundamentals of Experimental pharmacology 2nd edition (1984)	Ghosh M. N.
115	11347	Pharmacology and pharmacotherapeutics Vol.(1) revised eleventh edition 1988	R. S. Satoskar
116	11350	Pharmacology and pharmacotherapeutics Vol.(2) revised 11th edition 1988.	R. S. Satoskar, S. D. Bhandarkar
117	12175	Essentials of medical pharmacology 2nd edition (Reprint 1989)	Dr. K.D. Tripathi
118	12161	Drug Interactions 5th edition (1985)	Phillip D. Hansten
119	12187	Question bank (Book Series phase II pharmacology 1981)	Association of Indian Universities.
120	12267	Chambers English Dictionary	Edited by Catherin Schwarz, Pandoraleem frost etc.
121	10112	Modern Pharmacology, 1st edition 1982	Edited by Charles craig, robberts E. stitzel.
122	1561	The Pharm, Basis of Therapeutics, 4th edition 1970	Edited by L. S. Goodman & Alfred Gillman.
123	12465	Principles of medicinal chemistry 3rd edition 1989	Edited by William O. Foye
124	12678	Discoveries in pharmacology Vol.3(1986) pharm methods etc.	Edited by M. J. Parnham & J. Bruinvels
125	12679	Ulcer disease : New aspects of Pathogenesis & Pharmacology (1989)	Editors Sandor Szabo and Carl J. Pfeiffer.
126	12925	Beotra's law of Drugs, medicines & cosmetics 4th edition 1992	Revised by K. K. Singh
127	12595	Modern pharmacology 3rd edition 1990	Edited by Charle's R. Craig
128	13199	Color chemistry, synthesis, properties & applications of organix IInd revised ed.1991	Heinrich Zollinger
129	12356	Human Pharmacology (Molecular to clinical )1991	Lemuel B. Wingard. Theodore M. Brody Joseph Iarnor
130	13347	Quantitative aspects of chemical pharmacology (1980)	R. B. Barlow
131	13342	Pharmacology IInd edition (1991)	H. P. Rang & M. M. Dale
132	12894	Medicinal plants of India Vol 2(ICMR) 1987	Edited by G.V. Satyavati
133	13426	Clinical Pharmacology seventh edition 1992	D. R. Laurance 13667
134	13667	Clinical epidemiology and biostatistics (1992)NMS	Rebecca G. Knapp & M. Clinton Miller.
135	13934	Modern Pharmacology fourth edition 1994	Cherle's R. Craig Robert E.
136	13914	Pharmacology 3rd edition NMS for Indep. Study (1992)	Leonard S. Jacob.
137	14128	Dorlana's illustrated Medical Dictionary 28th ed.	International edition W.B.
138	14150	Essentials of medical Pharmacology 3rd ed. 1994	K.D. Tripathi.
139	14094	Calcium-Antagonists in clinical medicine 1992	Murray Eppstein
140	14416	Essentials of medical pharmacology 3rd ed. 1994	K. D. Tripathi
141	14207	A review with questions and explanations pharmacology IInd edition 1993	Manuchair Ebadi.



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS .**

Sr. No.	Ac.No.	Name of the books	Authors
142	14293	Indian medicinal plants Vol. I 1994	Vaidyaratham ps VARIOR'S
143	14294	Indian medicinal plants Vol. II 1994	Vaidyaratham ps VARIOR'S
144	14367	Indian medicinal plants. Vol. III 1995( <b>Return to Central Library on 11.3.2003</b> )	Vaidyaratham ps VARIOR'S
145	14334	Paediatric pharmacology and therapeutics 2nd edition 1993	Ingeborg C. Radde stuart
146	14335	Neurotransmitters and drugs 3rd edition 1993	Zygmunt L. Kruk.
147	14375	Pharmacology & Pharmacotherapeutics Vol. I 14th edition	R. S. Satoskar, S.D. Bhandakar
148	14378	Pharmacology and pharmacotherapeutics Vol. II 14th edition	R. S. Satoskar, S.D. Bhandakar
149	14372	Drug evaluation annual 1993	Americal medical association.q
150	14291	Quantitative Analysis of drugs in pharma formulation, 2nd edition 1993	P..D Sethi
151	14854	"Pharmacology" Int. student edition 3rd edtion	H.P. Rang, M.M. Dale
152	14853	Meminn's Functional & clinical anatomy 1995by moshy	Robert M. H. Minn
153	15060	Goodman and Gillman,s The pharmacological basis of therapeutics 19th edition 1996	International edition edited by J.G. Hardman
154	14598	Indian medicinal plants Vol. 4 A compendium of 500 species, 1st edition 1995	Vaidyaratnam P.S.
155	12537	Poisonous and medicinal plants 1990	Will H. Blackwell
156	15437	sex education 1989 1st edition	I. c. Gupta
157	15431	Color atlas of pharmacology 1993	Heinz, Lullmann, Katus mohr
158	15600	Pharmacology and pharmacotherapeutics 15th edition 1997 Vol. I	R. S. Satoskar, S. D. Bhandarkar
159	15601	Pharmacology and pharmacotherpaeutics 15th edition 1997 Vol. II	R. S. Satoskar, S.D. Bhandarkar
160	14991	Indian pharmaceutical Guide 1995	Pamposh pulbication editor M.C. Bazaz
161	15241	Principles of pharmacology-Basic concepts and clinical applications-1995	ROBERT A
162	15472	Pharmacology 1995 first published in 1995	K.DAS
163	15444	Essentials of medical pharmacology third edition 1995	K.D.TRIPATHI
164	15441	Harrison's principles of internal medicine vol I 13th edition 1994	J.ISSELPACHEN
165	15442	Harrison's principles of internal medicine vol II 13th edition 1994	J.ISSELPACHEN
166	16462	Textbook of pharmacology first edition 1998	S.D.SETH
167	15964	Basic and clinical pharmacology 7th edition 1998	G.KATZUNG
168	16445	Drugs in sport 2nd edition 1996	R.DAVID R.
169	16718	Pharmacology and pharmacotherapeutics 16th edition 1999	R.A.SATOSHKAR
170	16903	Pharmacology and pharmacotherapeutics 16th edition 1999	R.A.SATOSHKAR
171	16901	Essentials of medical pharmacology 4th edition 1999	K.D.TRIPATHI
172	16902	Pharmacology and therapeutics 16th edition 1999	SATOSHKAR
173	16841	MCQ in pharmacology first edition 1996	K.D.TRIPATHI
174	17084	A guide to pharmacology viva vice second edition 1996	K.D.CHAUDHARY

**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS**

Sr. No.	Ac. No.	Name of the books	Authors
175	17132	Textbooks of pharmacology second edition 1999	S.B.SETH
176	17332	Pharmacology an illustrated review with questions and explanations third edition 1996	MANUCHAIR EBADI
177	14729	Davidsons principles and practice of medicine 17th edition 1995	C.R.W . EDWARDS
178	17661	Prayer faith and healing 1999	KENNETH WINSTON
179	17652	Natures pharmacy 1998	DR.LYLLEPAIGE
180	17654	Metabolic drug interaction 2000	RENE H LEVY
181	17326	Essentials of medical pharmacology fourth edition 1999	K.D.TRIPATHI
182	17866	Viva in pharmacology and therapeutics first edition 2000	DR.AVINASH
183	17906	1000 MCQ for divisions principles and practice of medicine fourth edition 1999	A.T.ELDER
184	18190	Basic and clinical pharmacology 8th edition 2001	G.KATZUNG
185	17421	Pharmacology and pharmacotherapeutics reverse 16th edition 1999	R.A.SATOSHKAR
186	17649	Pharmaceutical doses forms and drug delivery system 17th edition 1999	HOWRD ALFCO
187	17858	1998 mosbys medical drug reference	ALLAL J ELLSWORTH
188	17656	Text book of therapeutic drugs and disease management seventh edition 2000	ERIL T
189	18097	Core JAWA 2 vol ,advanced features 2000	CAY S HORTMAN
190	18096	Core JAWA 1 vol, fundamentals 2000	CAY S HORTMAN
191	17651	Appleton and larges 1999 drug guide	MARGART T SHANNON
192	18369	Textbook of organic medicinal and pharmaceutical chemistry 10th edition 1998	WILLIAM A REMERS
193	18333	Textbook of medical physiology 10th edition 2000	ARTHUR C GUYTON
194	18339	Remingtons "The pharmacy science and practice of pharmacy" Vol. 1, 20th edition 2000	ALFONSO R GENNARO
195	18340	Remingtons the science and practice of pharmacology vol 2 20th edition	ALFONSO R GENNARO
196	18344	Harpers biochemistry 25th edition 2000	ROBERT K MURRAY
197	18351	Organic chemistry vol 1 sixth edition 2000	I L FINAR
198	18355	The text book of pharmaceutical analysis third edition 1999	KENNETH A CONNOR
199	18593	Instrumental method of chemical analysis first edition reprint 2000	GURUDEEP CHATWAL
200	18594	Pharmacognosy seventeenth edition 2001	DR.C.K.KOKATE
201	18596	The Theory and practice of Industrial pharmacy, 3rd edition 1990	Leon Lachman, Harbert A. Cieberrman, Joseph L. kenig.
202	18570	Essentials of medical pahrmacology4rh edition updated reprint 2001	K.D Tripathi
203	18566	Goodman and Gillman's "The pharm. Basi of therapeutics, 10th edition 2001.	Edited by Joel G. Hardman, LEE &Limbird etc.
204.	18599	The concise oxford dictionary 10th edition 2001	Edited by Judy Pearsall.
205	15250	Dorland's Illustrated medical dictionary 28th edition 1994	W. B. Saunders
206	14623	Lippincott's pharmacology.	
207	12289	Pharmaceutical dosage forms and drugs delivery system	Howard C. Ansel Nicholas G, Poporich
208	18743	Goodman and Gillman's "The pharmacological Basic of Therapeutics" of therapeutics 10th edition.	Alfred Goodman Gilman.



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS**

Sr. No.	Ac.No.	Name of the books	Authors
209	18571	Essentials of medical pharmacology 4th edition	K. D. Tripathi
210	18741	Pharmacology and Pharmacotherapeutics revised 17th edition	R.S .SATOSKAR, s. d. Bhandarkar.
211	19264	1200 multiple choice questions in pharmacology 2nd edition	R. W. Foster.
212	19271	Review of pharmacology	U.N. Panda
213	19106	Companion to pharmacology 2nd edition	M.M.DALE A. H. Dickenson
214	19091	Pharmacology 4th edition	H.P. Rang, M.M.Dale.
215	19276	Essential of medical pharmacology 4th edition	K. D. Tripathi
216	19089	Mosby's Drug consult 2002	Msoby
217	19092	Controlled and novel drug delivery	N. K. Jain
218	19205	The Forensic pharmacology of Drugs of Abuse	Olaf H. Drummer.
219	19087	A-Z of medical statistics	Eilom,ena pereiramanwell.
220	19088	Psycho pharmacology of cognitive and psychiatric disorders in elderly	Edited by David wheately and David smith.
221	19268	Biotechnology and its applications in pharmacy	Girirraj Kulkarni T.
222	19090	Clinical Pharmacology and drug therapy, 3rd edition	D. G. Grahame smith and J. K. Aronson.
223	19277	Lippincott's illustrated reviews pharmacology 2nd edition	Mary J. Mycek, Richard a
224	19527	Basic of clinical pharmacology 8th edition	Bertraim G. Kzatzung
225	19512	a. Handbook of medicinal plants	Prajapati, Purohit.
226	19578	Pharmacology recall	Anand Remashandran
227	19894	Essentials of medical Pharmacology 5th edition	K. D. Tripathi
228	20011	Essential of medical pharmacology 5th	K. D.Tripathi
229	20012	Pharmacology and pharmacotherapeutics revised eighteenth edition	R. S. SATOSKAR
230	20013	Pharmacology and Pharmacotherapetutics revised Eighteenth edition	R. S. Satoskar, S. D. Bhandarkar
231	20305	Basic & clinical pharmacology 9th edition International editions	Bertram G. Katzung
232	19921	Practical Biochemistry for medical, dental & applied courses	Rajgopal G. Dr. B. D. Toora
233	20431	Modern pharmacology with clinical applications	Charles R. craing Robert E. stitized
234	19916	Core concepts in pharmacology	Manuchair Ebadi
235	19917	The Bio-chemical Basis of Neuropharmacology	Jack R. Cooper
236	20420	Clinical pharmacology 9th edition	P.N. Bennet
237	19914	Lippincott's review series	Catherine Paradiso
238	19915	Essential of pharmacology for health occupations 4th editions	Ruth Woodrow
239	20024	Pharmacokinetics 2nd edition	Milo Gibaldi Donald Perrier
240	20428	MCQ in pharmacology Jaypee	Meenakshi Iyer
241	20029	Respiratory care in pharmacology	Joseph L.Rau
242	20023	Clinical drug trials tribulations	Allen E Cato
243	20021	Drugs calculations process and problems for clinical practice sixth edition	Brown Mulholland
244	20436	Integrated pharmacology	Page,Curtis,Walker ,Hoffman
245	19923	Harrisons principles of internal medicines 15th edition vol 2	Braunwald,fauci
246	19918	Abe of monitoring drug therapy	J.K.Aronson M.Hardman D.j.M.Reynold

**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS**

Sr. No.	Ac.No.	Name of the books	Authors
247	20025	Adverse drug reactions	Anne Lee
248	20022	Biochemistry illustrated edition 2000	Peter n.campbell Anthony D.Smith
249	19922	Principles of internal medicine vol 1 15th edition	Braunwald and Harrison
250	20553	Goodman and Gilman pharmacological basis of therapeutics tenth edition	Editors-Joel G.Hardman Lee e.Limbird
251	20552	Davidson's principles and practice of medicine 19th edition	Christopher ,Haslett,Edwin R.Chilvers etc.
252	20551	Guyton & Hall – Text book of medical physiology 10th edition	Arthur C. Guyton & John E. mHall.
253	20591	Drug Therapy made Easy	T. Bhaskarr Rao
254	-	Practical Pharmacology for MBBS	Dr. K. V. Ramesh
255	-	Contemporary perspectives on clinical pharmacotherapeutics	Madhur Gupta, Sheela Tejwani
256	22467	Godman & Gilman the pharmacological basis of therapeutics 11th edition.;	Laurence L. Bruvton John S. Lazo
257	22844	Essentials of medical pharmacology 5th edition.	K. D. Tripathi
258	22845	Essential of medical pharmacology 5ht edition	K.D. Tripathi
259	23791	Essentials of Medical Pharmacology 6 <sup>th</sup> Edition	K. D. Tripathi
260	23792	Essentials of Medical Pharmacology 6 <sup>th</sup> Edition	K. D. Tripathi
261	24206	Hand book of Phase I/II Clinical Drug Trials	John O. Grady, Pieter H.
262	24303	Pharmacology 4 <sup>th</sup> Edition	Gray C, Rosented
263	24295	Orphan Drugs	Fred E. Karch
264	24290	Biomarkers in Clinical Drug Development Vol.132	John C. Bloom, Robert A. Dean
265	24296	Human Genetics and Genomics 3 <sup>rd</sup> edition	Bruce R. Korf.
266	24207	Experimental Pharmacology	M.C. Prabhakar
267	23959	Practical Manual of Pharmacology	Dinesh Badyal (Jaypee)
268	24908	Pharmacology and Pharmacotherapeutics	R. S. Satoskar, S. D. Bhandarkar, N. Rege
269	24702	Text Book fo Pharmacology 3 <sup>rd</sup> ediction	S. D. Seth, Vimlesh seth
270	22466	The Pharmacological Basis of Therapeutics 11 <sup>th</sup> Edition (Good man & Gilmans)	Laurence L. Brunton, John S. Lazo, Keith Parkar
271	24795	Tenth ediction Clinical Pharmacologyyy	P. N. Bennet & M. J. Brown
272	22681	Trounces Clinical Pharmacology for Nurses 7 <sup>th</sup> Ed.	Ben Greenstein Nursing Advisor Dindth Gould
273	24712	Essentials of Medical Pharmacology 6 <sup>th</sup> ed.,	K. D. Tripathi(Jaypee)
274	24700	Drug Discovery and Development(Technology in Transition)	Edited by H. P. Rang
275	25949	T. B. Phaarmaognosy & Phytochemistry 1/E,2009	Shah
276	25960	Drug discovery & Clinical Research (ICRI) 1/E,2010-11	Gupta
277	25959	Basic Principles of Clinical Research And Methodology, 1/E,R.P.2009	Gupta
278	25962	Statistical Tests in Medical Research,1/E,2010-11	Jaykaran
279	25976	Fundamentals of Biostatistics(81-8061-814-5), 1/E,2006	Sarmukaddam
280	25979	Publish & Flourisha (A Practical Guide for Effective Scientific writing),1/E,2010	Sholapurkar
281	25986	Pharmacology for Nurses,2/E,2008	Udaykumar
282	25991	Ansel's Pharmaceutical Dosage Forms and Drug Delivery System(SAE):9/E,2011	Allen



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM**  
**LIST OF DEPARTMENTAL LIBRARY BOOKS**

Sr. No.	Ac.No.	Name of the books	Authors
283	26013	Evaluation of Drug Activities Pharmacometrics (2 Vol. Set) 2011	Laurence
284	26014	Evaluation of Drug Activities Pharmacometrics (2 Vol. Set) 2011	Laurence
285	26018	Screening Methods in Phamacology( 2 Vol. Set) 2009	Turner, Robert
286	26019	Screening Methods in Phamacology( 2 Vol. Set) 2009	Turner, Robert
287	26134	Drug Transport(ers) and the Diseased Brain (Sympsia vol. II) 2009	Debore,A.G.
288	26249	Applied therapeutics : The Clinical Use of Drugs 5/E, 2009	Koda-Kimble, Mury
289	26250	Goodman And Gillman's the Pharmacological Basis of Therapeutics 12/E,2011	Chabner, Bruce
290	26251	Applied Biopharmaceutics And Pharmcokinetics 5/E,2005	Shargel, Leon
291	26385	Clinical Trial Methodology, 2011.	Peace
292	25554	Principles of Pharmacology, 1st edition 2010	H.L. Sharma, K.K.Sharma
293	26675	Therapeutic Drugs, IInd edition, vol. 1	Colin Dollery, Alan Brois, Michel Ralling
294	26676	Therapeutic Drugs, IInd edition, vol. 2	Colin Dollery, Alan Brois, Michel Ralling
295	26582	Pharmacotherapy- Principles & Practice 2e/2012	Chisholm Burnsze 2010
296	26518	Principles of Pharmacology-The basis of drug therapy 3/e	Gulan D.david 3/e 212
297	26517	Drug interaction- The authority of drugs interactions	Tatro, Davis 2012
298	26516	Introduction of Pharmaceutics theory & practice 2012-13	Tripathi DK 2012-13
299	26521	Pharmacoethics- A problem based approach rep. 2011	Gettman David
300	26905	Pharmacology & Pharmacotherapeutics 22e	Satoskar
301	26514	Textbook of Pharmacovigilance 2011	Gupta SK
302	26515	Experimental Pharmacology	Sujatha Devi
303	26519	Clinical Pharmacology 10e/2008	Besmet PN
304	26634	Ethno-psycho-pharmacology- 2008	Ng. Cheets
305	26534	Clinical calculations with applications to general & special areas 7e213	Kee joyee
306	26505	Rang & Dale's Pharmacology	Rang HP
307	26513	Comparative Pharmacology	Ahmed, Armen
308	26506	Principles of Pharmacology revised ed. 2012	Sharma HL
309	26947	Lippin cott's illustrated reviews (Pharmacology 5 <sup>th</sup> ed. 2012)	Michale A. Clerk, Richard Finker, Jose A. Rey
310	25815	Davidson's Principles & practice of medicine 21 <sup>st</sup> edition 2010	Nicki R. Collere, Brian R. Walker, Stevert H. Rish

No. 25/471/2009-AWD  
Government of India  
Ministry of Fisheries, Animal Husbandry and Dairying  
Department of Animal Husbandry and Dairying  
O/o Committee for the purpose of Control and Supervision of Experiments on Animals  
\*\*\*\*\*

Krishi Bhawan, New Delhi – 110001  
Date: 10/07/2020

To  
Dr. Satish Kumar, Chairman IAEC,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram, Wardha (District) pin: 442102,  
Mobile: 9422144468  
E-mail: [satishkumar@mgims.ac.in](mailto:satishkumar@mgims.ac.in)

Subject: Revision of Institutional Animals Ethics Committee (IAEC) – regarding

Sir,

Kindly refer to your application on the above subject. CPCSEA hereby accords approval to your request for revision of IAEC.

2. Accordingly, the revised IAEC is as under:

S.No.	Name of IAEC Members	Designation in IAEC
1	Dr. Vijayshri Deotale	Biological Scientist
2	Dr. Vinod Shende	Scientist from different biological discipline, Member Secretary
3	Dr. Sushil Kumar Varma	Scientist from different biological discipline
4	Dr. Satish Kumar	Scientist In charge of Animal House Facility, Chairperson
5	Dr. Sandip Joge	Veterinarian
6	Dr. Kailash Marwah	Main Nominee
7	Mr. Jugalkishor V. Vyas	Link Nominee
8	Dr. Mohan M. Sagdeo	Scientist from outside the Institute
9	Shri. Vijay V. Bansod	Socially Aware Nominee

3. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6), and Main Nominee, Scientist from outside the Institute and Socially aware nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, Link Nominee should be invited once in a year to update him/her about the activities of IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

.....2



4. Further, you are advised that veterinarian should be available at the time of animal experiment in the animal house facility.
5. The above composition of IAEC is valid upto the renewed period of registration i.e. 14.09.2021.

Yours sincerely,




(Dr. S. K. Dutta)  
Member Secretary (CPCSEA)

Copy for information to Nominees of CPCSEA:


- 1 Dr. Kailash Marwah, Main Nominee
- 2 Mr. Jugalkishor V. Vyas, Link Nominee
- 3 Dr. Mohan M. Sagdeo, Scientist from outside the Institute
- 4 Shri. Vijay V. Bansod, Socially Aware Nominee

CPCSEA, Govt. of India Registered Central Animal House





### Enclosure VI: Lay out of Central Animal House



• Equipment: **Available**

Sr. No.	Equipment	Qty	Sr. No.	Equipment	Qty
1.	Real Time PCR Machine (Applied Biosystems)	1	29	Fraction collector	1
2.	PCR machines (Thermo cyclers) (Biometra & Applied Biosystems)	2	30	BOD incubator	1
3.	2-D Electrophoresis system (GE Healthcare)	1	31	LKB Minitan Ultra filtration equipment	1
4.	FPLC Equipment (Pharmacia Biotech & Akta Basic)	2	32	LKB minicold room with chromatography Equipment including fraction collector, Peristaltic pump, UV-monitor	1
5.	Hybridization oven	1	33	Klenzaid's Horizontal Laminar Flow Model	1
6.	Sub-marine multiphoresis electrophoresis apparatus	2	34	Vertical Laminar Flow units	2
7.	UV Trans-illuminator	1	35	Kontron Ultra centrifuge, model TGA 65	1
8.	SDS-PAGE (Apparatus)	4	36	Cryopreservation equipment (Forma scientific)	1
9.	Kodak Gel doc system	1	37	Pellicon Ultra Filtration System (Millipore)	1
10.	Water Purification System (Ultra Pure) (Millipore & Elga Water Labs)	2	38	Chemical balances	1
11.	ELISA Readers (Biorad Model 680, ERBA Mscan & Biotek)	3	39	Single pan electrical balances	4
12.	ELISA Washer (Biorad & Biotek)	2	40	Colorimeters	2
13.	UV visible Spectrophotometer ELICO	2	41	Stereo and binocular and monocular microscopes	4
14.	Western Blotting apparatus (Biorad, Biotech & GE Healthcare)	3	42	Dissection Microscope	2
15.	Nikon Inverted microscope	1	43	PH meters	3
16.	Fluorescence Microscope (Nippon & Carl Ziess)	2	44	Water baths	4
17.	Bright field Microscope (Carl Ziess)	1	45	Water distillation apparatus	2
18.	Incubator-Shakers (Scigenics)	3	46	Rotary evaporator	1



19.	CO <sub>2</sub> incubators	2	47	Rockers	4
20.	Liquid Scintillation Counter (Packard)	1	48	Homogenizer	1
21.	Walk in Cold room	1	49	Hot air ovens	2
22.	-86 <sup>0</sup> C Deep freezer (Thermo Scientific& NBS)	2	50	Hot plates	2
23.	Deep freezers -20 <sup>0</sup> C	3	51	Vacuum pump	1
24.	Freeze drier (Virtis)	1	52	Cyclo Mixers	4
25.	Ice Flaker	2	53	Microwave oven	1
26.	Sonicator	1	54	Magnetic stirrers	4
27.	Refrigerated centrifuge (Remi)	3	55	Refrigerators	6
28.	Portable high speed centrifuge	3			

**Practical Laboratories:**

<b>Experimental Pharmacology</b>	<b>Clinical Pharmacology &amp; Pharmacy</b>
----------------------------------	---

**a) Accommodation**

Size	140 sq.mt.	140 sq.mt.
Capacity	60	60

**b) Working arrangement**

Seats Availability 50

c) Main equipment available— HPLC, Elevated Y maze, plus maze, ECG, student Physiograph, Burn and Dale apparatus, cooks pole climbing apparatus, Rota Meter, analgesiometer, convulsimeter, lagendoffs apparatus, Dog experiment table with kymography.

**d) Ante-room/preparation room**

Size 14 sq.feet  
 Location in between pharmacy lab and experimental lab.

e) Whether laboratory manuals kept by students. Yes

f) Close circuits TV/Any other teaching aids: LED T.V and Computer

**Office Accommodation:**

- Departmental Office :- One
- Space :- 150 sft.
- Staff (Steno /Clerk). :- Yes/ 1
- Computer/ Typewriter: :- 2/1

Office Space for Teaching Faculty:

- HOD - adequate, 1 room.
- Professor - adequate, 2 rooms
- Assoc. Prof./ Reader - adequate, 2 rooms
- Lecturer/ Asstt. Professor - adequate, 2 rooms
- Demonstrator/Tutor room -- adequate, 2 rooms



**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM.**

**LIST OF TEACHING FACULTY**

Professor & Head	* Dr. Sushil Kumar, M. D.
Professor	* Dr. Devesh Gosavi, M. D.
Professor	* Dr. R. S. Kale, M. D.
Associate Professor	* Dr. Leena V. Chimurkar, M.D.
Associate Professor	* Dr. Mohan M. Pethe, M.D.
Tutors/ Demonstrators	* Dr. Ashish kumar Baheti * Dr. Ghanshyam Parmar

**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM.****LIST OF NON TEACHING STAFF.**

Pharmacist	*--
Technician	* Mr. Dinesh Wanmali * Mrs. M. A. Udhoji,
Jr. Clerk	* Mr. Vinit B. Patil
Attendants	* Mr. Dinesh Kamble * Mr. Praful Gosavi.
Artist	*Mr. Ashok Wahiwatkar (Common to the whole college)
Photographer	* Mr. Satish Shingare (Common to the whole college)



**Departmental Museum:**

- a) Size : 108 sq mt.
- b) How are the drug sample arranged? : Six glass Almirahs  
(Drugs arranged according to classification)
- c) Number of catalogues of the samples available to the students:
- |                  |       |
|------------------|-------|
| 1. No. of drugs  | : 200 |
| 2 No. of Charts  | : 72  |
| 3. No. of Models | : 8   |
- d) Total number of drug samples: : 200
- e) List of charts, photograph and other exhibits and their arrangement : 1 Charts and photographs on the walls  
2. Racks for panels (11+36 in glass almirah)
- f) Is there any section depicting "History of Medicine"? : Photographs of scientists with Illustrations (30)

**(i) Demonstration Room:**

a) Number : One

b) Accommodation

• Size : 55.5 sq mts

• Capacity : 50

c) Audio-Visual equipment available: LED T.V, Overhead Projector,  
Slide Projector

**ii) Departmental Library-cum-Seminar Room:**

a) Is there a separate departmental library? : Yes

b) Accommodation:

• Size : 28 sq mt.

• Capacity : 15

c) Number of Books in Pharmacology? : 310, List attached (Annexure III)

d) List of Journals : 5 journal in the central library.



**iii) Research Laboratory:**

- a) Size : 106 sq mt
- b) Equipments : HPLC, Pulse maze, Y maze, ECG, Student physiograph, Burn & Dales apparatus Cooks Pole climbing Apparatus, Rotameter, analgesiometer, Convulsiometer, Langendorffs apparatus Dog experiment table with kymograph etc.

**iv) OFFICE ACCOMMODATION**

- a) Professor and HOD : Yes, one room
- Professor : Yes, two room
- b) Associate Professors/Readers : Yes, two room
- c) Asst. Professors/Lecturers : Yes, two rooms
- d) Tutors/Demonstrators : Yes, two rooms
- e) Non-teaching and clerical staff: Office room & Computer room

**DEPARTMENT OF PHARMACOLOGY, MGIMS, SEWAGRAM.**

**LIST OF THE EQUIPMENTS**

1. Automatic Slide Projector
2. De-mineraliser
4. Electrophoresis power pack system.
5. Student Physiograph
6. Slab-Gel System for 8/7 cm Gel.
7. Langendroff's Apparatus
8. Square Wave stimulator
9. Colorimeter
10. Analgesiometer
11. Convulsiometer
12. Photoactometer
13. Cook's pole climbing
14. Trendelenburg's apparatus
15. Soxhlet apparatus
16. Rota Rod
17. Kymograph (For Dog experiment)
18. Burn and Dale's apparatus
19. Refrigerator
20. Water Still.
21. Overhead Projector
22. Tablet Dissolution Test apparatus
23. Digital Photoactometer
24. Yerk's Brightness discrimination Apparatus
25. Tablet Disintegration Test machine
26. Stereotoxis apparatus
27. Light discrimination apparatus
28. Plus maze
29. Y maze
30. HPLC



## LIST OF THE EQUIPMENTS FOR CLINICAL PHARMACOLOGY

1. Computerized student Physiology Lab. system 'Biopac (Genetech)
2. ECG
3. Flicker Fusion Apparatus
4. Digital Display Multiple Choice apparatus
5. Digital steadiness tester
6. Hair drier
7. Human thermometer
8. Bicycle ergograph
9. Blood Glucose monitor
10. Electronic Blood Pressure monitor.

## D. Library

### (b) Departmental Library

(i) Space	: 280 sqft.
(ii) No. of books	: 310
(iii) No. of Journals	:
National	:
International	:
(iv) Computer Facility Available	: Yes
No. of Computers	: 3
Internet Facility	: Dept. has intramail facility. Internet facility available in Central Library.



**Animal House**

a) Central/department : Department has got Animal room with AC & under the central animal house for purpose of maintaining the animals which are under experiments. Number of animals required for experimental work of PG Dissertation depends upon type of Experiments & permission to use animals granted by Institutional Animal Ethics Committee.

b) Administrative Control Under the Head of the Department

c) General lay out number of sections and stock in each temperature and light control Adequate

d) Number of animals used per year

For UG demonstration & PG Routine Practicals:

(Approximately)	Mice	20
	Rat	10
	Rabbit	01
	Frog	Nil

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khaikar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides

Ph. D. Doctoral Committee Member List

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	drshabaana@gmail.com	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	drshaileshnagpure@gmail.com	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	samarth21174@gmail.com	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	gargimudey@hotmail.com	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	anujab803@gmail.com, anuja_bhalerao@yahoo.com	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	sanjay.zodpey@phfi.org	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (C), Mumbai 400012	anitachalak@rediffmail.com	9850620123



**FOR Ph D COURSE for A.Y. 2023-24**  
(Please submit separate report for each subject)

**Date of Inspection:**

Faculty: **Medicine**

Subject/Specialty: **Community Medicine**

1. Name & Address of the College/Research Centre: **Mahatma Gandhi Institute of Medical Sciences, Sevagram, Dist- Wardha- 442102, MS PIN – 442102**

Name of Head of the Department: **Dr. Subodh S Gupta**

Designation: **Director-Professor & Head**

2 Department / Subject wise details of available PhD Guides: (Attach Annexure-A)

Sr. no	Name of Teacher	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. & Date
1	Dr. Subodh S Gupta	Dir. Prof. & Head	05/09/1967	2032	Two	Yes	MUHS/UDC(Ph.D)/Guideline/103/2021 dated 19/05/2021

4. Details of available infrastructure under Department:

- i) Adequate number of Computers with Internet facility is available? **Yes**
- ii) Adequate number of Books / Journals are available? **Yes**
- iii) Any other specific thing available at the Department

**Computer Lab & Public Health Laboratory**


5. Details of Central Research Laboratory:

- i) Available Area in sq.ft: **3230 Sq.ft.**
- ii) Is drugs / Medicines/Chemicals etc. are available for research? **Yes**
- iii) Is Adequate number of instruments are available? **Yes**
- iv) Is Record of Stock book available? **Yes**

6. Details of Central Animal House:

- i) Available Area in sq.ft: **1175 sq. ft.**
- ii) Functioning Central Animal House **Yes**

7. Details of Institutional Ethical Committee: (Attach Annexure 'B')

  
 Professor & Head  
 Dept. of Community Medicine  
 M. G. I. M. S; SEVAGRAM.

- i) Date of Composition: **As per available records, IEC started operations 2002 onwards. Registered on 20/04/2013 under Central Drugs Standard Control Organisation, Directorate General of Health Services and last re-registered (Re- registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and registered under Department of Health Research National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022)**
- ii) Total Number of Members: **13**
- iii) Number of meeting held in previous year: **13 (Oct 2021 – Oct. 2022)**
- iv) Whether Records of proceedings are maintained properly? : **Yes**
- v) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes**
- 8 Details of Research Advisory Committee: **(Attach Annexure 'C')**
- i) Date of Composition: **12<sup>th</sup> July, 2013**
- ii) Total Number of Members: **09**
- iii) Number of meeting held in previous year: **2 (2021-2022)**
- iv) Whether Records of proceedings are maintained properly? **Yes**
9. Is Doctoral Committee constituted in the lines of RAC? **Yes**
- i) If Yes, Date of Composition **21/07/2022**
- ii) Total Number of Members: **08**
- iii) Name of External Subject Expert **Dr. Sanjay Zodpey, President, Public Health Foundation of India, New Delhi.**
10. Is Plagiarism detection software facility available? **Yes**
- If Yes, Name of the Software **OURIGINAL**
11. Is attendance of the Ph D Scholar maintained properly? **Yes**
12. Whether Research Centre is registered under MPCB provisions? **Yes**
13. Whether BMW facility is available? **Yes**
14. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:

**The Department of Community Medicine at MGIMS, Sewagram is well-known for its work in the area of Community mobilization and Community-based research. It is a WHO Collaborating Center for Research and Training in Community Based Maternal, Newborn and child Health since 2009. Currently under a UNICEF supported project, the Department of Community Medicine is engaged in developing a scalable model for nurturing care interventions through existing opportunities within ICDS, health and other sectors all over Maharashtra. The Department is recognized for vaccine trials and has participated in several prestigious vaccine trials over the last 10 years.**

**Sulodh**  
 Professor & Head  
 Dept. of Community Medicine  
 M. G. I. M. S. SEVAGRAM.



### DECLARATION BY LIC

We the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research center. The overall observations of the Inspection Committee are as follows:

.....  
.....  
.....  
.....

Name of Inspectors		Sign of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4)	Member	



# महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक

## MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK

दिंडोरी रोड, म्हसळ, नाशिक-४२२००४ Dindori Road, Mhasrul, Nashik-422004

Phone : 0253 - 2539196/206, 0253 - 6659196/206

Email: udc@muhs.ac.in Website: www.muhs.ac.in

डॉ. सुनिल ह. फुगारे  
एमएस्सी. पीएच.डी.  
उपकुलसचिव

Dr. Sunil H. Fugare  
MSc.Ph.D.

Deputy Registrar

O.No. MUHS/UDC(Ph.D.)/Guide / 103/2021

Date : 19/05/2021

To,  
The Dean / Principal,  
Mahatma Gandhi Institute  
of Medical Sciences,  
Sewagram, Wardha  
Wardha :- 442 102  
Email - dean@mgims.ac.in

**Subject** : Recognition as Ph.D. Guide...  
**Reference** : 1) Your Application dated - 17/03/2021  
2) Ph.D. Direction No. 01/2020  
3) Board of Research Resolution No. 02/2021, dated - 05/05/2021

Sir/Madam,

With reference to the above cited subject, I am directed to inform you that Board of Research in its Meeting has Passed the Resolution No. 02/2021, dated 05/05/2021 to grant recognition as Ph.D. Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order, for guiding the Ph.D. student in the subject mentioned against his/her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D. Guide
1	Community Medicine	Dr. Gupta Subodh Sharan	Professor	Approved w.e.f. 05/05/2021, onwards

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service or till attaining the age of superannuation whichever happens earlier.

The above teacher is required to attend the Research Methodology Workshop conducted by this University or any other Centre authorized by the University.

(P.T.O.)



You are requested to handover the copy of this letter to the concerned teacher for further necessary action.

Yours,



**Dy. Registrar**  
University Dept. Cell  
(Ph.D.)

18/5/21

**[Note :-**

1. *In case, at later stage, if it is found that the information furnished in the Ph. D. recognition form by any Guide is incorrect, Ph.D. Guide Recognition granted by the University will stand cancelled.*
2. *It is required that the Dept. of Community Medicine, M. G. I. M. S. Sewagram, Wardha should be recognized place of research of Ph.D.]*

**Copy to :**

1. **Dr. Gupta Subodh Sharan**  
Professor,  
Dept. of Community Medicine  
Mahatma Gandhi Institute  
of Medical Sciences,  
Sewagram, Wardha  
**Wardha :- 442 102**  
**Email – [subodhsgupta@gmail.com](mailto:subodhsgupta@gmail.com)**



सत्यमेव जयते

Government of India  
Ministry of Health & Family Welfare  
Department of Health Research  
(National Ethics Committee Registry for Biomedical and Health Research)

2nd Floor, IRCS Building,  
Red Cross Road, New Delhi - 110001  
Date : 03-Mar-2022

FORM CT-03

(See rules 17 and 18)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO BIOMEDICAL HEALTH RESEARCH

Registration No. EC/NEW/INST/2022/MH/0072

The designated authority hereby registers and permits Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Kasturba Health Society Sevagram, City-Wardha, District-Wardha - Maharashtra - 442102 Contact No.: 07152-284341-355 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter IV of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 03-Mar-2022

ANU  
NAGAR  
Digitally signed  
by ANU NAGAR  
Date: 2022.03.03  
11:01:12 +05'30'  
Designated Registration Authority  
Stamp





**Mahatma Gandhi Institute of Medical Sciences**  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**



EC-CT-2021-0168


05 Mar 2021 - 04 Mar 2024


Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in)

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID. and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raison University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 advpawade@gmail.com	Chairman	Dean, School of Law, G H Raison University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. sushil@mgims.ac.in	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. bharatitaksande@mgims.ac.in	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 smita@mgims.ac.in	Clinician	Director Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 subodh@mgims.ac.in	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 manish@mgims.ac.in	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 drshaileshnagpure@gmail.com	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 wasudevdeodhe@gmail.com	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 hkchandak@yahoo.com	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 swati.sagare@gmail.com	Social Scientist	Chief Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 vgknc@rediffmail.com	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Karnalnayan Jamnalal Bajaj Foundation, Wardha (NGO)	9552689218 sonamphate@yahoo.com	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 vtaksande@gmail.com	Scientific Member	Professor, Faculty of Nursing

Date: 11<sup>th</sup> July 2022

  
Dr. Sushil Kumar Varma  
Member Secretary  
Institutional Ethics Committee  
Mahatma Gandhi Institute of Medical Sciences  
SEWAGRAM - 442102 Maharashtra, India

  
Dr. Ashok Pawade

Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India



सत्यमेव जयते

File No. EC/19/000199  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

S

ESWARA

REDDY

(Dr. S. Eswara Reddy)

Drugs Controller General (I) &  
Central Licensing Authority

Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:41:40 +05'30'

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19


The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licencing Authority  
Stamp  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:39:25 +05'30'



C/Gen/ 9978  
Office of the Dean,  
MGIMS, Sevagram  
Date: 15/02/2023

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides

**FOR Ph.D COURSE(S) FOR A. Y. 2022-2023<sup>4</sup>**

(Please submit separate report for each subject)

Date of Inspection	:	
--------------------	---	--

Faculty:.....Subject / Specialty : Pathology

**1. Name & Address of the College / Research Centre:-**

Mahatma Gandhi Institute of Medical Sciences, Sevagram, Dist. Wardha-442102

Name of Head of the Department: - Dr. Anupama Gupta

Designation : Director-Professor &amp; Head

**2. Department / Subject wise details of available PhD Guides:-  
(Attach Annexure "A")**

Sr. No.	Name of Ph.D. Guide		Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. And Date
1	Dr. Nitin Gangane		Dean	11.06.1961	13/01/2023	03	Yes	MUHS/UDC/Ph.D/454/2008 06/09/2008
2								
3								
4								
5								

**4. Details of available infrastructure for Research:**

- i) Adequate number of Computers with Internet facility is available ? Yes/No  
 ii) Adequate number of Books / Journals are available? Yes /No  
 iii) Any other specific thing available at the Department: **Research lab, Genetics lab.**

**5. Details of Central Research Laboratory:**

- i) Available Area (in sq. ft): **3230 sq. ft**  
 ii) Is Drugs / Medicines / Chemicals etc. are available for research? Yes/No  
 iii) Is Adequate number of Instruments are available? Yes /No  
 iv) Is Records of Stock book available? Yes /No

**6. Details of Central Animal House:**

- i) Available Area in sq. ft: **1175 sq. ft.**  
 ii) Functioning Central Animal House? Yes /No

**7. Details of Institutional Ethical Committee : (Attach Annexure "B")**




- i) Date of Composition: **As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022)**
- ii) Total Number of Members: **13**
- iii) Number of meetings held in previous year: **05 (October, 2021 to October, 2022)**
- iv) Whether Records of proceedings are maintained properly? **Yes/No**
- v) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes/No**
- 8. Details of Research Advisory Committee : (Attach Annexure "C")**
- i) Date of Composition: **12<sup>th</sup> July, 2013.**
- ii) Total number of Members: **08**
- iii) Number of meetings held in previous year: **02 (2021-22)**
- iv) Whether records of proceedings are maintained properly? **Yes/No**
- 9. Is Doctoral Committee constituted in the lines of RAC? **Yes/No****
- i) If Yes, Date of Composition : **21-07-2022**
- ii) Total number of Members : **15**
- iii) Name of External Subject Expert : **List attached.**
- 10. Is Plagiarism detection software facility available? **Yes/No****
- If Yes, Name of the Software **Ouriginal Software by Turnitin**
- 11. Is attendance of the Ph.D. Scholar maintained properly? **Yes/ No****
- 12. Whether Research Centre is registered under MPCB provisions? **Yes/ No****
- 13. Whether BMW facility is available? **Yes/No****
- 14. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department: **Yes/No****
- Trained faculty, research friendly environment Ethical code of conduct

**DECLARATION BY LIC**

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department / College / Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows:-

.....

.....

.....

Name of Inspectors		Sign. Of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	



महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK  
दिंडोरी रोड, म्हासरुळ, नाशिक-४२२००४ Vani-Dindori Road, Mhasrul, Nashik-422 004  
EPABX: 0253- 2539100/300, Fax: 0253 - 2539195, Ph.: 0253 - 2539191/291  
Email: academic1@muhs.ac.in Website: www.muhs.ac.in

डॉ. कालिदास द. चव्हाण  
एम.बी.बी.एस., एम.डी. (आयुर्वेदशास्त्र),  
कुलसचिव

Dr. Kalidas D. Chavan  
M.B.B.S., M.D. (Forensic Medicine)  
Registrar

No. MUHS/UG/E-1/53/1504/2479 /2018

Date: 26/06/2018

To  
The Secretary,  
Kasturba Health Society,  
Sevagram,  
Wardha - 442 102



- Sub. : Approval to the appointment of Dean of your college...  
Ref. : 1) Your letter No. KHS/613 dated 21/05/2018  
2) University letter No. MUHS/UG/E-1/53/1504/2120/2018 dated 25/05/2018  
3) Your letter No. KHS/832 dated 11/06/2018

Sir / Madam,

With reference to the above cited subject, regarding the proposal for approval to the appointment of Dean, I am inform you that Hon'ble Vice-Chancellor is pleased to grant approval (UG) to the appointment of following Dean as indicated below.

Sr. No.	Subject	Name of the teachers	Designation	Status of Approval
1	--	Dr. Nitin Gangane	Dean	w.e.f. 11/06/2018 & onwards.

You are requested to handover the photocopy of this letter to Dr. Nitin Gangane

07  
Registrar

Copy to:

Dr. Nitin Gangane,  
Mahatma Gandhi Institute  
of Medical Sciences,  
Sevagram,  
Wardha - 442 102


Copy to

① Dr. Gangane

② Personal file

BSG my





File No. EC/19/000199  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

(Dr. S. Eswara Reddy)  
Drugs Controller General (I) &  
Central Licensing Authority

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,

non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.

FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licensing Authority  
Stamp  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:39:25 +05'30'





File No. EC/NEW/INST/2020/490



Government of India  
Ministry of Health & Family Welfare  
Department of Health Research  
(National Ethics Committee Registry for Biomedical and Health Research)

2nd Floor, IRCS Building,  
Red Cross Road, New Delhi - 110001  
Date : 03-Mar-2022

**FORM CT-03**

(See rules 17 and 18)

**GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO BIOMEDICAL HEALTH RESEARCH**

Registration No. **EC/NEW/INST/2022/MH/0072**

The designated authority hereby registers and permits Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Kasturba Health Society Sevagram, City-Wardha, District-Wardha - Maharashtra - 442102 Contact No.: 07152-284341-355 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter IV of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 03-Mar-2022

**ANU** Digitally signed  
by ANU NAGAR  
**NAGAR** Date: 2022.03.03  
11:01:12 +05'30'  
Designated Registration Authority  
Stamp

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



a) Equipment:

**List of Equipment in the Department of Central Research Lab**

Sr. No.	Equipment	Qty	Sr. No.	Equipment	Qty
1.	Real Time PCR Machine (Applied Biosystems)	1	29	Fraction collector	1
2.	PCR machines (Thermo cyclers) (Biometra& Applied Biosystems)	2	30	BOD incubator	1
3.	2-D Electrophoresis system (GE Healthcare)	1	31	LKB Minitan Ultra filtration equipment	1
4.	FPLC Equipment (Pharmacia Biotech & Akta Basic)	2	32	LKB minicold room with chromatography Equipment including fraction collector, Peristaltic pump, UV-monitor	1
5.	Hybridization oven	1	33	Klenzaid's Horizontal Laminar Flow Model	1
6.	Sub-marine multiphoretic electrophoresis apparatus	2	34	Vertical Laminar Flow units	2
7.	UV Trans-illuminator	1	35	Kontron Ultra centrifuge, model TGA 65	1
8.	SDS-PAGE (Apparatus)	4	36	Cryopreservation equipment (Forma scientific)	1
9.	Kodak Gel doc system	1	37	Pellicon Ultra Filtration System (Millipore)	1
10.	Water Purification System (Ultra Pure) (Millipore& Elga Water Labs)	2	38	Chemical balances	1
11.	ELISA Readers (Biorad Model 680, ERBA Mscan&Biotek)	3	39	Single pan electrical balances	4
12.	ELISA Washer (Biorad&Biotek)	2	40	Colorimeters	2
13.	UV visible Spectrophotometer ELICO	2	41	Stereo and binocular and monocular microscopes	4
14.	Western Blotting apparatus (Biorad, Biotech & GE Healthcare)	3	42	Dissection Microscope	2
15.	Nikon Inverted microscope	1	43	PH meters	3
16.	Fluorescence Microscope (Nippon& Carl Ziess)	2	44	Water baths	4
17.	Bright field Microscope (Carl Ziess)	1	45	Water distillation apparatus	2
18.	Incubator-Shakers (Scigenics)	3	46	Rotary evaporator	1
19.	CO <sub>2</sub> incubators	2	47	Rockers	4
20.	Liquid Scintillation Counter (Packard)	1	48	Homogenizer	1
21.	Walk in Cold room	1	49	Hot air ovens	2
22.	-86°C Deep freezer (Thermo Scientific& NBS)	2	50	Hot plates	2
23.	Deep freezers -20°C	3	51	Vacuum pump	1
24.	Freeze drier (Virtis)	1	52	Cyclo Mixers	4
25.	Ice Flaker	2	53	Microwave oven	1
26.	Sonicator	1	54	Magnetic stirrers	4
27.	Refrigerated centrifuge (Remi)	3	55	Refrigerators	6
28.	Portable high speed centrifuge	3			

CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



**Ph. D. Doctoral Committee Member List**

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	drshabaana@gmail.com	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	drshaileshnagpure@gmail.com	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	samarth21174@gmail.com	8830267710
4	Microbiology	Dr. Cargi Mudey, HOD, Microbiology, JNMC, Sawangi	gargimudey@hotmail.com	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	anujab803@gmail.com anuja_bhalerao@yahoo.com	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	sanjay.zodpey@phfi.org	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acharya Dhonde Marg, Parali (E), Mumbai 400012	anitachalak@rediffmail.com	9850620123






महाराष्ट्र MAHARASHTRA

© 2019 ©

VZ 919745

25 FEB 2020

BEFORE NOTARY PUBLIC WARDHA (M.S.)




**AGREEMENT FOR COLLECTION, TRANSPORTATION,  
TREATMENT AND DISPOSAL OF BIO MEDICAL WASTE**

This agreement is executed on this 2<sup>nd</sup> day of April, 2020 at Wardha Between  
Dr. B. S. Garg, Secretary, Kasturba Health Society, Sevagram, Wardha - 442 102  
Hereinafter called waste generator or PARTY NO. 1

AND

M/s SUPERB HYGIENIC DISPOSALS,  
C/o. Mr. Bande, 8A, Damodar Colony,  
Near Surendra nagar Basketball Ground, Nagpur  
Through Mr. Atul S/o Marotrao Zoting, Managing Partner,  
Aged about 40 years, Occupation – Business, R/o Nagpur  
Hereinafter called as service provider or PARTY NO. 2





That, the service provider / Party No. 2 is having a Bio - Medical Waste Disposal Unit at Kh. No. 133, Mauza, Bhandewadi, Nagpur which is in association with Nagpur Municipal Corporation.

That, the waste generator / party No. 1 is having its Hospital in the Name of Kasturba Hospital attached to Mahatma Gandhi Institute of Medical Sciences run by Kasturba Health Society, a charitable organization having charitable objects in the field of research relating to education, health delivery to rural masses and other areas akin thereto.

On the request of Party No. 1, Party No. 2 has agreed to undertake the work of collection, transportation, treatment and disposal of Bio - Medical Waste generated in the Hospital / OPD / Laboratories of Party No. 1 on the following terms and conditions:

1. **Scope of Assignment:**

The area specified shall include -

Medicine Wards and OPD (New Medicine Building)

Surgery Wards and OPD

Orthopedics Wards and OPD

ENT Wards and OPD

Ophthalmology Wards and OPD

Pediatric OPD

Skin & VD Wards and OPD

Radiotherapy Wards and OPD

Psychiatry Wards and OPD

Anesthesiology - Operation Theatre

Microbiology Department and related sections

Pathology Department and related sections

Bio-Chemistry and related sections

Central Collection Laboratory

Trauma Centre and connected wards

Operation Theater Complex

Mother and Child Health Wing

Any other section generating Bio-medical waste shall be communicated to you as an addendum to the existing work order left out inadvertently.

2. Waste Generator hereby declares that in his Hospital, he is having beds for indoor patients and in house services like **Pathology, Blood Bank, X-ray unit and Multispecialty OPD.**
3. Service provider / Party No. 2 has accepted the work of collection, transportation, treatment and disposal of entire Bio - Medical Waste of the waste generator.
4. The Party No. 1 will arrange for non - chlorinated coloured plastic bags approved by Maharashtra Pollution Control Board/Central Pollution Control Board stocking and packing of Bio Medical Waste.
5. The waste generator or party No. 1 will arrange for collection and proper segregation of entire Bio-Medical waste generated in its various departments and wards as per the guidelines of the Bio - Medical Waste Management Rules 2016, and its segregation as per details annexed. Party No. 1 shall keep the material ready at the collection end point and Party No. 2 has agreed to collect the Bio - Medical Waste during 9 am to 6 pm or any other time, which may be mutually agreed upon. The Party No. 1 shall provide Bio - Medical Waste store room at end point.



6. Party No. 1 will pack the segregated Bio - Medical Waste as per rules at the collection end point in colour coded bags; label the said bags as per Schedule IV of the Bio - Medical Waste Management Rules, 2016 amended 2018 and 2019 as per Section 6, 8 and 25 of environment (Protection) Act, 1986.
7. The Party No. 2 shall collect Bio - Medical Waste ward wise, transport, treatment and dispose off the Bio - Medical Waste and for the purpose of collection shall engage / depute personnel and all such personnel shall be the employees of the Party No. 2.
8. Party No. 2 shall collect on daily basis the segregated Bio - Medical Waste generated.
9. That, the waste generator / Party No. 1 hereby agrees that they would pay service provider disposal charges, as per Annex. - 1
10. Taxes such as contract sale tax, service tax etc. if applicable shall be to the waste generator's / Party No. 1 account.
11. The Party No. 2 should rise two separate monthly bills (One Original and one carbon copy) in the name of Kasturba Hospital and Party No. 1 shall pay bill on monthly basis.
12. That, no change or modification or waiver of any of the terms of this agreement shall be effective unless agreed to in writing and signed by duly authorized officer of each of the parties hereto.
13. Party No. 2, the service provider and Party No. 1, waste generator agree that this agreement is valid w.e.f. 1/01/2020 to 31/12/2023 and after the expiry of the said period of this agreement, the parties will renew the agreement on fresh terms and conditions as would be mutually agreed upon. Party No. 2 shall make a request application of two months prior of the expiry of the term of this agreement for renewal. Both the parties may terminate the contract by serving one month advance notice.
14. The Party No. 2 shall deposit an amount of **Rs. 2,00,000/- (Rupees Two Lakhs Only)** as the Security Deposit in the Accounts Section of the Kasturba Health Society and the consideration for the assignment will be **Rs. 2,12,540/-** which will be paid by Party No. 1 if the assigned work is successfully completed by Party No. 2.
15. All disputes and questions in connection with this agreement arising between parties shall be referred to the arbitration of two arbitrators one to be appointed by each party and in case of their disagreement to an umpire appointed by the said arbitrator or in case of their default by the parties.





16. In the event there is any objection and / or notice for breach of the rules regarding transportation, treatment and disposal of bio medical waste, Party No. 2 shall be solely responsible in that behalf.
17. In case, the waste collection programme is not attended by the Party No. 2 for more than 2 days, a penalty of Rs. 1000/- per day shall be recovered from Party No. 2 by Party No. 1. Moreover, Party No. 2 shall have to redress the backlog by providing extra force on next day.
18. All the expenses with regard to stamp duty and registration charges if required and all legal expenses in respect of the preparation of the contract shall be exclusively borne by and paid by Party No. 2 i.e. Service Provider.
19. The Party No. 2, the Service Provider guarantees that Bio - Medical Waste shall be treated and disposed off in accordance with **Schedule I**, and in compliance with the standards prescribed in **Schedule II** completely at his own cost and for the same shall set up in accordance with the time - schedule in requisite Bio-Medical Waste treatment facilities like incinerator, autoclave, microwave system for the treatment of waste, or ensure requisite treatment of waste at a common waste treatment facility or any other waste treatment facility.
20. The Party No. 1 agrees to segregate the waste generated into containers / bags at the point of generation in accordance with **Schedule I** prior to its storage, transportation, treatment and disposal and Party No. 2 agrees to label the containers and carry information prescribed in **Schedule IV** during transportation which will be only such vehicle as may be authorised for the purpose by the competent authority as specified by the government.
21. Party No. 2 undertakes that no untreated Bio-Medical Waste shall be kept stored beyond a period of 48 hours and if for any reason it becomes necessary to store the waste beyond such period, Party No. 2 guarantees to take permission of the prescribed authority and take measures to ensure that the waste does not adversely affect human health and environment.
22. Party No. 2 shall maintain records related to the generation, collection, reception storage, transportation, treatment, disposal and/or any form of handling of Bio-Medical Waste in accordance with these rules and any guidelines issued and shall make them available for inspection and verification by the prescribed authority at any time.
23. In the event, Party No. 2 commits any default in the service, the Party No. 1 shall be at liberty to discontinue this agreement with prior written notice of one month.
24. This agreement is executed in Triplicate & one original signed copy will remain with Party No. 1.

#### 25. PENALTY CLAUSES

- (i) In case the contractor fails to commence/execute the work as stipulated in the agreement or there is a breach of any terms and conditions of the contract: Institute (KHS) reserves the right to forfeit the security deposits / performance guarantee etc.
- (ii) For any breach of contract, KHS, Sevagram or duly constituted committee by KHS, Sevagram shall be entitled to impose a penalty to the extent of Rs. 5000/-



only on the first occasion upon the agency in the event of breach, violation or contravention of any of the terms and conditions contained herein brought to the notice of the Committee

(iii) If the lapse is repeated again the extent of penalty will be doubled on each such occasion. The decision of the said officer/committee in this regard shall be final and binding upon the agency. Some of the instances in which penalty would be imposed are enumerated below. (but these are not exhaustive and penalty may be imposed on any violation/breach or contravention of any of the terms and conditions as well as assigned duties and responsibilities).

iv) Penalty will also be imposed if the personnel found indulging in smoking/drinking/sleeping during duty hours. The behaviour of personnel found is discourteous to anyone in the hospital including staff or patients.

v) Penalty will also be imposed if any personnel found performing duty by submitting a fake name and address.

vi) If any personnel found on duty other than those mentioned in the approved list is supplied by the agencies to the Institute authorities.

26. In case you fails to commence/execute the work as mentioned in the work order or there is a breach of any terms and conditions of the contract the Kasturba Health Society reserves the right to impose the penalty as detailed below:

Offences	Penalties ( In Rupees)
Not found displaying photo ID	100/- per instance.
Worker not in proper Uniform	500/- per instance.
Indulging in smoking/drinking/ sleeping or any other misconduct during duty hours	1000/- with removal of the offender
Duty performed by a worker for more than one shift in 24 hours	With Due permission from the Sanitary Officer, linked to Biometric attendance system, Not more than 5% of the total attendance. Penalty of 200/- per instance in case of non-compliance
Unsatisfactory performance	Individual Complaint: 1000/- per instance Adverse report by ad hoc Committee for inspection: 5000/- per instance Adverse Monthly report: 10,000/- per report
Absenteeism/Under deployed	1000/- per instance
Complaints are not registered or not redressed	Complaints are not registered or not redressed
Absence of personal protective gears	200/- per instance



For any other breach, violation or contravention of any terms and conditions	Rupees 5000/- will be imposed per day
In case the services remain consistently unsatisfactory for a period of more than 2 weeks	Penalty of 5% of the annual contract value will be imposed

27. In case of any loss or theft, it shall be made good by the agency and in the event of failure on their part to do so within a period of one month, the loss shall be made good equivalent to purchase cost by encashment of security deposit and if the amount of loss or damage exceeds the amount of security deposit, then the amount will be recovered from the bill in one or more instalments. In the event of any dispute arising in connection with the interpretation of any clause in the terms and conditions of the contract, agreement, or otherwise the matter shall be referred to the Arbitrator (Shri P. L. Tapadiya, Holding Trustee, Kasturba Health Society, Sevagram) appointed by the KHS shall have jurisdiction in connection with any dispute/litigation arising out of this contract).

IN WITNESS WHEREAS the parties have put their signature on the day and year as above mentioned in presence of the following witnesses at Wardha.

*[Signature]*  
PARTY NO. 1

Dr. B. S. Garg  
SECRETARY

SECRETARY  
Kasturba Health Society  
PO, Sevagram, Wardha.  
PIN - 42102

WITNESSES

1. *[Signature]*  
Sarang Kite  
Head, Clerk (Chand. Building)  
MHTMS, Sevagram

2. *[Signature]*  
Pratik Hende  
Prakt Manager  
Super. System, Prapada NSP

*[Signature]*  
PARTY NO. 2

Atul M. Zoting  
MANAGING PARTNER



Attested

Atul M. Zoting 2/4/2020

Atul M. Zoting

WITNESS

INDIA




**Annexure-I**

Sr. No.	Type of Bio-Medical Waste	Mode of Disposal	Type of Unit	Rate	Monthly Weight Limit	Collection, Transportation & Disposal Charges Fixed Per Month
1	Human Anatomical Waste, Microbiology & Biotechnology Waste, Waste Sharp, Discarded Medicine & Cytotoxic Drugs, Soiled Waste, Liquid Waste, Housekeeping & Chemical Waste	Incineration, Autoclaving, Shredding, Chemical Treatment, Effluent Treatment	660 Beds (Considering 70% occupancy of 934 beds)	Rs. 274/- per bed per month	5490 Kg Per Month	Rs. 1,30,840/-
			Pathology Lab	Rs. 3000/- month	30 Kg Per Month	Rs. 12,000/-
			Blood Bank	Rs. 3000/- month	30 Kg Per Month	
			Central Lab	Rs. 3000/- month	30 Kg Per Month	
			Cath Lab	Rs. 3000/- month	30 Kg Per Month	
			<b>Total Weight</b>		<b>6210 Kg per Month</b>	
2.	Employee	NA	2	Rs. 20000/- per month (for 2 employees)	NA	Rs. 20,000/-
					<b>Total</b>	<b>Rs. 2,12,840/-</b>

*B. S. Garg*  
**B. S. Garg**  
**SECRETARY**

SECRETARY  
 Kasturba Health Society  
 102, Seagram, Wardha  
 Ph - 442 102





# MAHARASHTRA POLLUTION CONTROL BOARD

Tel: 24010706/24010437  
 Fax: 24023516  
 Website: <http://mpcb.gov.in>  
 Email: [cac-cell@mpcb.gov.in](mailto:cac-cell@mpcb.gov.in)



Kalpataru Point, 2nd and  
 4th floor, Opp. Cine Planet  
 Cinema, Near Sion Circle,  
 Sion (E), Mumbai-400022

RED/L.S.I

Date: 03/02/2022

No:- Format1.0/CAC/UAN No.0000035753/CR - 2202000245

To,  
**MATATMA GANDHI INSTITUTE OF MEDICAL SCIENCES**  
**SEWAGRAM WARDHA**  
**SR. NO. 276,,SR. NO. 276, SEWAGRAM**  
**TAL & DIST-WARDHA**



Your Service is Our Duty

**Sub:** Combined consent and BMW Authorization under Red category

- Ref:**
1. Bio-Medical Authorization granted by the Board vide no. 30/PSO/BMW/Nagpur/2013-14 Dated 30.08.2013 valid up to 31.03.2016.
  2. Your application for Combine Consent and Bio-Medical Authorization dated 03.11.2017
  3. The minutes of Consent Appraisal Committee meeting dated 25.02.2019

Combined Consent to Renewal and BMW Authorization.

For: Under Section 26 of the Water (Prevention & Control of Pollution) Act, 1974 & under Section 21 of the Air (Prevention & Control of Pollution) Act, 1981 and Authorization under Rule 6 of the Hazardous & Other Wastes (Management & Transboundary Movement) Rules 2016 and Bio-Medical Waste Management Rules, 2016 and amendment thereof is considered and the consent is hereby granted subject to the following terms and conditions and as detailed in the schedule I, II, III & IV annexed to this order:

1. The Combined Consent to Renewal and BMW authorization is granted upto: 31.12.2023
2. The capital investment of the project is Rs.15.4359 Crs. ( ).
3. The Consent is valid for the Activity of

Sr No	Activity	Quantity	UOM
1)	Hospital		
a)	Beds	972	Nos
b)	Total Plot Area	155700.00	Sq.Mtrs
c)	Total Built up Area	68120.30	Sq.Mtrs

4. Conditions under Water (P&C) Act, 1974 for discharge of effluent:

No	Description	Quantity (In CMD)	Effluent Character	Disposal
1.	Trade effluent	15	As per Schedule -I	Treated effluent shall recycle up to maximum extent and remaining used on land for gardening / dispose in to sewerage system provided by local body.



Sr.No	Description	Permitted Qty (Kg/M)	Standards to be achieved	Disposal
2.	Domestic effluent,	390	As per Schedule - I	As above.

5. Conditions under the Air (Prevention) Act, 1981 for air emissions:

Sr.No	Description of Stack / source	Number of Stack	Standards to be achieved
1.	NA	1	As per Schedule -II

6. Conditions under Hazardous & Other Wastes (M & T W) Rules 2008 for treatment and disposal of hazardous waste:

Sr.No	Type of Waste	HW Category	Quantity	UoM	Treatment	Disposal
2	35.3 Chemical sludge from waste water treatment	34.3	1.43	Kg/Day	Landfill	CHWTSDF

7. Conditions about Non Hazardous Wastes:

Sr.No	Type of Waste	Quantity	UoM	Treatment	Disposal
1	STP Sludge	25	Kg/Day	Composting	Used as a manure
2	Wet Waste	300	Kg/Day	Composting	NA
3	Dry Waste	200	Kg/Day	Sale/ Composting	Reuse/ Composting

8. Treatment and Disposal of Biomedical Waste generated to CBMWTSDF:


Sr.No	Category	Type of Waste	Quantity not to exceed (Kg/M)	Segregation Color coding	Treatment & Disposal
1	Yellow	a) Human Anatomical waste	138.42	Yellow colored non-chlorinated plastic bags	CBMWTSDF
		b) Soiled Waste	3135.27		
		c) Expired or Discarded Medicines	1.14		
		d) Discarded linen, mattresses, beddings contaminated with blood or body fluid.	134.76		
		e) Microbiology Biotechnology and other clinical laboratory waste	14.34		
2	Red	Contaminated waste (Recyclable)	2184.33	Red colored non chlorinated plastic bags or containers	CBMWTSDF
3	White (Translucent)	Waste sharps including Metals	39.94	Puncture proof, Leak proof, tamper proof container	CBMWTSDF
4	Blue	a) Glassware	826.11	Puncture proof & leak proof boxes or containers with blue colored marking.	CBMWTSDF
		b) Metallic body implants	54.38		



9. PP shall comply the following guidelines published by the CPCB on February-2019 regarding handling of BMW for utilization
  1. HCE shall preferably handover Bio-medical wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms for production of drugs, reagent chemicals, markers etc. if any such as Pharmaceutical industry / Biotechnology firm approaches them for the same. If there are any difficulties in the matter, the same may be communicated to such firm and copied to the board also.
  2. HCE shall strictly follow the procedure for packaging & transportation of Bio-medical Wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms as per the guidelines of CPCB published in Feb-2019 for "Handling of BMW for utilization".
  3. HCEs shall submit the report to the Board office about type, quantity and frequency of handling over such BMW on yearly basis.
  4. Industry to enter into legal agreement with HCE's and inform the MPC Board and competent authority of State Public Health Department about such collection of BMW along with quantity and type of waste collected.
  5. In case of any technical difficulty towards handing over the required BMW, you shall inform to the Board accordingly.
  6. HCEs shall properly dispose and handover the waste to authorised user / facilities having valid consent to operate from MPCB,
10. This consent is issued subject to conditions mentioned below:
  - a. The "authorized Person" shall comply with provisions of the Environment (Protection) Act, 1986, and the Rules made there under.
  - b. Any unauthorized change in equipment or working conditions as mentioned in the application by the person authorized shall constitute a breach of this Authorization.
  - c. You shall submit details of Management and Handling of outdated, discarded, unused Cytotoxic drugs generated in the Cancer centers, research and health care in the format prescribed by CPCB which is available on [www.cpcb.nic.in](http://www.cpcb.nic.in) alongwith Annual Report to MPCB with a copy to CPCB before 31st January every year.
  - d. You shall manage the Mercury Waste in the HCE in environmentally sound manner (including storage, spilled collection, transportation and disposal) as per CPCB guidelines published on CPCB website [www.cpcb.nic.in](http://www.cpcb.nic.in) dated: 07.09.2010 as detailed in document entitled "Environmentally Sound Management of Mercury Waste in Health Care Facilities".
  - e. You shall ensure phase out of chlorinated plastic bags, gloves and blood bags by HCEs within two years.
  - f. You shall establish Bar code system within one year.
  - g. You shall ensure that the liquid waste is treated and disposed by all the occupier or operator of a CBWTF in accordance with the Water Act, 1974;
  - h. You shall maintain day to day basis and display the monthly record including Annual report on its website within two years from the date of Notification.
  - i. You shall submit separate Bank Guarantees towards compliance of condition mentioned at Annexure - IV to Regional Office, within 30 days.
  - j. You shall submit compliance of Bank Guarantee conditions every six months to Regional Officer, for verification purpose.

- k. You shall submit application for renewal of Combined Consent and Biomedical Waste authorization before 120 days along with appropriate fees.
11. This Board reserves the right to review, amend, suspend, revoke etc. this consent and the same shall be binding on the Industry.
  12. This consent should not be construed as exemption from obtaining necessary NOC/permission from any other Government agencies.
  13. PP shall install STP to treat domestic effluent within 6 months and submission of BG of Rs.3.0 Lakhs towards compliance of the same.
  14. PP shall submit BG's as per HCE's regime of the Board.
  15. PP shall dispose BMW at CBMWTSDF only and shall not operate incinerator. PP shall discontinue the operation of incinerator.

For and on behalf of the  
Maharashtra Pollution Control  
Board.

  
(Ashok Shingare IAS),  
Member Secretary

**Received Consent fee of -**

Sr No	Amount (Rs)	Transaction/ID No	Date	Transaction Type
1	250000.00	7606401	06/07/2018	NEFT
2	316250.00	MPCB-DR-0154	21/05/2020	RTGS
3	75000.00	7606401	06/07/2018	DD

**Copy to:**

1. Regional Officer, MPCB, Nagpur and Sub-Regional Officer, MPCB, Nagpur II  
- They are directed to ensure the compliance of the consent conditions.
2. Chief Accounts Officer, MPCB, Sion, Mumbai



**SCHEDULE-I**

**Terms & conditions for compliance of Water Pollution Control:**

1. A) As per your application, you have provided Effluent Treatment Plant (ETP) of designed capacity of 15.00 CMD consisting of Primary (Collection tank, Neutralization tank) .
- B) The Applicant shall operate the effluent treatment plant (ETP) to treat the trade effluent so as to achieve the following standards prescribed by the Board or under EP Act, 1986 and Rules made there under from time to time, whichever is stringent:

Sr.No	Parameters	Standards
	I. Compulsory Parameters	Limiting Concentration in mg/l, except for pH
(1)	pH	5.5 to 9.5
(2)	Oil & Grease	10 mg/l
(3)	BOD (3 days 27°C )	30 mg/l
(4)	Total Suspended Solids	100
(5)	COD	750

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
2. A) As per your application, you have provided Sewage Treatment Plant of designed capacity 1000 CMD for the treatment of 250 CMD of sewage.
- B) The Applicant shall operate the sewage treatment system to treat the sewage so as to achieve the following standards.

1	BOD	Not to exceed	30
2	COD	Not to exceed	100
3	Suspended Solids	Not to exceed	50

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
3. The Board reserves its rights to review plans, specifications or other data relating to plant setup for the treatment of waterworks for the purification there of & the system for the disposal of sewage or trade effluent or in connection with the grant of any consent conditions. The Applicant shall obtain prior consent of the Board to take steps to establish the unit or establish any treatment and disposal system or an extension or addition thereto.
4. The industry shall ensure replacement of pollution control system or its parts after expiry of its expected life as defined by manufacturer so as to ensure the compliance of standards and safety of the operation thereof.



5. The Applicant shall comply with the provisions of the Water (Prevention & Control of Pollution) Act, 1974 and as amended, by installing water meters and other provisions as contained in the said act:

Sr. No.	Purpose for which water is consumed	Water consumption quantity (CMD)
1.	Industrial Cooling, spraying in mine pits or boiler feed	1.00
2.	Domestic purpose	490.00
3.	Processing whereby water gets polluted & pollutants are easily biodegradable	16.00
4.	Processing whereby water gets polluted & pollutants are not easily biodegradable and are toxic	0.00
5.	Gardening	0

6. The Applicant shall provide suitable water pollution control system as per the conditions of EP Act, 1986 and shall have there a check from time to time/ Environmental Clearance/ CRCP guidelines.

**SCHEDULE-II**

**Terms & conditions for compliance of Air Pollution Control:**

1. As per your application, you have provided the Air pollution control (APC) system and erected following stack (s) to observe the following fuel pattern:

Stack No.	Stack Attached to	APC System	Height in Mtrs	Type of Fuel	Quantity & UoM	S% SO <sub>2</sub>
0	NA	0	0	NA	0--NA--	0.00

2. The applicant shall provide stack height of mtrs operate and maintain above mentioned air pollution control system, so as to achieve the level of pollutants to the following standards:

Total Particulate matter	Not to exceed	150 mg/Nm <sup>3</sup>
--------------------------	---------------	------------------------

3. The Applicant shall obtain necessary prior permission for providing additional control equipment with necessary specifications and operation thereof or alteration or replacement/alteration well before its life come to an end or erection of new pollution control equipment.
4. The Board reserves its rights to vary all or any of the condition in the consent, if due to any technological improvement or otherwise such variation (including the change of any control equipment, other in whole or in part is necessary).
5. Conditions for D.G. Set
- Noise from the D.G. Set should be controlled by providing an acoustic enclosure or by treating the room acoustically.
  - Industry should provide acoustic enclosure for control of noise. The acoustic enclosure/ acoustic treatment of the room should be designed for minimum 25 dB (A) insertion loss or for meeting the ambient noise standards, whichever is on higher side. A suitable exhaust muffler with insertion loss of 25 dB (A) shall also be provided. The measurement of insertion loss will be done at different points at 0.5 meters from acoustic enclosure/room and then average.



- c) Industry should make efforts to bring down noise level due to DG set, outside industrial premises, within ambient noise requirements by proper siting and control measures.
- d) Installation of DG Set must be strictly in compliance with recommendations of DG Set manufacturer.
- e) A proper routine and preventive maintenance procedure for DG set should be set and followed in consultation with the DG manufacturer which would help to prevent noise levels of DG set from deteriorating with use.
- f) D.G. Set shall be operated only in case of power failure.
- g) The applicant should not cause any nuisance in the surrounding area due to operation of D.G. Set.
- h) The applicant shall comply with the notification of MoEF dated 17.05.2002 regarding noise limit for generator sets run with diesel.

**SCHEDULE-III**  
**Details of Bank Guarantees:**

Sr. No.	Consent/Ceiling/CG	Amt. of BG Imposed	Submission Period	Purpose of BG	Compliance Period	Validity Date
NA						

\*\* The above Bank Guarantee(s) shall be submitted by the applicant in favour of Regional Officer at the respective Regional Office within 15 days of the date of issue of Consent.  
# Existing BG obtained for above purpose if any may be extended for period of validity as above.

Statement of conditions to be complied and Bank Guarantee imposed to ensure timely compliance to be issued for

Sr. No.	Activity/Condition to be Complied	Compliance Time/Period (Months)	Bank Guarantee Amount
1A	Operation and Maintenance		
1	To Segregate and Handle BMW as per Rule	Continuous	75000
2	Towards Operation and Maintenance of STP to achieve prescribed effluent discharge limits	6 months	300000
1B	Records		
1	To Maintain records of BMW and submission of Annual Report in Form -II before 31st January	Continuous	25000
2	To maintain records of BMW material delivered to BMW/MSDF	Continuous	25000
2	Performance		
1	To provide BMW separate storage facility as per guidelines of CPCB	Continuous	50000
2	Towards installation of STP to treat domestic effluent within 6 months	6 months	300000



Part 1

Sl. No.	Consent No.	Sl. No. of Model	Submission No.	Purpose of BE	Reason of BE
	023/020/020				Forfeiture
NA					

Part 2

Sl. No.	Consent No.	Sl. No. of Model	Submission No.	Purpose of BE	Amount of BE Returned
NA					

SCHEDULE-IV


**General Conditions:**

1. You shall provide facility for collection of environmental samples and samples of trade and sewage effluents, air emissions and hazardous waste to the Board staff at the terminal or designated points and shall pay to the Board for the services rendered in this behalf.
2. You should monitor effluent quality, stack emissions, noise and ambient air quality quarterly.
3. You shall provide ports in the chimney/(s) and facilities such as ladder, platform etc. for monitoring the air emissions and the same shall be open for inspection to/and for use of the Board's Staff. The chimney(s) vents attached to various sources of emission shall be designated by numbers such as S-1, S-2, etc. and these shall be painted/displayed to facilitate identification.
4. Whenever due to any accident or other unforeseen act or event, such emissions occur or is apprehended to occur in excess of standards laid down, such information shall be forthwith Reported to Board, concerned Police Station, office of Directorate of Health Services, Department of Explosives, inspectorate of Factories and Local Body. In case of failure of pollution control equipments, the production process connected to it shall be stopped.
5. You shall provide an alternate electric power source sufficient to operate all pollution control facilities installed to maintain compliance with the terms and conditions of the consent. In the absence, the applicant shall stop, reduce or otherwise, control production to abide by terms and conditions of this consent.
6. You shall submit, the Environmental Statement Report for the financial year ending 31st March in the prescribed Form-V as per the provisions of rule 14 of the Environment (Protection) (Second Amendment) Rules, 1992 to Regional Office, , the 30th day of September every year.
7. You shall recycle/reprocess/reuse/recover Hazardous Waste as per the provision contain in the HW (MH&TM) Rules 2008. which can be recycled /processed /reused /recovered and only waste which has to be incinerated shall go to incineration and waste which can be used for land filling and cannot be recycled/reprocessed etc should go for that purpose, in order to reduce load on incineration and landfill site/environment.
8. You shall comply with the Hazardous Waste (M, H & TM) Rules, 2008 and submit the Annual Returns to RO- as per Rule 5(6) & 22(2) of Hazardous Waste (M, H & TM) Rules, 2008 for the preceding year April to March in Form-IV by 30th June of every year.
9. An inspection book shall be opened and made available to the Board's officers during their visit to the HCE.



10. You shall strictly comply with the Water (P&CP) Act, 1974, Air (P&CP) Act, 1981 and Environmental Protection Act, 1986 and industry specific standard under EP Rules 1986 which are available on MPCB website ([www.mpcb.gov.in](http://www.mpcb.gov.in)).
11. You shall constitute an Environmental cell with qualified staff/personnel/agency to see the day to day compliance of consent & authorization condition towards Environment Protection.
12. Separate drainage system shall be provided for collection of trade and sewage effluents. Terminal manholes shall be provided at the end of the collection system with arrangement for measuring the flow. No effluent shall be admitted in the pipes/sewers downstream of the terminal manholes. No effluent shall find its way other than in designed and provided collection system.
13. Neither storm water nor discharge from other premises shall be allowed to mix with the effluents from the HCE.
14. You shall install a separate meter showing the consumption of energy for operation of domestic and industrial effluent treatment plants and air pollution control system. A register showing consumption of chemicals used for treatment shall be maintained.
15. You should not cause any nuisance in surrounding area.
16. You shall take adequate measures for control of noise levels from its own sources within the premises so as to maintain ambient air quality standard in respect of noise to less than 75 dB (A) during day time and 70 dB (A) during night time. Day time is reckoned in between 6 a.m. and 10 p.m. and night time is reckoned between 10 p.m. and 6 a.m.
17. You shall maintain good housekeeping.
18. You shall bring minimum 33% of the available open land under green coverage/ plantation. The applicant shall submit a yearly statement to Regional Office by 30th September every year on available open plot area, number of trees surviving as on 31st March of the year and number of trees planted by September end.
19. The non-hazardous solid waste arising in the factory premises, sweepings, etc. be disposed of scientifically so as not to cause any nuisance / pollution. The applicant shall take necessary permissions from civic authorities for disposal of solid waste.
20. You shall not change or alter the quantity, quality, the rate of discharge, temperature or the mode of the effluent/emissions or hazardous wastes or control equipments provided for without previous written permission of the Board. You will not carry out any activity, for which this consent has not been granted/without prior consent of the Board.
21. You shall submit Six Monthly statement in respect of obligation towards consent and pollution control compliance's duly supported with documentary evidences (format can downloaded from MPCB official site).
22. You shall submit official e-mail address and any change will be duly informed to the MPCB, forthwith.
23. You shall achieve the National Ambient Air Quality standards prescribed vide Government of India, Notification dtd. 16.11.2009 as amended
24. You shall observe provisions of E-waste (Management and Handling) Rules 2011 and Battery Waste (Management and Handling) Rules 2001, as amended.

For and on behalf of the  
Maharashtra Pollution Control Board.

  
(Ashok Shingare IAS),  
Member Secretary

**FOR Ph.D COURSE (S) FOR A.Y.2023-2024**

(Please submit separate report for each subject)

Date of Inspection : \_\_\_\_\_

Faculty: Dr. Vijayshree Khaikar (Deotale) Subject/Specialty: Microbiology

**I. Name & Address of the College/Research Centre:-**

Department of Microbiology, Mahatma Gandhi Institute of medical Sciences, Sevagram

Name of Head of the Department:- Dr. Vijayshree Khaikar (Deotale)

Designation: Director Professor &amp; Head

**2. Department/Subject wise details of available PhD Guides:-  
(Attach Annexure "A")**

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Vijayshree Khaikar (Deotale)	Director Professor & Head	27/12/1966	30/12/2030	02	Yes	MUHS/UDC/Ph.D/E-1/854/2017 dated 03/07/2017
2							
3							
4							
5							

**4. Details of available infrastructure for Research:**

i) Adequate number of Computers with Internet facility is available? Yes/No

ii) Adequate number of Books/Journals are available? Yes/No

iii) Any other specific thing available at the Department: .....

.....  
.....  
.....**5. Details of Central Research Laboratory:**

i) Available Area (in sq. ft): 3230 Sq.ft.

ii) Is Drugs/Medicines/Chemicals etc. are available for research? Yes/No

iii) Is Adequate number of Instruments are available? Yes/No

iv) Is Records of Stock book available? Yes/No

**6. Details of Central Animal House:**

i) Available Area in sq. ft: 1175 sq.ft.

ii) Functioning Central Animal House? Yes /No



7. **Details of Institutional Ethical Committee:(Attach Annexure "B")**
- i) Date of Composition: **As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022)**
  - ii) Total Number of Members: **13**
  - iii) Number of meetings held in previous year: **05 (October 2021 - October 2022)**
  - iv) Whether Records of proceedings are maintained properly? **Yes/No**
  - v) Is Human and Animal Ethics Committee, registered under the appropriate authority? **Yes/No**
8. **Details of Research Advisory Committee:(Attach Annexure "C")**
- i) Date of Composition: **12th July, 2013**
  - ii) Total number of Members: **08**
  - iii) Number of meetings held in previous year: **02 (2021-22)**
  - iv) Whether records of proceedings are maintained properly? **Yes/No**
9. **Is Doctoral Committee constituted in the lines of RAC?** **Yes/No**
- i) If Yes, Date of Composition: **21-7-22**
  - ii) Total number of Members: **15**
  - iii) Name of External Subject Expert: **List attached (Annexure "D")**
10. **Is Plagiarism detection software facility available?** **Yes/No**  
If Yes, Name of the Software **Ouriginal Software by Turnitin**
11. **Is attendance of the Ph.D. Scholar maintained properly?** **Yes/No**
12. **Whether Research Centre is registered under MPCB provisions?** **Yes/No**
13. **Whether BMW facility is available?** **Yes/No**
14. **Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:**

.....

**DECLARATION BY LIC**

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows:-

.....

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	



MUHS

महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक  
MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK

दिंडोरी रोड, म्हासुरुळ, नाशिक - ४२२००४ Dindori Road, Mhasrul, Nashik - 422004

Tel: (0253) 2539206/2539196, Fax: (0253) 2539197

Website: <http://www.muhs.ac.in>, E-mail: [udc@muhs.ac.in](mailto:udc@muhs.ac.in)

राजेंद्र चं. शहाणे

सहा.कुलसचिव

Rajendra C. Shahane

Asst. Registrar

O.No.: MUHS/UDC/Ph.D/E-1/ 854 /2017

Date: 03/07/2017

By Email &amp; By Post

To,  
The Dean / Principal  
Mahatma Gandhi Institute of Medical Sciences,  
Post - Sevagram,  
Wardha - 442 102  
Email - [dean@mgims.ac.in](mailto:dean@mgims.ac.in)



Sub: - Recognition as Ph.D Guide...

- Ref:- 1) Comments received dtd. 23/06/2017  
2) MGIMS, Sevagram, Wardha letter no. C/Gen/PhD/873 dtd. 05/04/2017  
3) Our letter no. MUHS/UDC/PFL-03/E-1/627/2017 dtd.25/04/2017  
4) MGIMS, Sevagram, Wardha letter no. C/PhD/6144 dtd. 24/11/2016  
5) Ph.D Direction no. 04/2015 (Amended in 2016)

Sir/Madam,

With reference to the above cited subject, I am directed to inform you that in view of the norms prescribed as per the provision u/s 29 (2) of (i) of MUHS Act, 1998 & clause 07 (2) (a) (i) of Direction No. 04/2015 ( Amended in 2016) Hon'ble Vice Chancellor is pleased to grant recognition as Ph.D Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order, for guiding the Ph.D student in the subject mentioned against his/her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D Guide
1.	Microbiology	Dr. Vijayshri Suresh Deotale	Professor & HOD	Approved w.e.f. 23/06/2017, onwards

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service of the said teaching college/institute/or till attaining the age of superannuation, whichever happens earlier.

(Page 02)

Dean

03/07/17


- SLS

Copy to Dr. Vijayshree



The above teacher is required to attend the Research Methodology Workshop conducted by Regional Centre, Pune of this University or any other centre authorised by the University.

You are requested to handover the copy of this letter to the concerned teacher for further necessary action.

Yours,  
  
Asst. Registrar  
University Dept. Cell

*[Note:- In case, at later stage, if it is found that the information furnished in the Ph.D recognition form by any Guide is incorrect, Ph.D Guide Recognition granted by the University will stand cancelled ]*

**Copy to:**

**Dr. Vijayshri Suresh Deotale**  
Professor & HOD  
Dept. of Microbiology  
Mahatma Gandhi Institute of Medical Sciences,  
Post - Sevagram, Wardha -- 442 102  
Email ID- [vijayshri@mgims.ac.in](mailto:vijayshri@mgims.ac.in)  
Mob - 9822501099



सत्यमेव जयते

File No. EC/19/000199  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

S

ESWARA

REDDY

(Dr. S. Eswara Reddy)

Drugs Controller General (I) &  
Central Licensing Authority

Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:41:40 +05'30'

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL  
TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licencing Authority  
Stamp  
ESWARA  
REDDY  
Digitally signed  
by S ESWARA  
REDDY  
Date: 2019.08.09  
13:39:25 +05'30'



Mahatma Gandhi Institute of Medical Sciences  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**

Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in)

Reg. No. ECR/47/Inst/MH/2013/RR-19  
(Under New Drugs and Clinical Trials Rules, 2019)



EC-CT-2021-0168

05 Mar 2021 - 04 Mar 2024

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID. and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raison University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Raison University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varna	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smita@mgims.ac.in">smita@mgims.ac.in</a>	Clinician	Director Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Chief Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jamnalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Professor, Faculty of Nursing

Date: 11<sup>th</sup> July 2022

Dr. Sushil Kumar Varna

*(Signature)*  
Secretary  
Institutional Ethics Committee  
MGIMS, Sevagram, India

Dr. Ashok Pawade

*(Signature)*  
Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India



File No. EC/NEW/INST/2020/490



सत्यमेव जयते

Government of India  
Ministry of Health & Family Welfare  
Department of Health Research  
(National Ethics Committee Registry for Biomedical and Health Research)

2nd Floor, IRCS Building,  
Red Cross Road, New Delhi – 110001  
Date : 03-Mar-2022

FORM CT-03

(See rules 17 and 18)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO BIOMEDICAL HEALTH RESEARCH

Registration No. EC/NEW/INST/2022/MH/0072

The designated authority hereby registers and permits Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Kasturba Health Society Sevagram, City-Wardha, District-Wardha - Maharashtra - 442102 Contact No.: 07152-284341-355 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter IV of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 03-Mar-2022

ANU

Digitally signed  
by ANU NAGAR

NAGAR

Date: 2022.03.03  
11:01:12 +05'30'

Designated Registration Authority  
Stamp

CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



a) Equipment:

**List of Equipment in the Department of Central Research Lab**

Sr. No.	Equipment	Qty	Sr. No.	Equipment	Qty
1.	Real Time PCR Machine (Applied Biosystems)	1	29	Fraction collector	1
2.	PCR machines (Thermo cyclers) (Biometra& Applied Biosystems)	2	30	BOD incubator	1
3.	2-D Electrophoresis system (GE Healthcare)	1	31	LKB Minitan Ultra filtration equipment	1
4.	FPLC Equipment (Pharmacia Biotech & Akta Basic)	2	32	LKB minicold room with chromatography Equipment including fraction collector, Peristaltic pump, UV-monitor	1
5.	Hybridization oven	1	33	Klenzaid's Horizontal Laminar Flow Model	1
6.	Sub-marine multiphoresis electrophoresis apparatus	2	34	Vertical Laminar Flow units	2
7.	UV Trans-illuminator	1	35	Kontron Ultra centrifuge, model TGA 65	1
8.	SDS-PAGE (Apparatus)	4	36	Cryopreservation equipment (Forma scientific)	1
9.	Kodak Gel doc system	1	37	Pellicon Ultra Filtration System (Millipore)	1
10.	Water Purification System (Ultra Pure) (Millipore& Elga Water Labs)	2	38	Chemical balances	1
11.	ELISA Readers (Biorad Model 680, ERBA Mscan&Biotek)	3	39	Single pan electrical balances	4
12.	ELISA Washer(Biorad&Biotek)	2	40	Colorimeters	2
13.	UV visible Spectrophotometer ELICO	2	41	Stereo and binocular and monocular microscopes	4
14.	Western Blotting apparatus (Biorad, Biotech & GE Healthcare)	3	42	Dissection Microscope	2
15.	Nikon Inverted microscope	1	43	PH meters	3
16.	Fluorescence Microscope (Nippon& Carl Ziess)	2	44	Water baths	4
17.	Bright field Microscope (Carl Ziess)	1	45	Water distillation apparatus	2
18.	Incubator-Shakers (Scigenics)	3	46	Rotary evaporator	1
19.	CO <sub>2</sub> incubators	2	47	Rockers	4
20.	Liquid Scintillation Counter (Packard)	1	48	Homogenizer	1
21.	Walk in Cold room	1	49	Hot air ovens	2
22.	-86°C Deep freezer (Thermo Scientific& NBS)	2	50	Hot plates	2
23.	Deep freezers -20°C	3	51	Vacuum pump	1
24.	Freeze drier (Virtis)	1	52	Cyclo Mixers	4
25.	Ice Flaker	2	53	Microwave oven	1
26.	Sonicator	1	54	Magnetic stirrers	4
27.	Refrigerated centrifuge (Remi)	3	55	Refrigerators	6
28.	Portable high speed centrifuge	3			

CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned



Ph. D. Doctoral Committee Member List

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	drshabaana@gmail.com	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	drshaileshnagpure@gmail.com	9503509430
3	Pathology	Dr. Samarth Shukla Prof. Pathology, JNMC, Sawangi, Wardha	samarth21174@gmail.com	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	gargimudey@hotmail.com	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	anujab803@gmail.com, anuja_bhalerao@yahoo.com	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	sanjay.zodpey@phfi.org	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalalk), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acharya Dhonde Marg, Parali (C), Mumbai 400012	anitachalalk@rediffmail.com	9850620123

# MAHARASHTRA POLLUTION CONTROL BOARD

Tel: 24010706/24010437  
Fax: 24023516  
Website: <http://mpcb.gov.in>  
Email: [cac-cell@mpcb.gov.in](mailto:cac-cell@mpcb.gov.in)



Kalpataru Point, 2nd and  
4th floor, Opp. Cine Planet  
Cinema, Near Sion Circle,  
Sion (E), Mumbai-400022

RED/L.S.I

No:- Format1.0/CAC/UAN No.0000035753/CR - 2202000245

Date: 03/02/2022

To,  
MATATMA GANDHI INSTITUTE OF MEDICAL SCIENCES  
SEWAGRAM WARDHA  
SR. NO. 276,,SR. NO. 276, SEWAGRAM,  
TAL & DIST-WARDHA



**Sub: Combined consent and BMW Authorization under Red category**

- Ref:**
1. Bio-Medical Authorization granted by the Board vide no. BO/PSO/BMW/Nagpur/2013-14 Dated 30.08.2013 valid up to 31.03.2016.
  2. Your application for Combine Consent and Bio-Medical Authorization dated 03.11.2017
  3. The minutes of Consent Appraisal Committee meeting dated 25.02.2019

Combined Consent to Renewal and BMW Authorization.

For: Under Section 26 of the Water (Prevention & Control of Pollution) Act, 1974 & under Section 21 of the Air (Prevention & Control of Pollution) Act, 1981 and Authorization under Rule 6 of the Hazardous & Other Wastes (Management & Transboundary Movement) Rules 2016 and Bio-Medical Waste Management Rules, 2016 and amendment thereof is considered and the consent is hereby granted subject to the following terms and conditions and as detailed in the schedule I, II, III & IV annexed to this order:

1. **The Combined Consent to Renewal and BMW authorization is granted upto: 31.12.2023**
2. **The capital investment of the project is Rs.15.4359 Crs. ( ).**
3. **The Consent is valid for the Activity of**

Sr No	Activity	Quantity	UOM
1)	Hospital		
a)	Beds	972	Nos
b)	Total Plot Area	155700.00	Sq.Mtrs
c)	Total Built up Area	68120.30	Sq.Mtrs

4. **Conditions under Water (P&CP) Act, 1974 for discharge of effluent:**

Sr No	Description	Permitted (in CMD)	Standards to Acheive	Disposal
1.	Trade effluent	15	As per Schedule -I	Treated effluent shall recycle up to maximum extent and remaining used on land for gardening / dispose in to sewerage system provided by Local body.



Sr No	Description	Permitted (in CMD)	Standards to Achieve	Disposal
2.	Domestic effluent	390	As per Schedule - I	As above.

5. Conditions under the Air (P& CP) Act, 1981 for air emissions:

Sr.No	Description of stack / source	Number of Stack	Standards to be achieved
1	NA	1	As per Schedule -II

6. Conditions under Hazardous & Other Wastes (M & T M) Rules 2008 for treatment and disposal of hazardous waste:

Sr No	Type of Waste	HW Category.	Quantity	UoM	Treatment	Disposal
1	35.3 Chemical sludge from waste water treatment	34.3	1.43	Kg/Day	Landfill	CHWTSDF

7. Conditions about Non Hazardous Wastes:

Sr No	Type of Waste	Quantity	UoM	Treatment	Disposal
1	STP Sludge	25	Kg/Day	Composting	Used as a manure
2	Wet Waste	300	Kg/Day	Composting	NA
3	Dry Waste	200	Kg/Day	Sale/ Composting	Reuse/ Composting

8. Treatment and Disposal of Biomedical Waste generated to CBMWTSDF:

Sr.No	Category	Type of Waste	Quantity not to exceed (Kg/M)	Segregation Color coding	Treatment & Disposal
1	Yellow	a) Human Anatomical waste	138.42	Yellow colored non-chlorinated plastic bags	CBMWTSDF
		b) Soiled Waste	3135.27		
		c) Expired or Discarded Medicines	1.14		
		d) Discarded linen, mattresses, beddings contaminated with blood or body fluid.	134.76		
		e) Microbiology Biotechnology and other clinical laboratory waste	14.34		
2	Red	Contaminated waste (Recyclable)	2184.33	Red colored non chlorinated plastic bags or containers	CBMWTSDF
3	White (Translucent)	Waste sharps including Metals	39.94	Puncture proof, Leak proof, tamper proof container	CBMWTSDF
4	Blue	a) Glassware	826.11	Puncture proof & leak proof boxes or containers with blue colored marking.	CBMWTSDF
		b) Metallic body implants	54.38		




9. PP shall comply the following guidelines published by the CPCB on February-2019 regarding handling of BMW for utilization
1. HCE shall preferably handover Bio-medical wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms for production of drugs, reagent chemicals, markers etc. if any such as Pharmaceutical industry / Biotechnology firm approaches them for the same. If there are any difficulties in the matter, the same may be communicated to such firm and copied to the board also.
  2. HCE shall strictly follow the procedure for packaging & transportation of Bio-medical Wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms as per the guidelines of CPCB published in Feb-2019 for "Handling of BMW for utilization".
  3. HCEs shall submit the report to the Board office about type, quantity and frequency of handling over such BMW on yearly basis.
  4. Industry to enter into legal agreement with HCE's and inform the MPC Board and competent authority of State Public Health Department about such collection of BMW along with quantity and type of waste collected.
  5. In case of any technical difficulty towards handing over the required BMW, you shall inform to the Board accordingly.
  6. HCEs shall properly dispose and handover the waste to authorised user / facilities having valid consent to operate from MPCB.
10. This consent is issued subject to conditions mentioned below:
- a. The "authorized Person" shall comply with provisions of the Environment (Protection) Act, 1986, and the Rules made there under.
  - b. Any unauthorized change in equipment or working conditions as mentioned in the application by the person authorized shall constitute a breach of this Authorization.
  - c. You shall submit details of Management and Handling of outdated, discarded, unused Cytotoxic drugs generated in the Cancer centers, research and health care in the format prescribed by CPCB which is available on [www.cpcb.nic.in](http://www.cpcb.nic.in) alongwith Annual Report to MPCB with a copy to CPCB before 31st January every year.
  - d. You shall manage the Mercury Waste in the HCE in environmentally sound manner (including storage, spilled collection, transportation and disposal) as per CPCB guidelines published on CPCB website [www.cpcb.nic.in](http://www.cpcb.nic.in) dated: 07.09.2010 as detailed in document entitled "Environmentally Sound Management of Mercury Waste in Health Care Facilities".
  - e. You shall ensure phase out of chlorinated plastic bags, gloves and blood bags by HCEs within two years.
  - f. You shall establish Bar code system within one year.
  - g. You shall ensure that the liquid waste is treated and disposed by all the occupier or operator of a CBWTF in accordance with the Water Act, 1974;
  - h. You shall maintain day to day basis and display the monthly record Including Annual report on its website within two years from the date of Notification.
  - i. You shall submit separate Bank Guarantees towards compliance of condition mentioned at Annexure - IV to Regional Office, within 30 days.
  - j. You shall submit compliance of Bank Guarantee conditions every six months to Regional Officer, for verification purpose.



- k. You shall submit application for renewal of Combined Consent and Biomedical Waste authorization before 120 days along with appropriate fees.
11. This Board reserves the right to review, amend, suspend, revoke etc. this consent and the same shall be binding on the industry.
  12. This consent should not be construed as exemption from obtaining necessary NOC/permission from any other Government agencies.
  13. PP shall install STP to treat domestic effluent within 6 months and submission of BG of Rs.3.0 Lakhs towards compliance of the same.
  14. PP shall submit BG's as per HCE's regime of the Board.
  15. PP shall dispose BMW at CBMWTSDf only and shall not operate incinerator. PP shall discontinue the operation of incinerator.

For and on behalf of the  
Maharashtra Pollution Control  
Board.

  
(Ashok Shingare IAS),  
Member Secretary

Received Consent fee of -

Sr.No	Amount(Rs.)	Transaction/DR.No.	Date	Transaction Type
1	250000.00	7606401	06/07/2018	NEFT
2	316250.00	MPCB-DR-0154	21/06/2020	RTGS
3	75000.00	7606401	06/07/2018	DD

Copy to:

1. Regional Officer, MPCB, Nagpur and Sub-Regional Officer, MPCB, Nagpur II  
- They are directed to ensure the compliance of the consent conditions.
2. Chief Accounts Officer, MPCB, Sion, Mumbai

### SCHEDULE-I

#### Terms & conditions for compliance of Water Pollution Control:

1. A) As per your application, you have provided Effluent Treatment Plant (ETP) of designed capacity of 15.00 CMD consisting of Primary (Collection tank, Neutralization tank) .  
B) The Applicant shall operate the effluent treatment plant (ETP) to treat the trade effluent so as to achieve the following standards prescribed by the Board or under EP Act, 1986 and Rules made there under from time to time, whichever is stringent:

Sr.No	Parameters	Standards
	I. Compulsory Parameters	Limiting Concentration in mg/l, except for pH
(1)	pH	5.5 to 8.5
(2)	Oil & Grease	10 mg/l
(3)	BOD (3 days 27°C )	30 mg/l
(4)	Total Suspended Solids	100
(5)	COD	250

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
2. A) As per your application, you have provided Sewage Treatment Plant of designed capacity 1000 CMD for the treatment of 390 CMD of sewage.  
B) The Applicant shall operate the sewage treatment system to treat the sewage so as to achieve the following standards.

1	BOD	Not to exceed	30
2	COD	Not to exceed	100
3	Suspended Solids	Not to exceed	50

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
3. The Board reserves its rights to review plans, specifications or other data relating to plant setup for the treatment of waterworks for the purification there of & the system for the disposal of sewage or trade effluent or in connection with the grant of any consent conditions. The Applicant shall obtain prior consent of the Board to take steps to establish the unit or establish any treatment and disposal system or an extension or addition thereto.
  4. The industry shall ensure replacement of pollution control system or its parts after expiry of its expected life as defined by manufacturer so as to ensure the compliance of standards and safety of the operation thereof.



5. The Applicant shall comply with the provisions of the Water (Prevention & Control of Pollution) Act, 1974 and as amended, by installing water meters and other provisions as contained in the said act:

<b>Sr. No.</b>	<b>Purpose for water consumed</b>	<b>Water consumption quantity (CMD)</b>
1.	Industrial Cooling, spraying in mine pits or boiler feed	1.00
2.	Domestic purpose	490.00
3.	Processing whereby water gets polluted & pollutants are easily biodegradable	16.00
4.	Processing whereby water gets polluted & pollutants are not easily biodegradable and are toxic	0.00
5.	Gardening	0

6. The Applicant shall provide Specific Water Pollution control system as per the conditions of EP Act, 1986 and rule made there under from time to time/ Environmental Clearance/ CREP guidelines.

#### **SCHEDULE-II**

#### **Terms & conditions for compliance of Air Pollution Control:**

1. As per your application, you have provided the Air pollution control (APC) system and erected following stack (s) to observe the following fuel pattern:

<b>Stack No.</b>	<b>Stack Attached To</b>	<b>APC System</b>	<b>Height in Mtrs.</b>	<b>Type of Fuel</b>	<b>Quantity &amp; UoM</b>	<b>S% SO<sub>2</sub></b>
0	NA 0	0	0	NA	0 --NA--	0.00 0.00

2. The applicant shall provide stack height of mtrs operate and maintain above mentioned air pollution control system, so as to achieve the level of pollutants to the following standards:

Total Particulate matter	Not to exceed	150 mg/Nm <sup>3</sup>
--------------------------	---------------	------------------------

3. The Applicant shall obtain necessary prior permission for providing additional control equipment with necessary specifications and operation thereof or alteration or replacement/alteration well before its life come to an end or erection of new pollution control equipment.
4. The Board reserves its rights to vary all or any of the condition in the consent, if due to any technological improvement or otherwise such variation (including the change of any control equipment, other in whole or in part is necessary).
5. Conditions for D.G. Set
- Noise from the D.G. Set should be controlled by providing an acoustic enclosure or by treating the room acoustically.
  - Industry should provide acoustic enclosure for control of noise. The acoustic enclosure/ acoustic treatment of the room should be designed for minimum 25 dB (A) insertion loss or for meeting the ambient noise standards, whichever is on higher side. A suitable exhaust muffler with insertion loss of 25 dB (A) shall also be provided. The measurement of insertion loss will be done at different points at 0.5 meters from acoustic enclosure/room and then average.



- c) Industry should make efforts to bring down noise level due to DG set, outside industrial premises, within ambient noise requirements by proper siting and control measures.
- d) Installation of DG Set must be strictly in compliance with recommendations of DG Set manufacturer.
- e) A proper routine and preventive maintenance procedure for DG set should be set and followed in consultation with the DG manufacturer which would help to prevent noise levels of DG set from deteriorating with use.
- f) D.G. Set shall be operated only in case of power failure.
- g) The applicant should not cause any nuisance in the surrounding area due to operation of D.G. Set.
- h) The applicant shall comply with the notification of MoEF dated 17.05.2002 regarding noise limit for generator sets run with diesel.

### SCHEDULE-III

#### Details of Bank Guarantees:

Sr. No.	Consent(C2E/C2O/C2R)	Amt of BG Imposed	Submission Period	Purpose of BG	Compliance Period	Validity Date
NA						

\*\* The above Bank Guarantee(s) shall be submitted by the applicant in favour of Regional Officer at the respective Regional Office within 15 days of the date of issue of Consent.  
**# Existing BG obtained for above purpose if any may be extended for period of validity as above.**

**Statement of conditions to be complied and Bank Guarantee imposed to ensure timely compliance to be observed by:**

Sr.No	Activity / Condition to be Complied	Compliance Timeline(Months)	Bank Guarantee Amount
1A	Operation and Maintenance		
1	To Segregate and Handle BMW as per Rule	Continuous	75000
2	Towards Operation and Maintenance of STP/ETP to achieve prescribed discharge standards	Continuous	100000
1B	Records		
1	To Maintain records of BMW and submission of Annual Report in Form -II before 31st January	Continuous	25000
2	To maintain records of BMW material delivered to CBMWTSDF	Continuous	25000
2	Performance		
1	To provide BMW separate storage facility as per guidelines of CPCB	Continuous	50000
2	Towards installation of STP to treat domestic effluent within 6 months	6 months	300000



### BG Forfeiture History

Srno.	Consent (C2E/C2O/C2R)	Amount of BG Imposed	Submission Period	Purpose of BG	Amount of BG Forfeiture	Reason of BG Forfeiture
NA						

### BG Return details

Srno.	Consent (C2E/C2O/C2R)	BG imposed	Purpose of BG	Amount of BG Returned
NA				

### SCHEDULE-IV


#### General Conditions:

1. You shall provide facility for collection of environmental samples and samples of trade and sewage effluents, air emissions and hazardous waste to the Board staff at the terminal or designated points and shall pay to the Board for the services rendered in this behalf.
2. You should monitor effluent quality, stack emissions, noise and ambient air quality quarterly
3. You shall provide ports in the chimney/(s) and facilities such as ladder, platform etc. for monitoring the air emissions and the same shall be open for inspection to/and for use of the Board's Staff. The chimney(s) vents attached to various sources of emission shall be designated by numbers such as S-1, S-2, etc. and these shall be painted/displayed to facilitate identification.
4. Whenever due to any accident or other unforeseen act or even, such emissions occur or is apprehended to occur in excess of standards laid down, such information shall be forthwith Reported to Board, concerned Police Station, office of Directorate of Health Services, Department of Explosives, Inspectorate of Factories and Local Body. In case of failure of pollution control equipments, the production process connected to it shall be stopped.
5. You shall provide an alternate electric power source sufficient to operate all pollution control facilities installed to maintain compliance with the terms and conditions of the consent. In the absence, the applicant shall stop, reduce or otherwise, control production to abide by terms and conditions of this consent.
6. You shall submit, the Environmental Statement Report for the financial year ending 31st March in the prescribed Form-V as per the provisions of rule 14 of the Environment (Protection) (Second Amendment) Rules, 1992 to Regional Office, , the 30th day of September every year.
7. You shall recycle/reprocess/reuse/recover Hazardous Waste as per the provision contain in the HW (MH&TM) Rules 2008, which can be recycled /processed /reused /recovered and only waste which has to be incinerated shall go to incineration and waste which can be used for land filling and cannot be recycled/reprocessed etc should go for that purpose, in order to reduce load on incineration and landfill site/environment.
8. You shall comply with the Hazardous Waste (M, H & TM) Rules, 2008 and submit the Annual Returns to RO- as per Rule 5(6) & 22(2) of Hazardous Waste (M, H & TM) Rules, 2008 for the preceding year April to March in Form-IV by 30th June of every year.
9. An inspection book shall be opened and made available to the Board's officers during their visit to the HCE.



10. You shall strictly comply with the Water (P&CP) Act, 1974, Air (P&CP) Act, 1981 and Environmental Protection Act, 1986 and industry specific standard under EP Rules 1986 which are available on MPCB website ([www.mpcb.gov.in](http://www.mpcb.gov.in)).
11. You shall constitute an Environmental cell with qualified staff/personnel/agency to see the day to day compliance of consent & authorization condition towards Environment Protection.
12. Separate drainage system shall be provided for collection of trade and sewage effluents. Terminal manholes shall be provided at the end of the collection system with arrangement for measuring the flow. No effluent shall be admitted in the pipes/sewers downstream of the terminal manholes. No effluent shall find its way other than in designed and provided collection system.
13. Neither storm water nor discharge from other premises shall be allowed to mix with the effluents from the HCE.
14. You shall install a separate meter showing the consumption of energy for operation of domestic and industrial effluent treatment plants and air pollution control system. A register showing consumption of chemicals used for treatment shall be maintained.
15. You should not cause any nuisance in surrounding area.
16. You shall take adequate measures for control of noise levels from its own sources within the premises so as to maintain ambient air quality standard in respect of noise to less than 75 dB (A) during day time and 70 dB (A) during night time. Day time is reckoned in between 6 a.m. and 10 p.m. and night time is reckoned between 10 p.m. and 6 a.m.
17. You shall maintain good housekeeping.
18. You shall bring minimum 33% of the available open land under green coverage/ plantation. The applicant shall submit a yearly statement to Regional Office by 30th September every year on available open plot area, number of trees surviving as on 31st March of the year and number of trees planted by September end.
19. The non-hazardous solid waste arising in the factory premises, sweepings, etc. be disposed of scientifically so as not to cause any nuisance / pollution. The applicant shall take necessary permissions from civic authorities for disposal of solid waste.
20. You shall not change or alter the quantity, quality, the rate of discharge, temperature or the mode of the effluent/emissions or hazardous wastes or control equipments provided for without previous written permission of the Board. You will not carry out any activity, for which this consent has not been granted/without prior consent of the Board.
21. You shall submit Six Monthly statement in respect of obligation towards consent and pollution control compliance's duly supported with documentary evidences (format can downloaded from MPCB official site).
22. You shall submit official e-mail address and any change will be duly informed to the MPCB, forthwith.
23. You shall achieve the National Ambient Air Quality standards prescribed vide Government of India, Notification dtd. 16.11.2009 as amended
24. You shall observe provisions of E-waste (Management and Handling) Rules 2011 and Battery Waste (Management and Handling) Rules 2001, as amended.

For and on behalf of the  
Maharashtra Pollution Control Board.

  
(Ashok Shingare IAS),  
Member Secretary



**FOR Ph.D COURSE(S) FOR A.Y. 2022.....-2023.....**

(Please submit separate report for each subject)

<b>Date of Inspection</b> :	
-----------------------------	--

**Faculty:** Orthopaedis. .... **Subject/Specialty:** .....MS -Ortho.....

**1. Name & Address of the College/Research Centre: -**

.....Mahatma Gandhi Institute o Medical Sciences, Sewagram, Dist- Wardha-442102

**Name of Head of the Department:** - ...Dr. Chandrashekhar Martand Badole.....

**Designation:** ...Dir-Professor & Head.....

**2. Department / Subject wise details of available PhD Guides: -  
(Attach Annexure "A")**

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Chandrashekhar Martand Badole	Dir-Professor & Head	28.08.1961	28/08/2025	0	yes	MUHS/UDC/Ph.D/67/2009
2	Dr. Kisan Rajaramji Patond	Dir-Professor	26.02.1956	28/02/2018	1	yes	MUHS/UDC/Ph.D/47/2008

**4. Details of available infrastructure for Research:**

i) Adequate number of Computers with Internet facility is available?  Yes /  No

ii) ) Adequate number of Books / Journals are available ?  Yes /  No

iii) Any other specific thing available at the Department:.....

**5. Details of Central Research Laboratory:**

i) Available Area (in sq. ft) : . . . 3230Sq.ft. ....

ii) Is Drugs/Medicines/Chemicals etc. are available for research?  Yes /  No

iii) Is Adequate number of Instruments are available?  Yes /  No

iv) Is Records of Stock book available?  Yes /  No

**6. Details of Central Animal House:**

i) Available Area in sq. ft: . . . 1175 sq.ft. ....

ii) Functioning Central Animal House?  Yes /  No

**7. Details of Institutional Ethical Committee: (Attach Annexure "B")**

- i) Date of Composition: . As per available records IEC started operations 2002 onwards. Registered on 20/04/2013 under Central Drugs Standard Control Organization, Directorate General of Health services and last re-registered(Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 Aug. 2019) and Registered under Departement of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022. ....
- ii) Total Number of Members: .13 .....
- iii) Number of meetings held in previous year: .05(October,2021 to October,2022) .....
- iv) Whether Records of proceedings are maintained properly?  Yes /  No
- v) Is Human and Animal Ethics Committee, registered under the appropriate authority?  Yes /  No

**8. Details of Research Advisory Committee: (Attach Annexure "C")**

- i) Date of Composition: . 12<sup>th</sup> July, 2013. ....
- ii) Total number of Members: .08 .....
- iii) Number of meetings held in previous year: 02 (2021-22). ....

**9. Whether records of proceedings are maintained properly?**  Yes /  No

**10. Is Doctoral Committee constituted in the lines of RAC?**  Yes /  No

- i) If Yes, Date of Composition: . 21/07/2022 .....
- ii) Total number of Members: . 15. ....
- iii) Name of External Subject Expert.....

**Ph. D. Doctoral Committee Member List**

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	drshabaana@gmail.com	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	drshaileshnagpure@gmail.com	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	samarth21174@gmail.com	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	gargimudey@hotmail.com	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	anujab803@gmail.com. anuja_bhalerao@yahoo.com	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	sanjay.zodpey@phfi.org	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (€), Mumbai 400012	anitachalak@rediffmail.com	9850620123

**11. Is Plagiarism detection software facility available?**  Yes /  No

If Yes, Name of the Software..... Shodhshuddhi.....

**12. Is attendance of the Ph.D. Scholar maintained properly?**  Yes /  No

**13. Whether Research Centre is registered under MPCB provisions?**  Yes /  No



14. Whether BMW facility is available?

✓Yes / No

15. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:

..... BMD (Bone Mineral Density) Machine – EXA-3000 (Dual-xray Bone Densitometer)

**DECLARATION BY LIC**

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows: -

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	



File No. EC/19/000199  
 Government of India  
 Directorate General of Health Services  
 Central Drugs Standard Control Organization  
 (Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
 New Delhi - 110002, India  
 Dated: 09-Aug-2019

To

The Chairman  
 Institutional Ethics Committee  
 (Department of Pharmacology),  
 Mahatma Gandhi Institute of Medical sciences,  
 Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

S  
 ESWARA  
 REDDY  
 (Dr. S. Eswara Reddy)  
 Drugs Controller General (I) &  
 Central Licensing Authority

Digitally signed  
 by S ESWARA  
 REDDY  
 Date: 2019.08.09  
 13:41:40 +05'30'

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.





Mahatma Gandhi Institute of Medical Sciences  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**

Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in)

Reg. No. ECR/47/Inst/MH/2013/RR-19  
(Under New Drugs and Clinical Trials Rules, 2019)



EC-CT-2021-0168

05 Mar 2021 - 04 Mar 2024

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID, and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raison University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Raison University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smitta@mgims.ac.in">smitta@mgims.ac.in</a>	Clinician	Director Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development)	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Chief Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jamnalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Professor, Faculty of Nursing

Date: 11<sup>th</sup> July 2022

Dr. Sushil Kumar Varma

Member Secretary  
Institutional Ethics Committee  
Mahatma Gandhi Inst. of Medical Sciences  
SEVAGRAM - 442102 Maharashtra, India

Dr. Ashok Pawade

Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India


CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khairkar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned

### Ph. D. Doctoral Committee Member List

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	<a href="mailto:drshabaana@gmail.com">drshabaana@gmail.com</a>	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	<a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	<a href="mailto:samarth21174@gmail.com">samarth21174@gmail.com</a>	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	<a href="mailto:gargimudey@hotmail.com">gargimudey@hotmail.com</a>	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	<a href="mailto:anujab803@gmail.com">anujab803@gmail.com</a> , <a href="mailto:anuja_bhalerao@yahoo.com">anuja_bhalerao@yahoo.com</a>	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	<a href="mailto:sanjay.zodpey@phfi.org">sanjay.zodpey@phfi.org</a>	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (€), Mumbai 400012	<a href="mailto:anitachalak@rediffmail.com">anitachalak@rediffmail.com</a>	9850620123



**FOR Ph.D COURSE(S) FOR A.Y. 2023-2024**

(Please submit separate report for each subject)

Date of Inspection : 

Faculty: MEDICINE

Subject/Specialty: OBSTETRICS AND GYNAECOLOGY

## 1. Name &amp; Address of the College/Research Centre: -

MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRAM, WARDHA

Name of Head of the Department: DR. SHUCHI M. JAIN

Designation: PROFESSOR AND HEAD

2. Department / Subject wise details of available PhD Guides: -  
(Attach Annexure "A")

Sr. No.	Name of Ph.D. Guide	Designation	Date of Birth	Date of Retirement	Total No. of PhD Scholars Registered till date	Has completed six days Research Methodology Workshop? Yes/No	PhD Recognition No. and Date
1	Dr. Poonam Varma Shivkumar	Director-Professor & Medical Superintendent	17/09/1962	31/09/2026	1. Dr. Karan Wanere	Yes	MUHS/UDC (Ph.D)/Guide/73/2019 Dated 22/02/2019
2							
3							

## 3. Details of available infrastructure for Research:

i) Adequate number of Computers with Internet facility is available?

✓Yes / No

ii) Adequate number of Books / Journals are available ?

✓Yes / No

iii) Any other specific thing available at the Department:.....

*Advanced skill lab available*

## 5. Details of Central Research Laboratory:

i) Available Area (in sq. ft) : 3230 Sq.ft

ii) Is Drugs/Medicines/Chemicals etc. are available for research?

✓Yes / No

iii) Is Adequate number of Instruments are available?

✓Yes / No

iv) Is Records of Stock book available?

✓Yes / No

## 6. Details of Central Animal House:

i) Available Area in sq. ft: 1175 Sq.ft

ii) Functioning Central Animal House?

✓Yes / No

**7. Details of Institutional Ethical Committee: (Attach Annexure "B")**

- i) Date of Composition: **As per available records IEC started operations 2002 onwards. Registered on 20/4/2013 under Central Drugs Standard Control Organization, Directorate General of Health Services and last re-registered (Re-Registration No. ECR/47/Inst/MH/2013/RR-19 vide letter dated 09 August 2019) and Registered under Department of Health Research, National Ethics Committee Registry for Biomedical and Health Research (Registration No. EC/NEW/INST/2022/MH/0072, dated 03-Mar-2022)**
- ii) Total Number of Members: **13**
- iii) Number of meetings held in previous year: **5 (Oct,2021-Oct.2022)**
- iv) Whether Records of proceedings are maintained properly? ✓Yes / No
- v) Is Human and Animal Ethics Committee, registered under the appropriate authority? ✓Yes / No

**8. Details of Research Advisory Committee: (Attach Annexure "C")**

- i) Date of Composition: **12<sup>th</sup> July, 2013**
- ii) Total number of Members: **08**
- iii) Number of meetings held in previous year: **02 (2021-2022)**
- iv) Whether records of proceedings are maintained properly? ✓Yes / No

**9. Is Doctoral Committee constituted in the lines of RAC?** ✓Yes / No

- i) If Yes, Date of Composition: **21/07/2022**
- ii) Total number of Members: **15**
- iii) Name of External Subject Expert

**10. Is Plagiarism detection software facility available?** ✓Yes / No

If Yes, Name of the Software – **original software by Turnitin**

**11. Is attendance of the Ph.D. Scholar maintained properly?** ✓Yes / No

**Whether Research Centre is registered under MPCB provisions?** ✓Yes / No

**12. Whether BMW facility is available?** ✓Yes / No

**13. Any other important thing related to Research/Department/Facilities, which will be helpful to carry out good quality research under this department:**

.....

.....

.....



### DECLARATION BY LIC

We, the LIC Members, hereby certify that, we have thoroughly inspected and verified the Department/College/Research Centre, the available other facilities, required instruments and equipment, available at the research centre. The overall observations of the Inspection Committee are as follows: -

.....  
.....  
.....

Name of Inspectors		Sign. of Inspectors with Date
1)	Chairman	
2)	Member	
3)	Member	
4	Member	



MUHS

# महाराष्ट्र आरोग्य विज्ञान विद्यापीठ, नाशिक

## MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES, NASHIK

दिंडोरी रोड, म्हसळ, नाशिक-४२२००४ Dindori Road, Mhasrul, Nashik-422004

Tel : (0253) 2539206/196,

Website : [www.muhs.ac.in](http://www.muhs.ac.in), E-mail : [udc@muhs.ac.in](mailto:udc@muhs.ac.in)

डॉ. उदयसिंह एस. रावराणे  
[एम.डी.आयुर्वेद]  
उपकुलसचिव

Dr. Udaysinh S. Raorane  
M.D. (Ayurved).  
Dy. Registrar

O.No.MUHS/UDC(Ph.D.)/Guide/73/2019

Date: 22/02/2019

To,  
The Dean/Principal,  
Mahatma Gandhi Institute of,  
Medical Sciences, Post. Sevagram,  
Wardha - 442 102.  
Email - [dean@mgims.ac.in](mailto:dean@mgims.ac.in)

Subject : Recognition as Ph.D. Guide...  
Reference : 1) Your letter no. C/Ph.D./6223 Date - 25/10/2018.  
2) Ph.D. Direction No. 04/2015 (Amended in 2016).

Sir/Madam,

With reference to the above cited subject & References, I am directed to inform you that in view of the norms prescribed as per the provision u/s 29 (2) of (i) of MUHS Act, 1998 & clause 07 (2) (a) (ii) of Direction No. 04/2015 (Amended in 2016) Hon'ble Vice Chancellor is pleased to grant recognition as Ph.D. Guide to the following teacher of your College/ Institute, subject to the terms & conditions of appointment order, for guiding the Ph.D. student in the subject mentioned against his/her/their name.

Sr. No.	Subject	Name of the Teacher	Designation	Status of recognition as Ph.D Guide
1	Obstetrics and Gynaecology	Dr. Poonam Shivkumar Varma	Professor	Approved w.e.f. 18/02/2019, onwards

Kindly note that the recognition granted by the University is valid till the above said teacher is in the service of the said teaching college/institute or till attaining the age of superannuation whichever happens earlier.

The above teacher is required to attend the Research Methodology Workshop conducted by this University or any other Centre authorized by the University.

(P.T.O.)



You are requested to handover the copy of this letter to the concerned teacher for further necessary action.

Yours,



Dy. Registrar  
University Dept. Cell  
(Ph.D)

*[Note :-*

- 1. In case, at later stage, if it is found that the information furnished in the Ph.D. recognition form by any Guide is incorrect, Ph.D. Guide Recognition granted by the University will stand cancelled.*
- 2. It is required that the Dept. of Obstetrics and Gynaecology, M.G.I.M.S., Wardha should be recognized place of research of Ph.D.]*

Copy to :

- 1. Dr. Poonam Shivkumar Varma**  
Professor  
Dept. of Obstetrics and Gynaecology  
Mahatma Gandhi Institute of,  
Medical Sciences, Post. Sevagram,  
Wardha – 442 102.  
Email – [poonam@mgims.ac.in](mailto:poonam@mgims.ac.in)  
[poonamvarmask@yahoo.co.in](mailto:poonamvarmask@yahoo.co.in)

**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

Sr.No	Name of the book	Author	Year
1	Progress in Obstetrics and Gynaecology Volume-5	John Studd	1985
2	Infectious disease in Obstetrics and Gynaecology	Gilles R.G.Monif	1974
3	Obstetrics and Gynaecology Annual, Volume No.4	Ralph Wynn	1975
4	Progress in Obstetrics and Gynaecology Volume No.12	John Studd	1996
5	Progress in Obstetrics and Gynaecology, Volume No.2	John Studd	1982
6	Instruments operation and drugs in Obst and Gynae	G.V.Chophekar	1988
7	Obstetrics and Gynaecology, Pretest self Assessment and Review	Mark L.Evans	1987
8	Scientific foundation of Obstetrics and Gynaecology	Elliot Philip	1970
9	Obstetrical and Gynaecological Pathology Fourth Edition Volume No.2	Haines and Taylor	1962
10	Obstetrical and Gynaecological Pathology Fourth Edition Volume No.1	Haines and Taylor	1962
11	Practical cases in Obstetrics and Gynaecology 2 <sup>nd</sup> Edition	Kanan Yelikar	2015
12	Practical Gynaecology and Obstetrics	V. Padubidri	2006
13	Obstetrics and Gynaecology drugs index	Jagsonpal Pharmaceutical	2002
14	Recent advances in Obstetrics and Gynaecology	John Isonnar	1982
15	Recent Advances in Obstetrics and Gynaecology	Leslie Williams	1926
16	Progress in Obstetrics and Gynaecology Volume No.11	John Studd	1994
17	Progress in Obstetrics and Gynaecology Volume No.6	John Studd	1987
18	Controversy in Obstetrics and Gynaecology I	Reid and Borton	1969
19	Interventional Ultrasound in Obstetrics and Gynaecology and the breast	Joaquin Santolaya Forgas	1998
20	Current Obstetrics and Gynaecologic Diagnosis and Treatment	Ralph C.Benson	1976
21	Clinical Obstetrics and Gynaecology June 2015 Vol.58 No.2	Aaron Caughey	2015
22	Current Obstetric and Gynaecologic Diagnosis and Treatment 8 <sup>th</sup> Edition	Alan Cherney	1994
23	Milestones in Obstetrics and Gynaecology Yearbook 2001	S.B.Pharmaceuticals	2001
24	Controversy in Obstetrics and Gynaecology II	Reid and Christian	1974
25	Quick reference to Obst-Gynae Procedures	Hugh Barber, Edward Barber	1969
26	Gynaecologic and Obstetrics Pathology	Emil Novak	1952



**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

27	Integrated Obstetrics and Gynaecology	John Dewthrust	1984
28	Blue Prints Obst and Gynae 5 <sup>th</sup> Edition	Yamara Aaron	
29	Progress in Obst and Gynae Volume No.1	John Studd	
30	Obst and Gynae	Ralph Wynn	1981
31	Scientific of Obs and Gynae	Ronald Macdonald	1971
32	Gynaecology	V.Padubidri	1993
33	Current Obstetric and Gynaecologic Diagnosis & Treatment	Ralph C.Benson	1976
34	Recent Research on Gynaecological Endocrinology Volume No.2	A.R.Genazzani F.Patragha A.Volgha F.Farchinetti	1988
35	Textbook of Gynaecology	John J. Brewer Edwin J. Decosta	1967
36	Principals and Practice of Obstetric Anaesthesia	J. Salwyn Crawford	1972
37	Medical Gynaecology	James C. Janrney	1950
38	State of the ART atlas of Endoscopic Surgery in infertility and Gynaecology	Nutan Jain	2010
39	Modern Colposcopy Textbook and Atlas	E.J. Mayear Jr J. Thomas Cox	2012
40	Health and Disease in Developing Countries		
41	Mannual and Assisted Reproductive Technologies and Clinical Embriology	Lt.Col. Pankaj Talwar	2012
42	Vulvar Disease	Edward G. Friedrick Jr	1976
43	A Textbook of Gynaecology	K.M.Masavi	1971
44	Cancer of the uterus	Year book Medical Publisher INC 35 east wacker drive Chicago	1969
45	Office Gynaecology	J.P.Greenhili	1948
46	Exfoliative Cytology in Gynaecological Practices	Erica G. Wachtel	1969
47	Hawkins and Bourne, Shaw's textbook of Gynaecology, 15 <sup>th</sup> Edition	V.Padubidri Shirish N. Daftary	
48	Modern Trends in Gynaecology	R.J.Kelkar	1969
49	Management of High Risk Pregnancy – A practice Approach	Shobha Sagar Trivedi Manjil Puri Swati Agrawal	2016
50	Cervical and Lower genital tract Pre-cancer	Albert Singer Ashfaq M.Khan	2014
51	Comprehensive Gynaecology	Gretchon M.Lentz Roger A.Lobo David M. Vern L Ketz	2012
52	D.C.Dutta Textbook of Gynaecology, 2 <sup>nd</sup> Edition	D.C.Dutta	1994
53	Female and Male Diametric	P.A.Vankeep	1979
54	General Surgery in Gynaecological Practice	S.C.Simmons R.J.Luck	1971
55	Clinical Gynaecology	Wallace Barr	1972

**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

56	Gynaecologic Endocrinology	Edward A. Graber	1961
57	Office Gynaecology	Robert H. Glass	1976
58	Synopsis of Gynaecology	David Winston Woodward Davis	1972
59	Principals of Gynaecology	Sir Norman Teffcoate	1975
60	Texbook of Gynaecology	M.K. Basu Malik	1971
61	Novak's Textbook of Gynaecology	Edmund R. Novak	1975
62	Shaw's Textbook of Operative Gynaecology 4 <sup>th</sup> Edition	John Hopkins Christopher Hudson	1977
63	Textbook of Operative Gynaecology	John Howkins	1968
64	Baggish Karam Atlas of Pelvic Anatomy and Gynaecologic Surgery 2 <sup>nd</sup> Edition	Baggish and Karram	2005
65	Practical Manual for Laparoscopic and Hysteroscopic Gynaecologic Surgery	Schollmeyer Melter, Ruther, Alkatout	2013
66	Textbook of Gynaecology	Larry J. Copeland	2000
67	Disease of Women	Harry Kimpton	1953
68	Postgraduate Obstetrics and Gynaecology	F.J. Browne & J.C McClure Browne	1955
69	Abdominal Operation by Vaginal Route	Werner & Sederl	1958
70	Surgical Pathology of Gynaecologic Disease	Cory Dougherty	1968
71	Bonney' Gynaecological Surgery	Lopes, Spirtos, Naik, Monaghan	2011
72	The Linde's Operative Gynaecology	John Rock John Thompson	1997
73	The Broad Range of Clinical use of Phenytoin	Barry H. Smith Samuel Bogoch Jack Dragfas	1982
74	The Management of the Menopause and Postmenopause	Stuart Campbell	1976
75	Menopause- Current Concepts	C.N. Purandare	2004
76	Modern Radiotherapy- Gynaecological Cancer	Thomas J. Deeley	1971
77	Principles and Practices of Chemotherapy	Major Mirza Qaiser Baig	2012
78	Cancer Chemotherapy Principles and Practices	Bruce A. Chabner Jerry M. Collins	
79	Cervical Cancer Screening Programmes- Management guidelines	A.B. Miller	1992
80	Population genetic and Health Case issue and Futures strategies	Somnath Roy Salil Basu Anil Jindel	1985
81	Textbook of Gynaecology	John J. Brewer Edwin J. Decosta	1967
82	Gynaecology Illustrated	Matthew M. Garrey A.D.T. Govan C.H. Hegde Robin Collander	1972



**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

83	Disease of the Vulva	Vikolas Janovski Charles P. Doughlas	1968
84	Female Urinary Incontinence and Master management	Prakash Trivedi	
85	Surgery for Urinary Incontinence	Roger Dmochowski Mickey Karram W. Stuart Reynolds	2013
86	De Swiet's Medical Disorders in Obstetric Practices	De Swiet's	2010
87	DC Dutta's Textbook of Obstetrics	DC Dutta Hiralal Konar	2013
88	Practical Guide to High Risk Pregnancy and Delivery- 4 <sup>th</sup> Edition	Aria's	1984
89	William's Obstetrics-24 <sup>th</sup> Edition	William's Cunningham Leveno	2010
90	Beck's Obstetrical Practices and Fetal Medicine	E. Stewart Taylor	1976
91	Review Series Obstetrics	V. Padubidri	1993
92	Gynaecology Disease and Minor Surgery – 1 <sup>st</sup> Edition	Robert J. Lowrie	1952
93	Holland and Brew's Manual of Obstetrics	Robert Percival	1969
94	Symposium on the Functional Physiotherapy of the Fetus and Neonate	Harold Abramson	1971
95	Beck's Obstetrical Practices and Fetal Medicine	Stewart Taylor	1970
96	A Guide to effective care in Pregnancy and Childbirth	Murray Enkin	1995
97	Risk in the practices of Modern Obstetrics	Silvio Aladjem	1972
98	Practical Mother and Child Health Care	B.NS. Wallia P.M.Shah	1979
99	Critical Care Obstetrics- 4 <sup>th</sup> Edition	Gary A. Dildy	2004
100	Maternal – Fetal Medicine Principles and Practices	Robert Creasy	1989
101	Obstetric and Perinatal Infection	David Charles	1973
102	Interruption of Pregnancy A Total patient Approach	Roland Bolongnose	1975
103	Obstetrics	J.M.Holmes	1969
104	Textbook of Obstetrics	D.C.Dutta	2004
105	Drugs and Pregnancy Human Teratonensis and Related Problem	D.F.Howkins	1983
106	The Prostaglandis Progress Research	Prof. Sultan Karim	1972
107	Obstetrics by Ten Teachers	Stanley Clayton	1976
108	Recent Advances in Obstetrics and Gynaecology	John Bonnas	1990
109	Abortion and Sterilization Medical and Social Aspects	Jane Hodgson	1981
110	Prematurity and the Obstetrician	Denis Cavanagh	1969
111	Practical Obstetric Problem	Ian Donald	1974
112	Obstetrics by Ten Teachers	Stanley Clayton	1976
113	Obstetrics Forceps	Leonard Laufe	1968
114	Obstetrics by Ten Teachers	Stanley Clayton	1975

**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

115	Textbook of Obstetrics	K.M.Masani Mahendra Parikh	1986
116	Browne's Antenatal Care	J.C. McClure Browne and Geoffrey Dixan	1970
117	Evidence Based Obstetrics	David K. James K. Mohmmad L.M.Hill P.Stone W. Wijngarden	2004
118	Ectopic Pregnancy	K.M.Masani	1949
119	Tenovis Library Series- The Endocrinology of Pregnancy and Parturition	Pierrepoint	1971
120	Pregnancy Nephropathy	John Sophias	1972
121	Textbook of Obstetrics	K.M.Masani	1974
122	British Obstetric and Gynaecological Practices	Sir Eardley Holland Aleck Bourne	1959
123	Browne's Antenatal Care	J.C.McClure Browne Geoffrey Dixan	1978
124	Textbook of Obstetrics	D.C.Dutta	2004
125	Postgraduate Obstetrics and Gynaecology	M.K.Krishna Menon P.K.Devi K. Bhaskar Rao	1980
126	Implementing a Reproductive Health Agenda in India – The Beginning	Saroj Pachauri	1999
127	Personnel Administration and Labour relation in Health Care Facilities	James O. Hepner	1969
128	Looking Back, Looking Forward	Shirien J. Jejeebhay	2004
129	Sexual Behaviour and AIDS in India	Moni Nag	1996
130	Host Resistance to Commensal Bacteria	Torquil Macphee	1972
131	Population Policies Matter?	Anirudh Jain	1998
132	The Health Gap	Jennifer Kutts & Janet Hatcher Robert	1996
133	Breast feeding A Right of Infant	Dr. Sushila Nayar	1994
134	Educational Handbook for Health Professional	J.J.Guilbert	1987
135	Contemporary Obstetrics and Gynaecology	Geoffrey Chamberlain	1988
136	Sexually Transmitted Infections	Somesh Gupta Bhushan Kumar	2012
137	Report of WHO Assisted workshop of a Type Post Partum Centres for Development of Training Module and Guideline for practices of Contraceptive Technology and MTP for Medical Officers of Primary Health Centre		
138	Reproductive Health of Young Adults, Contraception, Pregnancy & Sexual Transmitted Disease	Family Health International	1997
139	The Essential of Contraceptive Technology	Robert Hatcher	1997



**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

		Ward Rinehart Richard Blackburn	
140	Contraception – An International Journal	Daniel Mishell	1994
141	Family Planning Operations Research	James Foreit Thomas Frejka	1998
142	Family Formation Pattern and Health	Omran, Standley	1976
143	Progress in Conception Control	Edwar Tyler	1969
144	Intrauterine Devices	Clive Wood	1971
145	Essential of Family Planning	Josephine Barner	1976
146	Manual of Family Planning & Contraceptive Practices	Mary Steichen Cldrone	1970
147	Advances in Female Sterilization Techniques	Sciarra Dmenemueller Joseph Spedel	1976
148	Responding to Cairo Case-Studies Changing Practices in Reproductive Health and Family Planning	Nicole Haberland Diana NEASHAM	2002
149	Improving Quality of Care in India's Family Welfare Programme	Michael Koenig M.E.Khan	1999
150	The Essential of Contraceptive Technology	Robert Hatcher Ward Rinchart Richard Blackburn Judith S.Heller	1997
151	Contraceptive Research and Development 1984 to 1994	P.F.A Van Look	1994
152	Family Planning Education – Parenthood and Social Disease Control	Charles Willian Hubbard	1973
153	Family Planning handbook for Doctors	Ronald Kleinman	1980
154	Non Descent Vaginal Hysterectomy made easy	Sudhir Shah Beena Trivedi Dipal Solanki	2009
155	Gyanecology for Undergraduates	Sisir Chattopadhayay M. Narayanaswamy	2006
156	The Fallopian Tube	J. Donald Woodruff Carl J. Pauerstein	1969
157	Clinical Gynaecology Endocrinology and Infertility	Leon Speroff Robert Glass Nathan Kase	1989
158	Manual of IUI What, When and Why	Nasrat Mahmud Narendra Malhotra Jaideep Malhotra	2013
159	Disease of Women	Clifford White	1946
160	Operating System Techniques	Hoare and Pernott	1972
161	Abdominal and Vaginal Hysterectomy	S.Joel-Cohen	1972
162	Tumour of the Ovary	H.Fox F.A.Langley	1976
163	Practical Laparoscopy	Siddharth Khandwala	1984

**DEPARTMENT OF OBSTETRICS & GYNAECOLOGY**  
**DEPARTMENTAL LIBRARY BOOKS LIST**

164	State of the ART Vaginal Surgery	Neerja Goel Shalini Rajaram Sumita Mehta	2013
165	Fertility Preservation advances and Controversion	Mohamed Bedairy Botros Rizk	2014
166	Ovarian Hyperstimulation Syndrome	Botros R.M.Rizk	2006
167	Global Fertility Transition	Rodolfo Bulatao John Casterline	2001
168	A Practical Guide to Setting up an IVF Lab Embray Culture System & Running the Unit	Alex Varghese Peter Sjoblom K. Jayaprakasan	2013
169	Fertility in the United State New Pattern, New Theories	John Casterline Ronald D.Lee Karen A. Foote	1996
170	Infertility Diagnosis, Management and IVF	Anil K Dubey	2012
171	Risk, Benefits and Controversies in Fertility Control	John Sciarra Gerald L. Zatuchni J. Joseph Speidal	1978
172	Infertility – A Clinical Guide to Diagnosis and Treatment	Melvin Taymore	1922
173	Principle and Practices and Assisted Reproductive Technology	Kamini A. Rao	2014
174	Anatomy	Smar Mitra	1981
175	Essential Human Anatomy Part II-Superior and Interior extremities	Asim Kumar Datta	1992
176	Gray's Anatomy	Peter L. William Roger Warwick Mary Dyson Lawrence H. Bannister	
177	Clinical Anatomy for Medical Students-6 <sup>th</sup> Edition	Richard S.Snell	2000
178	Clinical Neuro anatomy for Medical Students-Fourth Edition	Richard S.Snell	1997
179	Anatomy (Abdomen, Thorax and Interior Extremity)	Samarendra Mitra	1992
180	Essential of Human Anatomy (Part II- Head and Neck, Brain, Spinal Cord)	Asim Kumar Datta	
181	Anatomy Vol II	Smar Mitra	1977
182	De Swiet Medical Disorders in Obstetric Practices - 5 <sup>th</sup> Edition	Powrie Greene Camann	2010
183	Pregnancy at Risk- A Practical Approach to High Risk Pregnancy and Delivery-5 <sup>th</sup> Edition	Usha Khanna Duru Shah Vinita Salvi Nozer Sherier Kaizad R. Damania	2010



DEPARTMENT OF OBSTETRICS & GYNAECOLOGY  
MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRAM  
LIST OF BASIC EQUIPMENTS

Sr. No	Equipments	No
1	Pulse Oxymeters	10
2	Cardiac Monitor	3
3	NST Machine	6
4	USG Machine	2
5	Infusion Pump	7
6	Nebulizer	4
7	ECG Machine	4
8	Colposcope	1
9	Hysteroscope	1
10	Fetal Doppler	6
11	Cryocautery	1
12	Electrocautery	3
13	Phototherapy Machine	6
14	Suction Machine	9
15	B.P.Apparatus	20
16	Glucometer	3
17	Hemoglobinometer	2
18	Resuscitation equipment	2 Sets
19	Laryngoscope	7
20	Aminoscope	1
21	Magnoscope	1
22	Central Oxygen & Suction Plant	27 For LR/ Critical & ICU Area
23	Digital Camera	9
24	Printer	6
25	Printer, Scanner, Xerox	2
26	Overhead Projector	2
27	Slide Projector	1
28	View box	2
29	LCD Project	2
30	Sterilizer	5
31	Blower/ Warmer	17
32	Microscope	2
33	Incinerator Electric Distoyer	7
34	Television Set	2
35	Ventilator	1
36	Colpovideoscope	1
37	Laprosopy Set	1
38	Operative Hysteroscope with Resectoscope	1
39	Uterine Balloon Therapy Unit	1
40	Endotrainers	1

DEPARTMENT OF OBSTETRICS & GYNAECOLOGY  
 MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRAM  
 LIST OF MODELS AVAILABLE IN SKILLS LAB

Sr. No	Models	No
1	Flexible Baby	1
2	Child Birth Stimulator	3
3	Dummy	1
4	Dummy with Pelvis	1
5	Fetal Skull	2
6	Fetal Skull on stand	1
7	Fetal for Vaccum delivery	2
8	Labour Delivery module	2
9	Model of pregnant female with fetus	1
10	Model showing Female reproductive organs	1
11	Model showing perineum	1
12	Nurses training baby	1
13	Pelvis Skeleton Male	1
14	Pelvis Skeleton Female	1
15	Palpation Module for leopold's maneuver	2
16	Surgery and Laparoscopy trainer	1
17	Suture practice arm	1
18	Trocar trainer	1
19	Obstetrics training manikin kit	1
20	Articulated female pelvis	1
21	Articulated fetus	1
22	New Borne CPR manikin	1
23	Ambu bag for CPR newborn	1
24	Adult CPR torso with light controller	1
25	Ambu bag for adult CPR	1
26	Cervical Dilatation assessment module	1
27	IV Injection arm	1
CHARTS		
1	Educational Charts OPD	25
	Educational charts Wards	20
2	Do and Don't in LR	02
	Do and Don't – Wards	02
	Do and Don't – Critical Care	02
	Do and Don't – Eclampsia room	02
3	Chemotherapy charts	04
4	Malignancy Classification Charts	03
5	Charts related to Teaching Methodology	06
6	Scientists and Invention	04



DEPARTMENT OF OBSTETRICS & GYNAECOLOGY  
 MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRAM  
 LIST OF SPECIEMNS IN MUSEUM

<b>Fetus and Anomalies</b>	<b>Fibroid</b>
1. Hydrocephalus	1. Submucous fibroid
2. Fetus with Myelocele	2. Cervical fibroid
3. Normal Fetus	3. Broad ligament fibroid
4. Anencephaly	4. Intramural fibroid
5. Multiple Congenital malformation in fetus	5. Sibseopsal fibroid
6. Thoracophagus	6. Submucous fibroid
7. Multiple Congenital malformation in fetus	7. Cervical fibroid
8. Anencephaly	8. Multiple fibroid
9. Congenital malformation in fetus	9. Fibroid uterus
10. Congenital malformation in fetus	10. Submucosal fibroid
11. Anencephaly	11. Broad ligament fibroid
12. Hydrocephalus	12. Degenerated Submucous fibroid
13. Fetus with Myelocele	
14. Fetus triplets	
15. Fetus Papraceous	

DEPARTMENT OF OBSTETRICS & GYNAECOLOGY  
MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, SEVAGRAM  
LIST OF SPECIMENS IN MUSEUM

<b>UTERUS AND ANAMOLIES</b>	<b>OVARIAN TUMOURS</b>
1. Myohyperplasia with bulky cervix	1. Ovarian Tumour
2. Myohyperplasia	2. Myohyperplasia with ovarian cyst
3. Inversion of Uterus	3. Ruptured ovarian cyst
4. Myohyperplasia	4. Uterus with ovarian cyst
5. Cardiac Uterus	5. Myohyperplasia with ovarian cyst
6. Adenomyosis	6. Ovarian tumour
7. Adenomyosis	7. Multilocolated ovarian cyst
8. Myohyperplasia	8. Ovarian tumour
9. Myohyperplasia	9. Cystadenocarcinoma of ovary
10. Adenomyosis	10. Ovarian tumour
11. Adenomyosis	11. Fibroid with endometrial polyp with ovarian cyst
12. Myohyperplasia	12. Ovarian cyst
13. Adenomyosis	13. Ovarian mass
	14. Myohyperplasia with ovarian cyst
	15. Multilocolated ovarian cyst
	16. Ovarian mass
	17. Mucinous cystadenoma
	18. Uterus with ovarian cyst
	19. Mucinous cystadenoma
<b>PLACENTA</b>	<b>PREGNANCY WITH ANOMALIES</b>
1. Eccentric attachment of cord to placenta	1. Pregnancy with fibroid
2. Succinate placenta	2. Rudimentary horn with pregnancy
3. Circumvallate placenta	3. Partial molar pregnancy
4. Normal placenta	4. Pregnancy with CA cervix
	5. Ruptured ectopic pregnancy
<b>TEACHING SPECIMENS</b>	
1. Ca Cervix	14. Placenta
2. Adenomyosis	15. Partial mole
3. Intramural fibroid	16. Partial mole
4. Ca cervix	17. Partial mole
5. Dermoid cyst	18. Congenital abnormalities of Uterus
6. Ovarian Tumour	19. Cervical fibroid
7. Ovarian cyst	20. Conjoint twins
8. Ectopic Pregnancy	
9. Fibroid Uterus	
10. Ectopic pregnancy	
11. Adenomyosis	
12. Hydatidiform mole	
13. Placenta	





**Mahatma Gandhi Institute of Medical Sciences**  
Sewagram 442 102, Maharashtra, India  
**Institutional Ethics Committee**  
**For Research on Human Subjects**

Tel: (91) 7152-284341 - 355 (Ext. 266) Fax: (91) 7152-284333 E mail: [iec@mgims.ac.in](mailto:iec@mgims.ac.in) 05 Mar 2021 - 04 Mar 2024

*Annexure - B*  
Reg. No. ECR/47/Inst/MH/2013/RR-19  
(Under New Drugs and Clinical Trials Rules, 2019)



EC-CT-2021-0168

**LIST OF IEC MEMBERS**

S N	Name	Gender	Qualification with Specialization	Current Organization	Telephone number, fax number, e-mail ID. and mailing address	Designation/ Role of member in Ethics Committee	Affiliation of member with institute
1	Dr. Ashok Pawade	M	B.Com, LLB & LLM (Administrative law & Constitutional law) and Ph.D. (Constitutional law)	G H Raisoni University, Saikheda, Chhindwara, Madhya Pradesh	+91-7152-240678. 9422141721 <a href="mailto:advpawade@gmail.com">advpawade@gmail.com</a>	Chairman	Dean, School of Law, G H Raisoni University, Saikheda, Chhindwara, Madhya Pradesh
2	Dr. Sushil Kumar Varma	M	MD (Pharmacology)	MGIMS, Sevagram	9921418999. <a href="mailto:sushil@mgims.ac.in">sushil@mgims.ac.in</a>	Member Secretary	Director Professor & Head, Department of Pharmacology, MGIMS, Sevagram
3	Dr. Bharati Taksande	F	MD (Medicine)	MGIMS, Sevagram	9881017505. <a href="mailto:bharatitaksande@mgims.ac.in">bharatitaksande@mgims.ac.in</a>	Clinician	Professor, Department of Medicine, MGIMS, Sevagram
4	Dr. Smita Singh	F	MD (Ophthalmology), DNB (Ophthalmology),	MGIMS, Sevagram	8793132103 / 9834991602 <a href="mailto:smita@mgims.ac.in">smita@mgims.ac.in</a>	Clinician	Director Professor, Department of Ophthalmology, MGIMS, Sevagram.
5	Dr. Subodh Gupta	M	MD (Pediatrics), DNB (Social & Preventive Medicine)	MGIMS, Sevagram	9650766472 / 9822926934 <a href="mailto:subodh@mgims.ac.in">subodh@mgims.ac.in</a>	Clinician	Professor & Head, Department of Community Medicine, MGIMS, Sevagram.
6	Dr. Manish Jain	M	MD (Paediatrics)	MGIMS, Sevagram	9822695195 <a href="mailto:manish@mgims.ac.in">manish@mgims.ac.in</a>	Clinician	Professor & Head, Department of Paediatrics, MGIMS, Sevagram.
7	Dr. Shailesh Nagpure	M	MD (Pharmacology)	JNMC, Sawangi (Meghe), Wardha	9503509430 <a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	Basic Medical Scientist (Pharmacologist)	Associate Professor, Department of Pharmacology, JNMC, Sawangi (Meghe).
8	Mr. Wasudev Deodhe	M	10 <sup>th</sup> Fail		9552642526 <a href="mailto:wasudevdeodhe@gmail.com">wasudevdeodhe@gmail.com</a>	Layperson	Former Sarpanch, Warud Village Panchayat, Warud, Wardha.
9	Adv. Harish Chandak	M	B.Com, LLB, LLM & Adv. Dip. in Cyber law		9823292431 <a href="mailto:hkchandak@yahoo.com">hkchandak@yahoo.com</a>	Legal Expert	Professional lawyer and Panel advocate for various organizations
10	Mrs. Swati Sagare	F	MSW (URCD)	Dharamitra (NGO committed to sustainable rural development).	9730171517 <a href="mailto:swati.sagare@gmail.com">swati.sagare@gmail.com</a>	Social Scientist	Chief Programme Coordinator, Dharamitra
11	Mr. Vinay Gawali	M	MSc. Nursing (Community Health Nursing)	Kasturba Nursing College, Sevagram	9822530362 <a href="mailto:vgknc@rediffmail.com">vgknc@rediffmail.com</a>	Scientific Member	Associate Professor, Kasturba Nursing College, Sevagram.
12	Mrs. Sonali Phate	F	MSc. (Microbiology)	Kamalnayan Jamnalal Bajaj Foundation, Wardha (NGO)	9552689218 <a href="mailto:sonamphate@yahoo.com">sonamphate@yahoo.com</a>	Social Scientist	Project development and documentation officer
13	Mrs. Vaishali Taksande	F	MSc. Nursing (OBGYN) & M. Phil (Health Professional Education)	Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha	9970423710 <a href="mailto:vtaksande@gmail.com">vtaksande@gmail.com</a>	Scientific Member	Professor, Faculty of Nursing

Date: 11<sup>th</sup> July 2022

*[Signature]*  
Dr. Sushil Kumar Varma  
Member Secretary  
Institutional Ethics Committee  
Mahatma Gandhi Inst. of Medical Sciences  
SEVAGRAM - 442102 Maharashtra, India

*[Signature]*  
Dr. Ashok Pawade  
Chairperson  
Institutional Ethics Committee  
MGIMS, Sevagram, India

File No. EC/NEW/INST/2020/490



सत्यमेव जयते

Government of India  
Ministry of Health & Family Welfare  
Department of Health Research  
(National Ethics Committee Registry for Biomedical and Health Research)

2nd Floor, IRCS Building,  
Red Cross Road, New Delhi – 110001  
Date : 03-Mar-2022

FORM CT-03

(See rules 17 and 18)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO BIOMEDICAL HEALTH RESEARCH

Registration No. EC/NEW/INST/2022/MH/0072

The designated authority hereby registers and permits Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital Kasturba Health Society Sevagram, City-Wardha, District-Wardha - Maharashtra - 442102 Contact No.: 07152-284341-355 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter IV of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 03-Mar-2022

ANU  
NAGAR  
Digitally signed  
by ANU NAGAR  
Date: 2022.03.03  
11:01:12 +05'30'  
Designated Registration Authority  
Stamp





सत्यमेव जयते

File No. EC/19/000199  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,  
New Delhi - 110002, India  
Dated: 09-Aug-2019

To

The Chairman  
Institutional Ethics Committee  
(Department of Pharmacology),  
Mahatma Gandhi Institute of Medical sciences,  
Sevagram Wardha Maharashtra - 442102 India

Subject: Ethics Committee Re-Registration No. ECR/47/Inst/MH/2013/RR-19 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/3326 dated 06-May-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/47/Inst/MH/2013/RR-19. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

(Dr. S. Eswara Reddy)  
Drugs Controller General (I) &  
Central Licensing Authority

Conditions of Registration

1. The registration is valid from 20-Apr-2019 to 19-Apr-2024, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
  - (i) medical scientist (preferably a pharmacologist);
  - (ii) clinician;
  - (iii) legal expert;
  - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
  - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,



non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.
7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.
8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.
9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.
10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.
11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.
12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.
13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any
14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.
15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.
16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.
17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.
18. Where a clinical trial site does not have its own Ethics Committee clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.
19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall



such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.

FORM CT-02

(See rules 8, 9, 10 and 14)

GRANT OF REGISTRATION OF ETHICS COMMITTEE RELATING TO CLINICAL TRIAL OR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Registration No. ECR/47/Inst/MH/2013/RR-19

The Central Licencing Authority hereby registers and permits Institutional Ethics Committee, (Department of Pharmacology), Mahatma Gandhi Institute of Medical sciences, Sevagram, Wardha, Maharashtra - 442102 India, Contact No.: 07152-284341 Fax No.: 07152-284333 to perform duties of ethics committee as specified in the New Drugs and Clinical Trials Rules, 2019.

2. The ethics committee shall observe the conditions of registration specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940.

Place : New Delhi

Date : 09-AUG-2019

S  
Central Licensing Authority  
Stamp  
REDDY  
Digitally signed  
by S ESWARA  
Date: 2019.08.09  
13:39:25 +05'30'





CIRCULAR

The Research Committee of Mahatma Gandhi Institute of Medical Sciences is reconstituted with immediate effect. The Committee's terms of the reference will be as follows:

1. To review the applications of research grants for the research funds at institutional level.
2. To organize workshops / training programmes on research methodology for junior faculty and postgraduate including Ph.D. students.
3. To collect and disseminate the information regarding availability of research grants by the Government, National / International Agencies and other professional bodies.
4. To facilitate UG/PG students to use and understand the relevance of using statistical methods and tools required.
5. To facilitate UG/PG students in developing communication skills to present their research findings in various scientific platforms.
6. To create zeal amongst students and faculty members towards research and innovation.
7. To establish collaboration with other universities, public and private sectors and identify R & D projects consultancy services which could be undertaken at the institution.
8. To promote research in various departments of the institute.
9. The committee shall promote research and development activities by motivating students and faculty members for publishing research papers and motivating them to get patents for their works.
10. To organize regular seminars and workshops on emerging trends and technologies with a special focus innovations.

The Committee will be consisting of-

1.	Dr. A.K. Shukla, Dean, MGIMS, Sevagram	Chairman
2.	Dr. Manish Jain, Prof. & Head, Paediatrics	Coordinator
3.	Dr. J.E. Waghmare, Prof. & Head, Anatomy	Member
4.	Dr. Satish Kumar, Prof. & Head, Biochemistry	Member
5.	Dr. Vijayshri Khaikar, Prof. & Head, Microbiology	Member
6.	Dr. Anshu, Professor, Pathology	Member
7.	Dr. Smita Singh, Prof. & Head, Ophthalmology	Member
8.	Dr. Subodh Gupta, Prof. & Head, Community Medicine	Member
9.	Dr. Sameer Yelwatkar, Prof., Medicine	Member
10.	Mr. M.S. Bharambe, Assoc. Prof., Stat. & Demo, Com. Medicine	Member



Dr. A.K. Shukla  
DEAN

Cc to : Secretary, KHS  
: Medical Supdt.  
: All Head of the Departments  
: All concerned

CC/9831  
Office of the Dean  
MGIMS, Sevagram,  
Date: 08/02/2023

**CIRCULAR**

As per the guidelines of MUHS, Nashik vide their circular number 10/2022 dated 20/05/2022, we have constituted the Doctoral Committee for the verification and checking of six monthly progress report of Ph. D. students of this institute.

The Ph. D. Doctoral Advisory Committee members are as follows:-

1. Dr. A.K.Shukla, Dean, MGIMS, Sevagram
- ✓ 2. Dr. Satish Kumar, HOD, Medical Biochemistry & Ph.D. Guide, Medical Biochemistry
3. Dr. Sushil Kumar Varma, HOD, Pharmacology & Ph.D. Guide, Medical Pharmacology
4. Dr. Vijayshri Deotale, HOD, Microbiology & Ph.D. Guide Microbiology
5. Dr. Poonam Shivkumar, HOD, Ph.D. Obst. & Gyane & Guide, Obst. & Gyane
6. Dr. C.M. Badole, Prof. & Head, & Ph.D. Guide, Orthopedics
7. Dr. D.D. Gosavi, Prof. & Ph.D. Guide Pharmacology
8. Dr. Subodh Gupta, HOD, Community Medicine & Ph.D. Guide, Community Medicine (Research Co-ordinator)



Dean  
MGIMS, Sevagram

Copy to: Concerned HODs & Guides



### Ph. D. Doctoral Committee Member List

Sr. No.	Course	Name of Subject Expert	Email ID of Subject Expert	Mobile No. of Subject Expert
1	Medical Genetics	Dr Shabana Borate, Grant Med. College, Sir J.J.Hospital Compound, Byculla, Mumbai	<a href="mailto:drshabaana@gmail.com">drshabaana@gmail.com</a>	9821907712
2	Medical Pharmacology	Dr. Shailesh Nagpure, Assoc. Prof. JNMC, Sawangi Meghe Wardha	<a href="mailto:drshaileshnagpure@gmail.com">drshaileshnagpure@gmail.com</a>	9503509430
3	Pathology	Dr. Samarth Shukla, Prof. Pathology, JNMC, Sawangi, Wardha	<a href="mailto:samarth21174@gmail.com">samarth21174@gmail.com</a>	8830267710
4	Microbiology	Dr. Gargi Mudey, HOD, Microbiology, JNMC, Sawangi	<a href="mailto:gargimudey@hotmail.com">gargimudey@hotmail.com</a>	9860265849
5	Obst. & Gyane	Dr. Anuja Bhalerao, Professor & Head, Dept. of Obst. & Gynae, NKP Salve Medical College, Nagpur	<a href="mailto:anujab803@gmail.com">anujab803@gmail.com</a> , <a href="mailto:anuja_bhalerao@yahoo.com">anuja_bhalerao@yahoo.com</a>	9823680572
6	Community Medicine	Dr. Sanjay Zodpey, Vice President, Academics Public Health Foundation of India, New Delhi	<a href="mailto:sanjay.zodpey@phfl.org">sanjay.zodpey@phfl.org</a>	9871115640
7	Medical Biochemistry	Dr. Anita Kale (Chalak), Prof. & Head, Dept. of Biochemistry, Seth G.S. Medical College & K.E.M. Hospital, Acgharya Dhonde Marg, Parali (€), Mumbai 400012	<a href="mailto:anitachalak@rediffmail.com">anitachalak@rediffmail.com</a>	9850620123

# MAHARASHTRA POLLUTION CONTROL BOARD

Tel: 24010706/24010437  
Fax: 24023516  
Website: <http://mpcb.gov.in>  
Email: [cac-cell@mpcb.gov.in](mailto:cac-cell@mpcb.gov.in)



Kalpataru Point, 2nd and  
4th floor, Opp. Cine Planet  
Cinema, Near Sion Circle,  
Sion (E), Mumbai-400022

RED/L.S.I

No:- Format1.0/CAC/UAN No.0000035753/CR - 2202000245

Date: 03/02/2022

To,  
MATATMA GANDHI INSTITUTE OF MEDICAL SCIENCES  
SEWAGRAM WARDHA  
SR. NO. 276,,SR. NO. 276, SEWAGRAM,  
TAL & DIST-WARDHA



Your Service is Our Duty

**Sub: Combined consent and BMW Authorization under Red category**

- Ref:**
1. Bio-Medical Authorization granted by the Board vide no. BO/PSO/BMW/Nagpur/2013-14 Dated 30.08.2013 valid up to 31.03.2016.
  2. Your application for Combine Consent and Bio-Medical Authorization dated 03.11.2017
  3. The minutes of Consent Appraisal Committee meeting dated 25.02.2019

Combined Consent to Renewal and BMW Authorization.

For: Under Section 26 of the Water (Prevention & Control of Pollution) Act, 1974 & under Section 21 of the Air (Prevention & Control of Pollution) Act, 1981 and Authorization under Rule 6 of the Hazardous & Other Wastes (Management & Transboundary Movement) Rules 2016 and Bio-Medical Waste Management Rules, 2016 and amendment thereof is considered and the consent is hereby granted subject to the following terms and conditions and as detailed in the schedule I, II, III & IV annexed to this order:

1. **The Combined Consent to Renewal and BMW authorization is granted upto: 31.12.2023**
2. **The capital investment of the project is Rs.15.4359 Crs. ( ).**
3. **The Consent is valid for the Activity of**

Sr No	Activity	Quantity	UOM
1)	Hospital		
a)	Beds	972	Nos
b)	Total Plot Area	155700.00	Sq.Mtrs
c)	Total Built up Area	68120.30	Sq.Mtrs

4. **Conditions under Water (P&CP) Act, 1974 for discharge of effluent:**

Sr No	Description	Permitted (in CMD)	Standards to Achieve	Disposal
1.	Trade effluent	15	As per Schedule -I	Treated effluent shall recycle to maximum extent and remaining used on land for gardening / dispose in to sewerage system provided by Local body.



Sr No	Description	Permitted (in CMD)	Standards to Achieve	Disposal
2.	Domestic effluent	390	As per Schedule - I	As above.

5. Conditions under the Air (P& CP) Act, 1981 for air emissions:

Sr.No	Description of stack / source	Number of Stack	Standards to be achieved
1	NA	1	As per Schedule -II

6. Conditions under Hazardous & Other Wastes (M & T M) Rules 2008 for treatment and disposal of hazardous waste:

Sr No	Type of Waste	HW Category.	Quantity	UoM	Treatment	Disposal
1	35.3 Chemical sludge from waste water treatment	34.3	1.43	Kg/Day	Landfill	CHWTSDF

7. Conditions about Non Hazardous Wastes:

Sr No	Type of Waste	Quantity	UoM	Treatment	Disposal
1	STP Sludge	25	Kg/Day	Composting	Used as a manure
2	Wet Waste	300	Kg/Day	Composting	NA
3	Dry Waste	200	Kg/Day	Sale/ Composting	Reuse/ Composting

8. Treatment and Disposal of Biomedical Waste generated to CBMWTSDF:

Sr.No	Category	Type of Waste	Quantity not to exceed (Kg/M)	Segregation Color coding	Treatment & Disposal
1	Yellow	a) Human Anatomical waste	138.42	Yellow colored non-chlorinated plastic bags	CBMWTSDF
		b) Soiled Waste	3135.27		
		c) Expired or Discarded Medicines	1.14		
		d) Discarded linen, mattresses, beddings contaminated with blood or body fluid.	134.76		
		e) Microbiology Biotechnology and other clinical laboratory waste	14.34		
2	Red	Contaminated waste (Recyclable)	2184.33	Red colored non chlorinated plastic bags or containers	CBMWTSDF
3	White (Translucent)	Waste sharps including Metals	39.94	Puncture proof, Leak proof, tamper proof container	CBMWTSDF
4	Blue	a) Glassware	826.11	Puncture proof & leak proof boxes or containers with blue colored marking.	CBMWTSDF
		b) Metallic body implants	54.38		




9. PP shall comply the following guidelines published by the CPCB on February-2019 regarding handling of BMW for utilization
1. HCE shall preferably handover Bio-medical wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms for production of drugs, reagent chemicals, markers etc. if any such as Pharmaceutical industry / Biotechnology firm approaches them for the same. If there are any difficulties in the matter, the same may be communicated to such firm and copied to the board also.
  2. HCE shall strictly follow the procedure for packaging & transportation of Bio-medical Wastes such as pleural fluid, ascetic fluid, HBsAG positive blood, placenta etc. to the Pharmaceutical industry / Biotechnology firms as per the guidelines of CPCB published in Feb-2019 for "Handling of BMW for utilization".
  3. HCEs shall submit the report to the Board office about type, quantity and frequency of handling over such BMW on yearly basis.
  4. Industry to enter into legal agreement with HCE's and inform the MPC Board and competent authority of State Public Health Department about such collection of BMW along with quantity and type of waste collected.
  5. In case of any technical difficulty towards handing over the required BMW, you shall inform to the Board accordingly.
  6. HCEs shall properly dispose and handover the waste to authorised user / facilities having valid consent to operate from MPCB.
10. This consent is issued subject to conditions mentioned below:
- a. The "authorized Person" shall comply with provisions of the Environment (Protection) Act, 1986, and the Rules made there under.
  - b. Any unauthorized change in equipment or working conditions as mentioned in the application by the person authorized shall constitute a breach of this Authorization.
  - c. You shall submit details of Management and Handling of outdated, discarded, unused Cytotoxic drugs generated in the Cancer centers, research and health care in the format prescribed by CPCB which is available on [www.cpcb.nic.in](http://www.cpcb.nic.in) alongwith Annual Report to MPCB with a copy to C B before 31st January every year.
  - d. You shall manage the Mercury Waste in the HCL in environmentally sound manner (including storage, spilled collection, transportation and disposal) as per CPCB guidelines published on CPCB website [www.cpcb.nic.in](http://www.cpcb.nic.in) dated: 07.09.2010 as detailed in document entitled "Environmentally Sound Management of Mercury Waste in Health Care Facilities"?
  - e. You shall ensure phase out of chlorinated plastic bags, gloves and blood bags by HCEs within two years.
  - f. You shall establish Bar code system within one year.
  - g. You shall ensure that the liquid waste is treated and disposed by all the occupier or operator of a CBWTF in accordance with the Water Act, 1974;
  - h. You shall maintain day to day basis and display a monthly record Including Annual report on its website within two years from the date of Notification.
  - i. You shall submit separate Bank Guarantees towards compliance of condition mentioned at Annexure - IV to Regional Office, within 30 days.
  - j. You shall submit compliance of Bank Guarantee conditions every six months to Regional Officer, for verification purpose.



- k. You shall submit application for renewal of Consented Consent and Biomedical Waste authorization before 120 days along with appropriate fees.
11. This Board reserves the right to review, amend, suspend, revoke etc. this consent and the same shall be binding on the industry.
  12. This consent should not be construed as exemption from obtaining necessary NOC/permission from any other Government agencies.
  13. PP shall install STP to treat domestic effluent within 6 months and submission of BG of Rs.3.0 Lakhs towards compliance of the same.
  14. PP shall submit BG's as per HCE's regime of the Board.
  15. PP shall dispose BMW at CBMWTSDf only and shall not operate incinerator. PP shall discontinue the operation of incinerator.

For and on behalf of the  
Maharashtra Pollution Control  
Board.

  
(Ashok Shingare IAS),  
Member Secretary

**Received Consent fee of -**

Sr.No	Amount(Rs.)	Transaction/DR.No.	Date	Transaction Type
1	250000.00	7606401	06/07/2018	NEFT
2	316250.00	MPCB-DR-0154	21/06/2020	RTGS
3	75000.00	7606401	06/07/2018	DD

**Copy to:**

1. Regional Officer, MPCB, Nagpur and Sub-Regional Officer, MPCB, Nagpur II  
- They are directed to ensure the compliance of the consent conditions.
2. Chief Accounts Officer, MPCB, Sion, Mumbai

### SCHEDULE-I

#### **Terms & conditions for compliance of Water Pollution Control:**

1. A) As per your application, you have provided Effluent Treatment Plant (ETP) of designed capacity of 15.00 CMD consisting of Primary (Collection tank, Neutralization tank).
- B) The Applicant shall operate the effluent treatment plant (ETP) to treat the trade effluent so as to achieve the following standards prescribed by the Board or under EP Act, 1986 and Rules made there under from time to time, whichever is stringent:

Sr.No	Parameters	Standards
	I. Compulsory Parameters	Limiting Concentration in mg/l, except for pH
(1)	pH	5.5 to 8.5
(2)	Oil & Grease	10 mg/l
(3)	BOD (3 days 27°C )	30 mg/l
(4)	Total Suspended Solids	100
(5)	COD	250

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
2. A) As per your application, you have provided Sewage Treatment Plant of designed capacity 1000 CMD for the treatment of 390 CMD of sewage.
  - B) The Applicant shall operate the sewage treatment system to treat the sewage so as to achieve the following standards.

1	BOD	Not to exceed	30
2	COD	Not to exceed	100
3	Suspended Solids	Not to exceed	50

- C) The treated sewage shall be recycled for secondary purposes to the maximum extent and remaining shall be discharged on land for gardening within premise and remaining shall be disposed in sewerage system provided by local body. In no case, sewage shall find its way outside hospital premises.
3. The Board reserves its rights to review plans, specifications or other data relating to plant setup for the treatment of waterworks for the purification there of & the system for the disposal of sewage or trade effluent or in connection with the grant of any consent conditions. The Applicant shall obtain prior consent of the Board to take steps to establish the unit or establish any treatment and disposal system or an extension or addition thereto.
  4. The industry shall ensure replacement of pollution control system or its parts after expiry of its expected life as defined by manufacturer so as to ensure the compliance of standards and safety of the operation thereof.



5. The Applicant shall comply with the provisions of the Water (Prevention & Control of Pollution) Act, 1974 and as amended, by installing water meters and other provisions as contained in the said act:

Sr. No.	Purpose for water consumed	Water consumption quantity (CMD)
1.	Industrial Cooling, spraying in mine pits or boiler feed	1.00
2.	Domestic purpose	490.00
3.	Processing whereby water gets polluted & pollutants are easily biodegradable	16.00
4.	Processing whereby water gets polluted & pollutants are not easily biodegradable and are toxic	0.00
5.	Gardening	0

6. The Applicant shall provide Specific Water Pollution control system as per the conditions of EP Act, 1986 and rule made there under from time to time/ Environmental Clearance/ CREP guidelines.

#### SCHEDULE-II

#### Terms & conditions for compliance of Air Pollution Control:

1. As per your application, you have provided the Air pollution control (APC) system and erected following stack (s) to observe the following fuel pattern:

Stack No.	Stack Attached To	APC System	Height in Mtrs.	Type of Fuel	Quantity & UoM	S% SO <sub>2</sub>
0	NA 0	0	0	NA	0 --NA--	0.00 0.00

2. The applicant shall provide stack height of mtrs operate and maintain above mentioned air pollution control system, so as to achieve the level of pollutants to the following standards:

Total Particulate matter	Not to exceed	150 mg/Nm <sup>3</sup>
--------------------------	---------------	------------------------

3. The Applicant shall obtain necessary prior permission for providing additional control equipment with necessary specifications and operation thereof or alteration or replacement/alteration well before its life come to an end or erection of new pollution control equipment.
4. The Board reserves its rights to vary all or any of the condition in the consent, if due to any technological improvement or otherwise such variation (including the change of any control equipment, other in whole or in part is necessary).
5. Conditions for D.G. Set
- Noise from the D.G. Set should be controlled by providing an acoustic enclosure or by treating the room acoustically.
  - Industry should provide acoustic enclosure for control of noise. The acoustic enclosure/ acoustic treatment of the room should be designed for minimum 25 dB (A) insertion loss or for meeting the ambient noise standards, whichever is on higher side. A suitable exhaust muffler with insertion loss of 25 dB (A) shall also be provided. The measurement of insertion loss will be done at different points at 0.5 meters from acoustic enclosure/room and then average.



- c) Industry should make efforts to bring down noise level due to DG set, outside industrial premises, within ambient noise requirements by proper siting and control measures.
- d) Installation of DG Set must be strictly in compliance with recommendations of DG Set manufacturer.
- e) A proper routine and preventive maintenance procedure for DG set should be set and followed in consultation with the DG manufacturer which would help to prevent noise levels of DG set from deteriorating with use.
- f) D.G. Set shall be operated only in case of power failure.
- g) The applicant should not cause any nuisance in the surrounding area due to operation of D.G. Set.
- h) The applicant shall comply with the notification of MoEF dated 17.05.2002 regarding noise limit for generator sets run with diesel.

**SCHEDULE-III**  
**Details of Bank Guarantees:**

Sr. No.	Consent(C2E/C 2O/C2R)	Amt of BG Imposed	Submission Period	Purpose of BG	Compliance Period	Validity Date
NA						

\*\* The above Bank Guarantee(s) shall be submitted by the applicant in favour of Regional Officer at the respective Regional Office within 15 days of the date of issue of Consent.  
# Existing BG obtained for above purpose if any may be extended for period of validity as above.

Statement of conditions to be complied and Bank Guarantee Imposed to ensure timely compliance to be observed by:

Sr.No	Activity / Condition to be Complied	Compliance Timeline(Months)	Bank Guarantee Amount
1A	Operation and Maintenance		
1	To Segregate and Handle BMW as per Rule	Continuous	75000
2	Towards Operation and Maintenance of STP/ETP to achieve prescribed discharge standards	Continuous	100000
1B	Records		
1	To Maintain records of BMW and submission of Annual Report in Form -II before 31st January	Continuous	25000
2	To maintain records of BMW material delivered to CBMWTSDF	Continuous	25000
2	Performance		
1	To provide BMW separate storage facility as per guidelines of CPCB	Continuous	50000
2	Towards installation of STP to treat domestic effluent within 6 months	6 months	300000



### BG Forfeiture History

Srno.	Consent (C2E/C2O/C2R)	Amount of BG imposed	Submission Period	Purpose of BG	Amount of BG Forfeiture	Reason of BG Forfeiture
NA						

### BG Return details

Srno.	Consent (C2E/C2O/C2R)	BG imposed	Purpose of BG	Amount of BG Returned
NA				

### SCHEDULE-IV


#### General Conditions:

1. You shall provide facility for collection of environmental samples and samples of trade and sewage effluents, air emissions and hazardous waste to the Board staff at the terminal or designated points and shall pay to the Board for the services rendered in this behalf.
2. You should monitor effluent quality, stack emissions, noise and ambient air quality quarterly
3. You shall provide ports in the chimney/(s) and facilities such as ladder, platform etc. for monitoring the air emissions and the same shall be open for inspection to/and for use of the Board's Staff. The chimney(s) vents attached to various sources of emission shall be designated by numbers such as S-1, S-2, etc. and these shall be painted/ displayed to facilitate identification.
4. Whenever due to any accident or other unforeseen act or even, such emissions occur or is apprehended to occur in excess of standards laid down, such information shall be forthwith Reported to Board, concerned Police Station, office of Directorate of Health Services, Department of Explosives, Inspectorate of Factories and Local Body. In case of failure of pollution control equipments, the production process connected to it shall be stopped.
5. You shall provide an alternate electric power source sufficient to operate all pollution control facilities installed to maintain compliance with the terms and conditions of the consent. In the absence, the applicant shall stop, reduce or otherwise, control production to abide by terms and conditions of this consent.
6. You shall submit, the Environmental Statement Report for the financial year ending 31st March in the prescribed Form-V as per the provisions of rule 14 of the Environment (Protection) (Second Amendment) Rules, 1992 to Regional Office, , the 30th day of September every year.
7. You shall recycle/reprocess/reuse/recover Hazardous Waste as per the provision contain in the HW (MH&TM) Rules 2008, which can be recycled /processed /reused /recovered and only waste which has to be incinerated shall go to incineration and waste which can be used for land filling and cannot be recycled/reprocessed etc should go for that purpose, in order to reduce load on incineration and landfill site/environment.
8. You shall comply with the Hazardous Waste (M, H & TM) Rules, 2008 and submit the Annual Returns to RO- as per Rule 5(6) & 22(2) of Hazardous Waste (M, H & TM) Rules, 2008 for the preceding year April to March in Form-IV by 30th June of every year.
9. An inspection book shall be opened and made available to the Board's officers during their visit to the HCE.



10. You shall strictly comply with the Water (P&CP) Act, 1974, Air (P&CP) Act, 1981 and Environmental Protection Act, 1986 and industry specific standard under EP Rules 1986 which are available on MPCB website ([www.mpcb.gov.in](http://www.mpcb.gov.in)).
11. You shall constitute an Environmental cell with qualified staff/personnel/agency to see the day to day compliance of consent & authorization condition towards Environment Protection.
12. Separate drainage system shall be provided for collection of trade and sewage effluents. Terminal manholes shall be provided at the end of the collection system with arrangement for measuring the flow. No effluent shall be admitted in the pipes/sewers downstream of the terminal manholes. No effluent shall find its way other than in designed and provided collection system.
13. Neither storm water nor discharge from other premises shall be allowed to mix with the effluents from the HCE.
14. You shall install a separate meter showing the consumption of energy for operation of domestic and industrial effluent treatment plants and air pollution control system. A register showing consumption of chemicals used for treatment shall be maintained.
15. You should not cause any nuisance in surrounding area.
16. You shall take adequate measures for control of noise levels from its own sources within the premises so as to maintain ambient air quality standard in respect of noise to less than 75 dB (A) during day time and 70 dB (A) during night time. Day time is reckoned in between 6 a.m. and 10 p.m. and night time is reckoned between 10 p.m. and 6 a.m.
17. You shall maintain good housekeeping.
18. You shall bring minimum 33% of the available open land under green coverage/ plantation. The applicant shall submit a yearly statement to Regional Office by 30th September every year on available open plot area, number of trees surviving as on 31st March of the year and number of trees planted by September end.
19. The non-hazardous solid waste arising in the factory premises, sweepings, etc. be disposed of scientifically so as not to cause any nuisance / pollution. The applicant shall take necessary permissions from civic authorities for disposal of solid waste.
20. You shall not change or alter the quantity, quality, the rate of discharge, temperature or the mode of the effluent/emissions or hazardous wastes or control equipments provided for without previous written permission of the Board. You will not carry out any activity, for which this consent has not been granted/without prior consent of the Board.
21. You shall submit Six Monthly statement in respect of obligation towards consent and pollution control compliance's duly supported with documentary evidences (format can downloaded from MPCB official site).
22. You shall submit official e-mail address and any change will be duly informed to the MPCB, forthwith.
23. You shall achieve the National Ambient Air Quality standards prescribed vide Government of India, Notification dtd. 16.11.2009 as amended
24. You shall observe provisions of E-waste (Management and Handling) Rules 2011 and Battery Waste (Management and Handling) Rules 2001, as amended.

For and on behalf of the  
Maharashtra Pollution Control Board.

  
(Ashok Shingare IAS),  
Member Secretary





महाराष्ट्र MAHARASHTRA

© 2019 ©

VZ 919745

25 FEB 2020

BEFORE NOTARY PUBLIC WARDHA (M.S.,

NOTARIAL REG.

ENTRY NO. 2595

DATE 21/1/2020

**AGREEMENT FOR COLLECTION, TRANSPORTATION,  
TREATMENT AND DISPOSAL OF BIO MEDICAL WASTE**

This agreement is executed on this 2<sup>nd</sup> day of April, 2020 at Wardha Between  
Dr. B. S. Garg, Secretary, Kasturba Health Society, Sevagram, Wardha - 442 102  
Hereinafter called waste generator or PARTY NO. 1

AND

M/s SUPERB HYGIENIC DISPOSALS,


C/o. Mr. Bande, 8A, Damodar Colony,

Near Surendra nagar Basketball Ground, Nagpur

Through Mr. Atul S/o Marotrao Zoting, Managing Partner,

Aged about 40 years, Occupation – Business, R/o Nagpur

Hereinafter called as service provider or PARTY NO. 2





That, the service provider / Party No. 2 is having a Bio - Medical Waste Disposal Unit at **Kh. No. 133, Mauza, Bhandewadi, Nagpur** which is in association with **Nagpur Municipal Corporation**.

That, the waste generator / party No. 1 is having its Hospital in the Name of **Kasturba Hospital** attached to **Mahatma Gandhi Institute of Medical Sciences** run by **Kasturba Health Society**, a charitable organization having charitable objects in the field of research relating to education, health delivery to rural masses and other areas akin thereto.

On the request of Party No. 1, Party No. 2 has agreed to undertake the work of collection, transportation, treatment and disposal of Bio - Medical Waste generated in the Hospital / OPD / Laboratories of Party No. 1 on the following terms and conditions:

**1. Scope of Assignment:**

The area specified shall include –

Medicine Wards and OPD (New Medicine Building)

Surgery Wards and OPD

Orthopedics Wards and OPD

ENT Wards and OPD

Ophthalmology Wards and OPD

Pediatric OPD

Skin & VD Wards and OPD

Radiotherapy Wards and OPD

Psychiatry Wards and OPD

Anesthesiology – Operation Theatre

Microbiology Department and related sections

Pathology Department and related sections

Bio-Chemistry and related sections

Central Collection Laboratory


Trauma Centre and connected wards

Operation Theater Complex

Mother and Child Health Wing

Any other section generating Bio-medical waste shall be communicated to you as an addendum to the existing work order left out inadvertently.

2. Waste Generator hereby declares that in his Hospital, he is having beds for indoor patients and in house services like **Pathology, Blood Bank, X-ray unit and Multispecialty OPD**.
3. Service provider / Party No. 2 has accepted the work of collection, transportation, treatment and disposal of entire Bio - Medical Waste of the waste generator.
4. The Party No. 1 will arrange for non – chlorinated coloured plastic bags approved by Maharashtra Pollution Control Board/Central Pollution Control Board stocking and packing of Bio Medical Waste.
5. The waste generator or party No. 1 will arrange for collection and proper segregation of entire Bio-Medical waste generated in its various departments and wards as per the guidelines of the Bio – Medical Waste Management Rules 2016, and its segregation as per details annexed. Party No. 1 shall keep the material ready at the collection end point and Party No. 2 has agreed to collect the Bio - Medical Waste during 9 am to 6 pm or any other time, which may be mutually agreed upon. The Party No. 1 shall provide Bio - Medical Waste store room at end point.





6. Party No. 1 will pack the segregated Bio - Medical Waste as per rules at the collection end point in colour coded bags; label the said bags as per Schedule IV of the Bio - Medical Waste Management Rules, 2016 amended 2018 and 2019 as per Section 6, 8 and 25 of environment (Protection) Act, 1986.
7. The Party No. 2 shall collect Bio - Medical Waste ward wise, transport, treatment and dispose off the Bio - Medical Waste and for the purpose of collection shall engage / depute personnel and all such personnel shall be the employees of the Party No. 2.
8. Party No. 2 shall collect on daily basis the segregated Bio - Medical Waste generated.
9. That, the waste generator / Party No. 1 hereby agrees that they would pay service provider disposal charges, as per Annex. - I
10. Taxes such as contract sale tax, service tax etc. if applicable shall be to the waste generator's / Party No. 1 account.
11. The Party No. 2 should rise two separate monthly bills (One Original and one carbon copy) in the name of Kasturba Hospital and Party No. 1 shall pay bill on monthly basis.
12. That, no change or modification or waiver of any of the terms of this agreement shall be effective unless agreed to in writing and signed by duly authorized officer of each of the parties hereto.
13. Party No. 2, the service provider and Party No. 1, waste generator agree that this agreement is valid w.e.f. 1/01/2020 to 31/12/2023 and after the expiry of the said period of this agreement, the parties will renew the agreement on fresh terms and conditions as would be mutually agreed upon. Party No. 2 shall make a request application of two months prior of the expiry of the term of this agreement for renewal. Both the parties may terminate the contract by serving one month advance notice.
14. The Party No. 2 shall deposit an amount of **Rs. 2,00,000/- (Rupees Two Lakhs Only)** as the Security Deposit in the Accounts Section of the Kasturba Health Society and the consideration for the assignment will be **Rs. 2,12,840/-** which will be paid by Party No. 1 if the assigned work is successfully completed by Party No. 2.
15. All disputes and questions in connection with this agreement arising between parties shall be referred to the arbitration of two arbitrators one to be appointed by each party and in case of their disagreement to an umpire appointed by the said arbitrator or in case of their default by the parties.





16. In the event there is any objection and / or notice for breach of the rules regarding transportation, treatment and disposal of bio medical waste, Party No. 2 shall be solely responsible in that behalf.
17. In case, the waste collection programme is not attended by the Party No. 2 for more than 2 days, a penalty of Rs. 1000/- per day shall be recovered from Party No. 2 by Party No. 1. Moreover, Party No. 2 shall have to redress the backlog by providing extra force on next day.
18. All the expenses with regard to stamp duty and registration charges if required and all legal expenses in respect of the preparation of the contract shall be exclusively borne by and paid by Party No. 2 i.e. Service Provider.
19. The Party No. 2, the Service Provider guarantees that Bio - Medical Waste shall be treated and disposed off in accordance with **Schedule I**, and in compliance with the standards prescribed in **Schedule II** completely at his own cost and for the same shall set up in accordance with the time - schedule in requisite Bio-Medical Waste treatment facilities like incinerator, autoclave, microwave system for the treatment of waste, or ensure requisite treatment of waste at a common waste treatment facility or any other waste treatment facility.
20. The Party No. 1 agrees to segregate the waste generated into containers / bags at the point of generation in accordance with **Schedule I** prior to its storage, transportation, treatment and disposal and Party No. 2 agrees to label the containers and carry information prescribed in **Schedule IV** during transportation which will be only such vehicle as may be authorised for the purpose by the competent authority as specified by the government.
21. Party No. 2 undertakes that no untreated Bio-Medical Waste shall be kept stored beyond a period of 48 hours and if for any reason it becomes necessary to store the waste beyond such period, Party No. 2 guarantees to take permission of the prescribed authority and take measures to ensure that the waste does not adversely affect human health and environment.
22. Party No. 2 shall maintain records related to the generation, collection, reception storage, transportation, treatment, disposal and/or any form of handling of Bio-Medical Waste in accordance with these rules and any guidelines issued and shall make them available for inspection and verification by the prescribed authority at any time.
23. In the event, Party No. 2 commits any default in the service, the Party No. 1 shall be at liberty to discontinue this agreement with prior written notice of one month.
24. This agreement is executed in Triplicate & one original signed copy will remain with Party No. 1.

#### 25. PENALTY CLAUSES

- (i) In case the contractor fails to commence/execute the work as stipulated in the agreement or there is a breach of any terms and conditions of the contract: Institute (KHS) reserves the right to forfeit the security deposits / performance guarantee etc.
- (ii) For any breach of contract, KHS, Sevagram or duly constituted committee by KHS, Sevagram shall be entitled to impose a penalty to the extent of Rs. 5000/-





only on the first occasion upon the agency in the event of breach, violation or contravention of any of the terms and conditions contained herein brought to the notice of the Committee.

- (iii) If the lapse is repeated again the extent of penalty will be doubled on each such occasion. The decision of the said officer/committee in this regard shall be final and binding upon the agency. Some of the instances in which penalty would be imposed are enumerated below. (but these are not exhaustive and penalty may be imposed on any violation/breach or contravention of any of the terms and conditions as well as assigned duties and responsibilities).
- iv) Penalty will also be imposed if the personnel found indulging in smoking/drinking/sleeping during duty hours. The behaviour of personnel found is discourteous to anyone in the hospital including staff or patients.
- v) Penalty will also be imposed if any personal found performing duty by submitting a fake name and address.
- vi) If any personnel found on duty other than those mentioned in the approved list is supplied by the agencies to the Institute authorities.

26. In case you fails to commence/execute the work as mentioned in the work order or there is a breach of any terms and conditions of the contract the Kasturba Health Society reserves the right to impose the penalty as detailed below:

Offences	Penalties ( In Rupees)
Not found displaying photo ID	100/- per instance.
Worker not in proper Uniform	500/- per instance.
Indulging in smoking/drinking/ sleeping or any other misconduct during duty hours	1000/- with removal of the offender
Duty performed by a worker for more than one shift in 24 hours	With Due permission from the Sanitary Officer, linked to Biometric attendance system, Not more than 5% of the total attendance. Penalty of 200/- per instance in case of non-compliance
Unsatisfactory performance	Individual Complaint: 1000/- per instance Adverse report by ad hoc Committee for inspection: 5000/- per instance Adverse Monthly report: 10,000/- per report
Absenteeism/Under deployed	1000/- per instance
Complaints are not registered or not redressed	Complaints are not registered or not redressed
Absence of personal protective gears	200/- per instance



For any other breach, violation or contravention of any terms and conditions	Rupees 5000/- will be imposed per day
In case the services remain consistently unsatisfactory for a period of more than 2 weeks	Penalty of 5% of the annual contract value will be imposed

27. In case of any loss or theft, it shall be made good by the agency and in the event of failure on their part to do so within a period of one month, the loss shall be made good equivalent to purchase cost by encashment of security deposit and if the amount of loss or damage exceeds the amount of security deposit, then the amount will be recovered from the bill in one or more instalments. In the event of any dispute arising in connection with the interpretation of any clause in the terms and conditions of the contract, agreement, or otherwise the matter shall be referred to the Arbitrator (Shri P. L. Tapadiya, Holding Trustee, Kasturba Health Society, Sevagram) appointed by the KHS shall have jurisdiction in connection with any dispute/litigation arising out of this contract).

IN WITNESS WHEREAS the parties have put their signature on the day and year as above mentioned in presence of the following witnesses at Wardha.

*B. S. Garg*  
PARTY NO. 1

Dr. B. S. Garg  
SECRETARY

SECRETARY  
Kasturba Health Society  
P.O. Sevagram, Wardha.  
Pin - 442 102

WITNESSES

1. *B. Kite*  
.....  
Sarang Kite.....  
Head. KESH (Land & Building)  
MATHS. Sevagram.....
2. *P. Punde*  
.....  
Pratik Punde.....  
P. Unit Manager  
Supac. system. Pimpri NCP

*Atul M. Zoting*  
PARTY NO. 2

Atul M. Zoting

MANAGING PARTNER



Attested

*A. H. Sabane* 2/4/2020

A. H. SABANE

NOTARY

WARDHA DIST (M.S.) INDIA



**Annexure-I**

Sr. No.	Type of Bio-Medical Waste	Mode of Disposal	Type of Unit	Rate	Monthly Weight Limit	Collection, Transportation & Disposal Charges Fixed Per Month
1	Human Anatomical Waste, Microbiology & Biotechnology Waste, Waste Sharp, Discarded Medicine & Cytotoxic Drugs, Soiled Waste, Liquid Waste, Housekeeping & Chemical Waste	Incineration, Autoclaving, Shredding, Chemical Treatment, Effluent Treatment	660 Beds (Considering 70% occupancy of 934 beds)	Rs. 274/- per bed per month	5490 Kg Per Month	Rs. 1,80,840/-
			Pathology Lab	Rs. 3000/- month	30 Kg Per Month	
			Blood Bank	Rs. 3000/- month	30 Kg Per Month	
			Central Lab	Rs. 3000/- month	30 Kg Per Month	
			Cath Lab	Rs. 3000/- month	30 Kg Per Month	
				<b>Total Weight</b>	<b>6210 Kg per Month</b>	
2.	Employee	NA	2	Rs. 20000/- per month (for 2 employees)	NA	Rs. 20,000/-
					<b>Total</b>	<b>Rs. 2,12,840/-</b>

*B. S. Garg*  
**B. S. Garg**  
**SECRETARY**

**SECRETARY**  
 Kasturba Health Society  
 P.O. Sevagram, Wardha.  
 Pin - 442 102

